Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-15-375630.txt : 20151112 0001193125-15-375630.hdr.sgml : 20151112 20151112160534 ACCESSION NUMBER: 0001193125-15-375630 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151112 DATE AS OF CHANGE: 20151112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RXi Pharmaceuticals Corp CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36304 FILM NUMBER: 151224808 BUSINESS ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 10-Q 1 d82772d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 000-54910

RXi Pharmaceuticals Corporation

(Exact name of registrant as specified in its charter)

Delaware

45-3215903

(State of incorporation)

(I.R.S. Employer

Identification No.)

257 Simarano Drive, Suite 101, Marlborough, MA 01752

(Address of principal executive office) (Zip code)

Registrant’s telephone number: (508) 767-3861

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter time that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of November 6, 2015, RXi Pharmaceuticals Corporation had 65,349,121 shares of common stock, $0.0001 par value, outstanding.

RXi PHARMACEUTICALS CORPORATION

FORM 10-Q — QUARTER ENDED SEPTEMBER 30, 2015

INDEX


Part No.	Item No.	Description	Page No.
I		FINANCIAL INFORMATION

	1	Financial Statements (unaudited)		3
		Condensed Balance Sheets as of September 30, 2015 and December 31, 2014		3
		Condensed Statements of Operations for the Three and Nine Months ended September 30, 2015 and 2014		4
		Condensed Statements of Cash Flows for the Nine Months ended September 30, 2015 and 2014		5
		Notes to Condensed Financial Statements		6
	2	Management’s Discussion and Analysis of Financial Condition and Results of Operations		12
	3	Quantitative and Qualitative Disclosures about Market Risk		16
	4	Controls and Procedures		16

II		OTHER INFORMATION		17

	1	Legal Proceedings		17
	1A	Risk Factors		17
	2	Unregistered Sales of Equity Securities and Use of Proceeds		17
	3	Defaults Upon Senior Securities		17
	4	Mine Safety Disclosures		17
	5	Other Information		17
	6	Exhibits		18

Signatures				19

PART I — FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

RXi PHARMACEUTICALS CORPORATION

CONDENSED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

(Unaudited)


	September 30, 2015			December 31, 2014
ASSETS
Current assets:
Cash and cash equivalents	$	4,035		$	8,496
Restricted cash		50			50
Short-term investments		8,000			—
Prepaid expenses and other current assets		432			442

Total current assets		12,517			8,988
Property and equipment, net		162			183
Other assets		18			18

Total assets	$	12,697		$	9,189

LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	222		$	285
Accrued expenses and other current liabilities		1,443			1,002
Deferred revenue		—			47

Total current liabilities		1,665			1,334

Commitments and contingencies
Convertible preferred stock:
Series A convertible preferred stock, $0.0001 par value, 15,000 shares authorized; 0 and 5,110 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively (at liquidation value)		—			5,110
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 authorized
Series A-1 convertible preferred stock, $0.0001 par value, 10,000 shares authorized; 0 and 1,578 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively (at liquidation value)		—			1,578
Common stock, $0.0001 par value, 100,000,000 shares authorized; 64,949,121 and 21,984,272 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively		6			2
Additional paid-in capital		65,515			48,047
Accumulated deficit		(54,489	)		(46,882	)

Total stockholders’ equity		11,032			2,745

Total liabilities, convertible preferred stock and stockholders’ equity	$	12,697		$	9,189

The accompanying notes are an integral part of these financial statements.

RXi PHARMACEUTICALS CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Amounts in thousands, except share and per share data)

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Revenue	$	—		$	16		$	34		$	57
Operating expenses:
Research and development (1)		1,734			1,459			5,202			4,118
General and administrative (1)		770			766			2,447			2,459

Total operating expenses		2,504			2,225			7,649			6,577

Operating loss		(2,504	)		(2,209	)		(7,615	)		(6,520	)
Other income
Interest income, net		8			4			10			15
Other income (expense), net		—			(1	)		(2	)		9

Total other income		8			3			8			24

Net loss		(2,496	)		(2,206	)		(7,607	)		(6,496	)
Series A and Series A-1 convertible preferred stock dividends		—			(700	)		(209	)		(3,668	)

Net loss applicable to common stockholders	$	(2,496	)	$	(2,906	)	$	(7,816	)	$	(10,164	)

Net loss per common share applicable to common stockholders:
Basic and diluted	$	(0.04	)	$	(0.17	)	$	(0.18	)	$	(0.69	)

Weighted average common shares: basic and diluted		64,949,121			17,494,109			44,451,927			14,726,417

(1) Non-cash stock-based compensation expenses included in operating expenses are as follows:
Research and development	$	174		$	216		$	552		$	632
General and administrative		211			238			691			770

The accompanying notes are an integral part of these financial statements.

RXi PHARMACEUTICALS CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)


	Nine Months Ended September 30,
	2015			2014
Cash flows from operating activities:
Net loss	$	(7,607	)	$	(6,496	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		60			68
Gain on disposal of equipment		—			(10	)
Non-cash stock-based compensation		1,243			1,402
Fair value of common stock issued in exchange for patent and technology rights		228			—
Changes in operating assets and liabilities:
Prepaid expenses and other assets		10			(207	)
Accounts payable		(63	)		(26	)
Accrued expenses and other current liabilities		441			(837	)
Deferred revenue		(47	)		(57	)

Net cash used in operating activities		(5,735	)		(6,163	)

Cash flows from investing activities:
Purchase of short-term investments		(8,000	)		(5,000	)
Maturities of short-term investments		—			3,000
Cash paid for purchase of property and equipment		(39	)		(86	)
Proceeds from disposal of property and equipment		—			12

Net cash used in investing activities		(8,039	)		(2,074	)

Cash flows from financing activities:
Net proceeds from the issuance of common stock		9,266			1,947
Proceeds from the issuance of common stock upon the exercise of warrants		16			—
Proceeds from the issuance of common stock in connection with the employee stock purchase plan		31			30

Net cash provided by financing activities		9,313			1,977

Net decrease in cash and cash equivalents		(4,461	)		(6,260	)
Cash and cash equivalents at the beginning of period		8,496			11,390

Cash and cash equivalents at the end of period	$	4,035		$	5,130

Supplemental disclosure of non-cash investing and financing activities:
Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock	$	2,000		$	3,000

Conversion of Series A and Series A-1 convertible preferred stock into common stock	$	6,814		$	3,582

Fair value of Series A and Series A-1 convertible preferred stock dividends	$	209		$	3,668

Series A and Series A-1 convertible preferred stock dividends	$	126		$	447

The accompanying notes are an integral part of these financial statements.

RXi PHARMACEUTICALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of Business and Basis of Presentation

RXi Pharmaceuticals Corporation (“RXi,” “we,” “our” or the “Company”) is a biotechnology company focused on discovering and developing innovative therapies, primarily in the areas of dermatology and ophthalmology, that address high unmet medical needs. Our development programs are based on our siRNA technology and immunotherapy agents. Our clinical development programs include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA^®) compounds for the treatment of dermal and ocular scarring and an immunomodulating agent, Samcyprone™, for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. In addition to these clinical programs, we have a pipeline of discovery and preclinical product candidates in our core therapeutic areas, as well as in other areas of interest. The Company’s pipeline, coupled with our extensive patent portfolio, provides support to further discover and develop innovative therapies either on our own or in collaboration with strategic partners.

Basis of Presentation

The accompanying condensed financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed financial statements have been included. Interim results are not necessarily indicative of results for a full year.

Uses of Estimates in Preparation of Financial Statements

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit.

Restricted Cash

Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.

Short-term Investments

Short-term investments consist of certificates of deposit with original maturities ranging from 3 months to 1 year.

Revenue Recognition

The principal source of revenue consists of government research grants. Revenue is recognized provided there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured, and no contingencies remain outstanding. Payments received prior to the recognition of revenue are recorded as deferred revenue.

Research and Development Expenses

Research and development costs are charged to expense as incurred and relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and our clinical trials. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed us with respect to services provided and/or materials that we have received.

Preclinical and clinical trial expenses relate to third-party services, subject-related fees at the sites where our clinical trials are being conducted, laboratory costs, analysis costs, toxicology studies and investigator fees. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that we have adequately provided for preclinical and clinical expenses during the proper period, we maintain an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the number of subjects and clinical trial sites and length of the study. Actual results may differ from these estimates and could have a material impact on our reported results. Our historical accrual estimates have not been materially different from our actual costs.

Stock-based Compensation

The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers and non-employee directors, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.

For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.” Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the requisite service period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.

Net Loss per Share

The Company accounts for and discloses net loss per share attributable to common stockholders in accordance with FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

Comprehensive Loss

The Company’s net loss is equal to its comprehensive loss for all periods presented.

2. Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 9, 2015, the FASB voted to delay the effective date of the new revenue standard by one year but to permit entities to choose to adopt the standard as of the original effective date. The new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact the update may have on its financial position and results of operations.

3. Net Loss per Share Attributable to Common Stockholders

The following table sets forth the potential common shares excluded from the calculation of net loss per common share attributable to common stockholders because their inclusion would be anti-dilutive:


	September 30,
	2015		2014
Options to purchase common stock		3,308,761		2,987,264
Common stock underlying Series A and Series A-1 convertible preferred stock		—		16,743,495
Warrants to purchase common stock		25,969,615		4,615

Total		29,278,376		19,735,374

4. Fair Value Measurements

The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The Company categorized its restricted cash, cash equivalents and short-term investments as Level 2 hierarchy. The assets classified as Level 2 have initially been valued at the applicable transaction price and subsequently valued, at the end of each reporting period, using other market observable data. Observable market data points include quoted prices, interest rates, reportable trades and other industry and economic events. Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:


Description	September 30, 2015		Quoted Prices In Active Markets (Level 1)		Other Significant Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets:
Restricted cash	$	50	$	—	$	50	$	—
Cash equivalents		1,500		—		1,500		—
Short-term investments		8,000		—		8,000		—

Total	$	9,550	$	—	$	9,550	$	—


Description	December 31, 2014		Quoted Prices In Active Markets (Level 1)		Other Significant Observable Inputs (Level 2)		Unobservable Inputs (Level 3)

Assets:
Restricted cash	$	50	$	—	$	50	$	—
Cash equivalents		4,000		—		4,000		—

Total	$	4,050	$	—	$	4,050	$	—

Fair Value of Financial Instruments

The carrying amounts reported in the balance sheet for restricted cash, cash equivalents, short-term investments, accounts payable and accrued expenses approximate their fair values due to their short-term nature.

5. Convertible Preferred Stock

As of September 30, 2015, the Company had authorized for issuance a total of 15,000 shares of Series A convertible preferred stock (“Series A Preferred Stock”), $0.0001 par value per share. There were no shares of Series A Preferred Stock outstanding at September 30, 2015. As described in Note 8, on November 6, 2015, the Company filed a Certificate Eliminating the Series A Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, in order to eliminate from the Amended and Restated Certificate of Incorporation of the Company, as amended (the “Charter”) all matters set forth in the Charter, including the related certificate of designation, relating to the Series A Preferred Stock.

Dividends

On May 22, 2015, the Company entered into an agreement (the “Acceleration and Conversion Agreement”) with Tang Capital Partners, L.P. (“TCP”) pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A Preferred Shares outstanding after such date.

There were no dividends paid on the Series A Preferred Stock during the three months ended September 30, 2015, as all outstanding shares of Series A Preferred Stock were converted into common stock on May 27, 2015. The Company paid dividends in additional shares of Series A Preferred Stock of 87 shares for the three months ended September 30, 2014. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A Preferred Stock dividends was $421,000 for the three months ended September 30, 2014.

The Company paid dividends in additional shares of Series A Preferred Stock of 105 and 268 shares for the nine months ended September 30, 2015 and 2014, respectively. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A Preferred Stock dividends was $172,000 and $2,056,000 for the nine months ended September 30, 2015 and 2014, respectively.

Conversion

There were no conversions of the Series A Preferred Stock during the three months ended September 30, 2015, as all remaining outstanding shares of Series A Preferred Stock were converted into common stock on May 27, 2015. During the three months ended September 30, 2014, there were no shares of Series A Preferred Stock converted into shares of common stock.

During the nine months ended September 30, 2015, 3,215 shares of Series A Preferred Stock were converted into 7,837,400 shares of common stock and during the nine months ended September 30, 2014, 166 shares of Series A Preferred Stock were converted into 405,720 shares of common stock.

6. Stockholders’ Equity

The Company currently has authorized for issuance 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share.

Series A-1 Preferred Stock

As of September 30, 2015, the Company had authorized for issuance a total of 10,000 shares of Series A-1 convertible preferred stock (“Series A-1 Preferred Stock”), $0.0001 par value per share. There were no shares of Series A-1 Preferred Stock outstanding at September 30, 2015. As described in Note 8, on November 6, 2015, the Company filed a Certificate Eliminating the Series A-1 Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, in order to eliminate from the Charter all matters set forth in the Charter, including the related certificates of designation and increase, relating to the Series A-1 Preferred Stock.

Dividends

On May 22, 2015, the Company entered into the Acceleration and Conversion Agreement with TCP pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A-1 Preferred Shares outstanding after such date.

There were no dividends paid on the Series A-1 Preferred Stock during the three months ended September 30, 2015, as all outstanding shares of Series A-1 Preferred Stock were converted into common stock on May 27, 2015. The Company paid dividends in additional shares of Series A-1 Preferred Stock of 57 shares for the three months ended September 30, 2014. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A-1 Preferred Stock dividends was $279,000 for the three months ended September 30, 2014.

The Company paid dividends in additional shares of Series A-1 Preferred Stock of 21 and 209 shares for the nine months ended September 30, 2015 and 2014, respectively. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A-1 Preferred Stock dividends was $37,000 and $1,612,000 for the nine months ended September 30, 2015 and 2014, respectively.

Conversion

There were no conversions of the Series A-1 Preferred Stock during the three months ended September 30, 2015, as all remaining outstanding shares of Series A-1 Preferred Stock were converted into common stock on May 27, 2015. During the three months ended September 30, 2014, 2,557 shares of Series A-1 Preferred Stock were converted into 6,232,862 shares of common stock.

During the nine months ended September 30, 2015, 3,599 shares of Series A-1 Preferred Stock were converted into 8,772,903 shares of common stock and during the nine months ended September 30, 2014, 3,416 shares of Series A-1 Preferred Stock were converted into 8,326,721 shares of common stock.

Common Stock

Hapten License Agreement

On December 17, 2014, the Company entered into an assignment and exclusive license agreement, (the “Hapten Assignment and License Agreement”) with Hapten Pharmaceuticals, LLC (“Hapten”) under which Hapten agreed, effective at a closing that occurred on February 4, 2015, to sell and assign to us certain patent rights and related assets and rights, including an investigational new drug application and clinical data, for Hapten’s Samcyprone™ products for therapeutic and prophylactic use. Upon the closing of the Hapten Assignment and License Agreement on February 4, 2015, the Company paid to Hapten a one-time upfront cash payment of $100,000 and issued 200,000 shares of common stock, the fair value of which was determined using the quoted market price of the Company’s common stock on the date of issuance. Accordingly, the cash payment of $100,000 and the fair value of the common stock of $228,000 were recorded as research and development expense during the quarter ended March 31, 2015.

Lincoln Park Capital Equity Line

During the nine months ended September 30, 2015, the Company sold a total of 50,000 shares of common stock for net proceeds of approximately $64,000 to Lincoln Park Capital Fund, LLC (“LPC”) pursuant to and subject to the limitations and conditions set forth in that certain purchase agreement (the “LPC Purchase Agreement”) between the Company and LPC dated December 18, 2014. There were no sales made under the LPC Purchase Agreement during the three months ended September 30, 2015. Per the terms of the public offering (see below), the Company cannot access the equity line until the expiration of the 13-month Overallotment Purchase Rights (defined below).

June 2015 Public Offering

On June 2, 2015, the Company sold a total of 26,000,000 units at a price of $0.40 per unit in a public offering (the “Offering”). Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the “Overallotment Purchase Rights”) and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the “Warrants”). As a result of the Offering, the Company received gross proceeds of approximately $10,400,000 and net proceeds of approximately $9,200,000 after placement agent fees and estimated Offering expenses, and assuming the Overallotment Purchase Rights and Warrants are not exercised.

The Company first assessed the Overallotment Purchase Rights and the Warrants under FASB ASC Topic 480 (“ASC 480”), “Distinguishing Liabilities and Equity” and determined that the Overallotment Purchase Rights and the Warrants were outside the scope of ASC 480. The Company next assessed the Overallotment Purchase Rights and Warrants under FASB ASC Topic 815 (“ASC 815”), “Derivatives and Hedging.” Under the related guidance, a reporting entity shall not consider a contract to be a derivative instrument if the contract is both (1) indexed to the entity’s own stock and (2) classified in stockholders’ equity. The Company determined that the warrant contracts are indexed to the Company’s stock, as the agreements do not contain any exercise contingencies and the warrants’ settlement amount equals the difference between the fair value of the Company’s common stock price and the warrant contract strike price, and the only variables which could affect the settlement amount would be inputs to the fair value for a fixed-for-fixed option on equity shares. The Company also assessed the classification in stockholders’ equity and determined the warrant contracts meet all of the criteria for classification as equity under ASC 815. Based on this analysis, the Company determined that the Overallotment Purchase Rights and the Warrants should be classified as equity.

No warrants were exercised during the three months ended September 30, 2015. During the nine months ended September 30, 2015, 35,000 warrants were exercised for gross proceeds of $16,000.

Refer to the Series A Preferred Stock and Series A-1 Preferred Stock conversions described above in this Note and Note 5 for shares issued as a result of the conversions of Series A and Series A-1 Preferred Stock during the three and nine months ended September 30, 2015 and 2014, respectively.

7. Stock-based Compensation

Stock-based Compensation

The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2015 and 2014, the following assumptions were used:

For the Three Months Ended
September 30,

For the Nine Months Ended
September 30,

2015

2014

2015

2014

Risk-free interest rate

1.82 – 2.43%

2.52 %

1.47 – 2.43%

1.60 – 2.73%

Expected volatility

85.29 – 116.81%

103.47%

85.29 – 116.81%

97.91 – 107.01%

Weighted average expected volatility

107.49%

103.47%

89.43%

101.50%

Expected lives (in years)

6.25 – 10.0

10.0

5.20 – 10.0

Expected dividend yield

0.00%

The weighted average fair value of options granted during the three month periods ended September 30, 2015 and 2014 was $0.44 and $2.71, respectively. The weighted average fair value of options granted during the nine month periods ended September 30, 2015 and 2014 was $0.41 and $2.46, respectively.

The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the volatility of a composition of comparable companies. The expected life assumption for employee grants was based upon the simplified method provided for under ASC 718 and the expected life assumption for non-employees was based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends.

The following table summarizes the activity of the Company’s stock option plan for the period from January 1, 2015 to September 30, 2015:


	Total Number of Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Balance at January 1, 2015		3,000,264		$	3.39
Granted		390,164			0.55
Exercised		—			—
Cancelled		(81,667	)		3.07

Balance at September 30, 2015		3,308,761		$	3.06		7.39 years	$	—

Exercisable at September 30, 2015		2,376,045		$	3.33		7.00 years	$	—

Stock-based compensation expense for the three months ended September 30, 2015 and 2014 was approximately $385,000 and $454,000, respectively. Of this, the Company recognized approximately $3,100 and $24,000 of expense related to non-employee stock options for the same respective periods.

Stock-based compensation expense for the nine months ended September 30, 2015 and 2014 was approximately $1,243,000 and $1,402,000 respectively. Of this, the Company recognized approximately $18,700 of income and $71,000 of expense related to non-employee stock options for the same respective periods.

8. Subsequent Events

Subsequent to September 30, 2015, 400,000 Overallotment Purchase Rights were exercised for gross proceeds of $182,000.

On November 6, 2015, the Company filed a Certificate Eliminating the Series A Convertible Preferred Stock from the Certificate of Incorporation of the Company and a Certificate Eliminating the Series A-1 Convertible Preferred Stock from the Certificate of Incorporation of the Company (together, the “Certificates of Elimination”) with the Secretary of State of the State of Delaware, in order to eliminate from the Charter all matters set forth in the Charter, including the related certificates of designation and increase, relating to the previously issued series of preferred stock of the Company. As a result, the 15,000 shares of unissued Series A Preferred Stock and 10,000 shares of unissued Series A-1 Preferred Stock were returned to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series or preferences or rights. The foregoing summary of the Certificates of Elimination is qualified in its entirety by reference to the full text of the Certificates of Elimination, which are attached hereto as Exhibits 3.1 and 3.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In this document, “we,” “our,” “ours,” “us,” “RXi” and the “Company” refer to RXi Pharmaceuticals Corporation.

This management’s discussion and analysis of financial condition as of September 30, 2015 and results of operations for the three and nine months ended September 30, 2015 and 2014 should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014 which was filed with the SEC on March 30, 2015.

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “intend,” “believe,” “indicate,” “plan,” “expect,” “may,” “should,” “designed to,” “will” and similar references. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively “our product candidates”); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; and the future success of our strategic partnerships. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: the risk that our clinical trials with our product candidates may not be successful in evaluating the safety and tolerability of these candidates or providing evidence of increased surgical scar reduction compared to placebo; the successful and timely completion of clinical trials; uncertainties regarding the regulatory process; the availability of funds and resources to pursue our research and development projects, including our clinical trials with our product candidates; general economic conditions; and those identified in our Annual Report on Form 10-K for the year ended December 31, 2014 under the heading “Risk Factors” and in other filings the Company periodically makes with the Securities and Exchange Commission. Forward-looking statements contained in this Quarterly Report on Form 10-Q speak as of the date hereof and the Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this report.

Overview

Our RNAi therapies are designed to “silence,” or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. The Company’s first RNAi clinical product candidate, RXI-109, is a self-delivering RNAi compound (sd-rxRNA) that commenced human clinical trials in 2012. RXI-109 is designed to reduce the expression of connective tissue growth factor (“CTGF”), a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin. RXI-109 is currently being evaluated in Phase 2a clinical trials to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids.

The Company is also directing its development efforts toward advancing RXI-109 forward for the treatment of an ophthalmic indication, of which our current areas of focus include retinal and corneal scarring. To date, we have shown that CTGF protein levels are reduced in a dose-dependent manner in both the retina and cornea following an intravitreal injection of RXI-109 in monkeys. The Company holds an active investigational new drug application (“IND”) for RXI-109 as a potential therapeutic for the scarring component of retinal diseases in the eye, such as wet age-related macular degeneration and commenced a Phase 1/2 clinical trial in this indication in November 2015.

In December 2014, the Company broadened its clinical pipeline with an exclusive, global license to Samcyprone™, our second clinical candidate. Samcyprone™ is a proprietary topical formulation of diphenylcyclopropenone (“DPCP”), an immunomodulator that works by initiating a T-cell response, and is currently being developed for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. The use of Samcyprone™ allows sensitization using much lower concentrations of DPCP than possible with existing DPCP solutions, avoiding hyper-sensitization to subsequent challenge doses. In March 2015, the Company was granted Orphan Drug Designation for Samcyprone™ by the U.S. Food and Drug Administration for the treatment of malignant melanoma stage IIb to IV. The Company also expects to initiate a Phase 2a clinical trial for the treatment of cutaneous warts with Samcyprone™ by the end of 2015.

The Company continues to advance additional preclinical and discovery programs using our sd-rxRNA technology. In particular, within our dermatology program, the Company has selected collagenase (“MMP1”) and tyrosinase (“TYR”) as gene targets for our self-delivering RNAi platform. MMP1 is a matrix metalloproteinase involved in the breakdown of extracellular matrix. Selected reduction of MMP1 may be beneficial in the treatment of skin aging disorders, arthritis, acne scarring, blistering skin disorders, corneal erosions, endometriosis and possible cancer metastasis. TYR is the key enzyme in the synthesis of melanin. Melanin is produced by melanocytes and is the pigment that gives human skin, hair and eyes their color. The inhibition of tyrosinase can play a key role in the management of diseases including cutaneous hyperpigmentation disorders such as lentigines (freckles, age spots and liver spots), and possibly melanoma.

In October 2015, the Company announced the selection of lead compounds targeting MMP1 and TYR for cosmeceutical development. RXI-185, an sd-rxRNA compound targeting MMP1, is being developed as a cosmeceutical product that may improve skin appearance. RXI-231, an sd-rxRNA compound targeting TYR, is being developed as a cosmeceutical product that may act as a skin lightening agent. These targets, MMP1 and TYR, were selected because they have great potential as clinically relevant pharmaceutical gene targets, however, they also have great potential as cosmeceutical targets. The term “cosmeceuticals” refers to compounds that can affect the appearance of the skin. Cosmeceuticals can be developed more rapidly than pharmaceutical drugs, and the path to market could be much shorter. The Company’s next steps include plans to complete functional and safety testing for both compounds, as well as to develop a method for skin penetration that would be compatible with our compounds.

Since inception, we have incurred significant losses. Substantially all of our losses to date have resulted from research and development expenses in connection with our clinical and research programs and from general administrative costs. At September 30, 2015, we had an accumulated deficit of $54.5 million. We expect to continue to incur significant losses for the foreseeable future, particularly as we advance our development program for RXI-109 in dermatology and ophthalmology and commence human clinical trials with Samcyprone™.

Research and Development

To date, our research programs have focused on developing technology necessary to make RNAi compounds available by local administration for diseases for which we intend to develop an RNAi therapeutic, identifying and testing RNAi compounds against therapeutically relevant targets in the fields of dermatology and ophthalmology, and identifying lead product candidates and moving those product candidates into the clinic. Since we commenced operations, research and development has comprised a significant proportion of our total operating expenses and is expected to comprise the majority of our spending for the foreseeable future.

There are risks in any new field of drug discovery that preclude certainty regarding the successful development of a product. We cannot reasonably estimate or know the nature, timing and costs of the efforts necessary to complete the development of, or the period in which material net cash inflows are expected to commence from, any product candidate. Our inability to make these estimates results from the uncertainty of numerous factors, including but not limited to:

•

Our ability to advance product candidates into preclinical research and clinical trials;

•

The scope and rate of progress of our preclinical program and other research and development activities;

•

The scope, rate of progress and cost of any clinical trials we commence;

•

The cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;

•

Clinical trial results;

•

The terms and timing of any collaborative, licensing and other arrangements that we may establish;

•

The cost and timing of regulatory approvals;

•

The cost of establishing clinical and commercial supplies of our product candidates and any products that we may develop;

•

The cost and timing of establishing sales, marketing and distribution capabilities;

•

The effect of competing technological and market developments; and

•

The effect of government regulation and insurance industry efforts to control healthcare costs through reimbursement policy and other cost management strategies.

Failure to complete any stage of the development of our product candidates in a timely manner could have a material adverse effect on our operations, financial position and liquidity.

Critical Accounting Policies and Estimates

There have been no significant changes to our critical accounting policies since the beginning of this fiscal year. Our critical accounting policies are described in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended December 31, 2014, which we filed with the SEC on March 30, 2015.

Results of Operations

The following data summarizes the results of our operations for the periods indicated, in thousands:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
Revenue	$	—		$	16		$	34		$	57
Operating expenses		(2,504	)		(2,225	)		(7,649	)		(6,577	)
Operating loss		(2,504	)		(2,209	)		(7,615	)		(6,520	)
Net loss		(2,496	)		(2,206	)		(7,607	)		(6,496	)
Net loss applicable to common stockholders	$	(2,496	)	$	(2,906	)	$	(7,816	)	$	(10,164	)

Comparison of the Three and Nine Months Ended September 30, 2015 and 2014

Revenue

To date, the Company’s principal source of revenue has consisted of government grants. The following table summarizes our total revenue for the periods indicated, in thousands:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Revenue	$	—	$	16	$	34	$	57

No revenue was recognized for the three months ended September 30, 2015, compared with $16,000 for the three months ended September 30, 2014. The decrease of $16,000, or 100%, was due to the completion of work on the Company’s outstanding government grant during the three months ended March 31, 2015.

Total revenue was approximately $34,000 for the nine months ended September 30, 2015, compared with $57,000 for the nine months ended September 30, 2014. The decrease of $23,000, or 40%, was due to the completion of work on the Company’s outstanding government grant during the three months ended March 31, 2015.

Operating Expenses

The following table summarizes our total operating expenses, for the periods indicated, in thousands:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Research and development	$	1,734	$	1,459	$	5,202	$	4,118
General and administrative		770		766		2,447		2,459

Total operating expenses	$	2,504	$	2,225	$	7,649	$	6,577

Research and Development

Research and development expenses consist of compensation-related costs for our employees dedicated to research and development activities, fees related to our Scientific Advisory Board members, expenses related to our ongoing research and development efforts primarily related to our clinical trials, drug manufacturing, outside contract services, licensing and patent fees and laboratory supplies and services for our research programs. We expect research and development expenses to increase as we expand our discovery, preclinical and clinical activities.

Total research and development expenses were approximately $1,734,000 for the three months ended September 30, 2015, compared with $1,459,000 for the three months ended September 30, 2014. The increase of $275,000, or 19%, was primarily due to an increase of $317,000 in research and development expenses driven by a new drug manufacture of RXI-109 that commenced early in the quarter, offset by decreases in employee and non-employee stock-based compensation expense related to the change in the fair value of options quarter over quarter.

Total research and development expenses were approximately $5,202,000 for the nine months ended September 30, 2015, compared with $4,118,000 for the nine months ended September 30, 2014. The increase of $1,084,000, or 26%, was primarily due to an increase of $1,164,000 in research and development expenses related to the new drug manufacture of RXI-109 that began early in the third quarter of the year, subject- and trial-related fees for the Company’s second hypertrophic Phase 2a trial 1402 and Samcyprone™-related fees in preparation for the planned Phase 2 trial in cutaneous warts, offset by a decrease of $90,000 in non-employee stock-based compensation related to the change in the fair value of options year over year.

General and Administrative

General and administrative expenses consist primarily of compensation-related costs for our employees dedicated to general and administrative activities, legal fees, audit and tax fees, consultants, professional services and general corporate expenses.

General and administrative expenses were approximately $770,000 for the three months ended September 30, 2015, compared with $766,000 for the three months ended September 30, 2014. General and administrative expenses for the three months ended September 30, 2015 were consistent with general and administrative expenses in the same quarter of the prior year.

General and administrative expenses were approximately $2,447,000 for the nine months ended September 30, 2015, compared with $2,459,000 for the nine months ended September 30, 2014. The decrease of $12,000, or less than 1%, was primarily due to a decrease in employee stock-based compensation expense, offset by an increase in consulting expenses.

Series A and Series A-1 Preferred Stock Dividends

The following table summarizes our Series A and Series A-1 Preferred Stock dividends for the periods indicated, in thousands:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Series A and Series A-1 Preferred Stock dividends	$	—	$	700	$	209	$	3,668

There were no dividends paid on the Series A and Series A-1 Preferred Stock during the three months ended September 30, 2015, as all outstanding shares of Series A and Series A-1 Preferred Stock were converted into common stock on May 27, 2015. $700,000 in dividends were paid on the Series A and Series A-1 Preferred Stock for the three months ended September 30, 2014. The decrease of $700,000, or 100%, was due to the full conversion of Series A and Series A-1 Preferred Stock during the three months ended June 30, 2015, resulting in no further accumulation and payment of dividends on these series of preferred stock during the three months ended September 30, 2015.

Total Series A and Series A-1 Preferred Stock dividends were approximately $209,000 for the nine months ended September 30, 2015, compared with $3,668,000 for the nine months ended September 30, 2014. The decrease of $3,459,000, or 94%, was due to a decrease in the Company’s common stock price on the dividend payment dates and the number of preferred shares earning dividends each quarter and the full conversion of Series A and Series A-1 Preferred Stock during the three months ended June 30, 2015 resulting in no further accumulation and payment of dividends on these series of preferred stock.

No shares of the Series A and Series A-1 Preferred Stock remained outstanding at September 30, 2015, and as a result no further dividends will continue to accrue. On November 6, 2015, the Company filed the Certificates of Elimination with respect to the Series A and Series A-1 Preferred Stock, as described further in Item 5.

Liquidity and Capital Resources

We had cash, cash equivalents and short-term investments of approximately $12.0 million as of September 30, 2015, compared with approximately $8.5 million in cash and cash equivalents as of December 31, 2014.

On June 2, 2015, the Company sold a total of 26,000,000 units at a price of $0.40 per unit in a public offering (the “Offering”). Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the “Overallotment Purchase Rights”) and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the “Warrants”). As a result of the Offering, the Company received net proceeds of approximately $9.2 million after placement agent fees and estimated Offering expenses, and assuming the Overallotment Purchase Rights and Warrants are not exercised.

During the nine months ended September 30, 2015, the Company sold a total of 50,000 shares of common stock for net proceeds of approximately $64,000 to Lincoln Park Capital Fund, LLC (“LPC”) pursuant to and subject to the limitations and conditions set forth in that certain purchase agreement (the “LPC Purchase Agreement”) between the Company and LPC dated December 18, 2014. There have been no other sales under the LPC Purchase Agreement to date. Per the terms of the Offering, the Company cannot access the equity line until the expiration of the Overallotment Purchase Rights.

We believe that our existing cash, cash equivalents and short-term investments should be sufficient to fund our operations for at least the next twelve months. We have generated significant losses to date, have not generated any product revenue to date and may not generate product revenue in the foreseeable future, or ever. In the future, we will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, funded research and development programs and payments under partnership and collaborative agreements, in order to maintain our operations and meet our obligations to licensors. There is no guarantee that debt, additional equity or other funding will be available to the Company on acceptable terms, or at all. If we fail to obtain additional funding when needed, we may be forced to scale back or terminate operations or to seek to merge with or to be acquired by another company.

Net Cash Flow from Operating Activities

Net cash used in operating activities was $5,735,000 and $6,163,000 for the nine months ended September 30, 2015 and 2014, respectively. The decrease in cash used in operating activities of $428,000 was primarily due to changes in operating assets and liabilities of $1,468,000 partially offset by an increase in net loss of $1,111,000 and an increase in non-cash items of $71,000.

Net Cash Flow from Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2015 was $8,039,000, of which $8,000,000 was attributable to the purchase of short-term investments and the remainder to fixed asset purchases. Net cash used in investing activities for the nine months ended September 30, 2014 was $2,074,000 and primarily related to the purchase of short-term investments of $5,000,000 offset by short-term investments of $3,000,000 maturing during the period.

Net Cash Flow from Financing Activities

Net cash provided by financing activities was $9,313,000 for the nine months ended September 30, 2015 and was primarily due to net proceeds of $9,266,000 from the issuance of 26 million units in connection with the Offering in June 2015 and from the issuance of shares of our common stock to LPC in connection with the LPC Purchase Agreement. Net cash provided by financing activities was $1,977,000 for the nine months ended September 30, 2014 and was primarily due to net proceeds of $1,947,000 for the issuance of shares of our common stock to LPC during the prior year period.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements or relationships.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this quarterly report on Form 10-Q, Dr. Geert Cauwenbergh, our Chief Executive Officer and acting Chief Financial Officer (the “Certifying Officer” ), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the “Exchange Act”), such as this Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officer, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officer has concluded, that, as of the end of the period covered by this quarterly report on Form 10-Q:

(a)

Our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and

(b)

Our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There has not been any change in our internal control over financial reporting that occurred during the quarterly period ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

None.

ITEM 1A.

RISK FACTORS

You should consider the “Risk Factors” included under Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on March 30, 2015.

We may not be able to regain compliance with the continued listing requirements of The Nasdaq Capital Market.

On May 7, 2015, we received written notice (the “Notification Letter”) from the Nasdaq Stock Market (“Nasdaq”) notifying us that we are not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of our common stock for the 30 consecutive business days prior to the date of the Notification Letter, we no longer meet the minimum bid price requirement. The Notification Letter provided an initial 180-day period to regain compliance, which was extended for a second 180-day period on November 4, 2015. As a result of the extension, we have until May 2, 2016 to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. In the event that we do not regain compliance by that date, Nasdaq may commence delisting proceedings, which could adversely impact us by, among other things, reducing the liquidity and market price of our common stock; reducing the number of investors willing to hold or acquire our common stock; limiting our ability to issue additional securities in the future; and limiting our ability to fund our operations.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

ITEM 6.

EXHIBITS

EXHIBIT INDEX


Exhibit Number		Incorporated by Reference Herein
Exhibit Number	Description	Form	Date

3.1	Certificate Eliminating the Series A Convertible Preferred Stock from the Certificate of Incorporation of RXi Pharmaceuticals Corporation*

3.2	Certificate Eliminating the Series A-1 Convertible Preferred Stock from the Certificate of Incorporation of RXi Pharmaceuticals Corporation*

31.1	Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer and Chief Financial Officer*

32.1	Sarbanes-Oxley Act Section 906 Certification of Chief Executive Officer and Chief Financial Officer.*

101	The following financial information from the Quarterly Report on Form 10-Q of RXi Pharmaceuticals Corporation for the quarter ended September 30, 2015, formatted in XBRL (eXtensible Business Reporting Language): (1) Condensed Balance Sheets as of September 30, 2015 and December 31, 2014; (2) Condensed Statements of Operations for the Three and Nine Months ended September 30, 2015 and 2014; (3) Condensed Statements of Cash Flows for the Nine Months ended September 30, 2015 and 2014; and (4) Notes to Condensed Financial Statements (Unaudited).*

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


RXi Pharmaceuticals Corporation (Registrant)

By:		/s/ Geert Cauwenbergh
		Geert Cauwenbergh, Dr. Med. Sc.
		President, Chief Executive Officer and acting Chief Financial Officer

		Date: November 12, 2015

EX-3.1 2 d82772dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

CERTIFICATE ELIMINATING

THE SERIES A CONVERTIBLE

PREFERRED STOCK FROM THE

CERTIFICATE OF INCORPORATION

RXI PHARMACEUTICALS CORPORATION

Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware (the “DGCL”), it is hereby certified that:

1. The name of the corporation is RXi Pharmaceuticals Corporation (the “Corporation”).

2. The designation of the series of shares of stock of the Corporation to which this certificate relates is Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”).

3. The voting powers, designations, preferences, and the relative, participating, optional, or other rights, and the qualifications, limitations, and restrictions of the said series of shares of stock were provided for in a resolution adopted by the Board of Directors of the Corporation (the “Board”) on January 23, 2012 pursuant to authority expressly vested in it by the Certificate of Incorporation of the Corporation. That certain Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock, dated as of February 1, 2012, setting forth the said resolution, has been heretofore filed with the Secretary of State of the State of Delaware pursuant to the provisions of Section 151(g) of the DGCL.

4. The Board has adopted the following resolutions:

NOW, THEREFORE, BE IT RESOLVED, that none of the authorized shares of Series A Preferred Stock are outstanding;

RESOLVED FURTHER, that no shares of Series A Preferred Stock will be issued; and

RESOLVED FURTHER, that each of the officers of the Corporation, acting alone or with one or more such officers be, and hereby is, authorized, empowered and directed to file a certificate setting forth these resolutions with the Secretary of State of the State of Delaware pursuant to the provisions of Section 151(g) of the DGCL for the purpose of eliminating from the Certificate of Incorporation of the Corporation all reference to the Series A Preferred Stock.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Elimination to be signed by its duly authorized officer this 6th day of November, 2015.


RXI PHARMACEUTICALS CORPORATION

By:		/s/ Geert Cauwenbergh
		Geert Cauwenbergh, Dr. Med. Sc. Chief Executive Officer

EX-3.2 3 d82772dex32.htm EX-3.2 EX-3.2

Exhibit 3.2

CERTIFICATE ELIMINATING

THE SERIES A-1 CONVERTIBLE

PREFERRED STOCK FROM THE

CERTIFICATE OF INCORPORATION

RXI PHARMACEUTICALS CORPORATION

Pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware (the “DGCL”), it is hereby certified that:

1. The name of the corporation is RXi Pharmaceuticals Corporation (the “Corporation”).

2. The designation of the series of shares of stock of the Corporation to which this certificate relates is Series A-1 Convertible Preferred Stock, par value $0.0001 per share (the “Series A-1 Preferred Stock”).

3. The voting powers, designations, preferences, and the relative, participating, optional, or other rights, and the qualifications, limitations, and restrictions of the said series of shares of stock were provided for in a resolution adopted by the Board of Directors of the Corporation (the “Board”) on August 13, 2013 pursuant to authority expressly vested in it by the Certificate of Incorporation of the Corporation. That certain Certificate of Designations, Preferences and Rights of Series A-1 Convertible Preferred Stock, dated as of August 13, 2013 and amended by that certain Certificate of Increase of Series A-1 Convertible Preferred Stock, dated as of January 24, 2014, setting forth the said resolution, has been heretofore filed with the Secretary of State of the State of Delaware pursuant to the provisions of Section 151(g) of the DGCL.

4. The Board has adopted the following resolutions:

NOW, THEREFORE, BE IT RESOLVED, that none of the authorized shares of Series A-1 Preferred Stock are outstanding;

RESOLVED FURTHER, that no shares of Series A-1 Preferred Stock will be issued; and

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Elimination to be signed by its duly authorized officer this 6th day of November, 2015.


RXI PHARMACEUTICALS CORPORATION

By:		/s/ Geert Cauwenbergh
		Geert Cauwenbergh, Dr. Med. Sc. Chief Executive Officer

EX-31.1 4 d82772dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Geert Cauwenbergh, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of RXi Pharmaceuticals Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Dated: November 12, 2015

/s/ Geert Cauwenbergh

Geert Cauwenbergh, Dr. Med. Sc.

President, Chief Executive Officer and acting Chief Financial Officer

(as Principal Executive and Financial Officer)

EX-32.1 5 d82772dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of RXi Pharmaceuticals Corporation (the “Company”) on Form 10-Q for the period ended September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the Company’s financial condition and result of operations.

/s/ Geert Cauwenbergh

Geert Cauwenbergh, Dr. Med. Sc.

President, Chief Executive Officer and acting Chief Financial Officer

(as Principal Executive and Financial Officer)

November 12, 2015

EX-101.INS 6 rxii-20150930.xml XBRL INSTANCE DOCUMENT 65349121 10000 15000

0.40

0.52

0.455

5130000

3308761

100000000

3.06

64949121

0.0001

2376045

10000000

64949121

3.33

0.0001

11032000

65515000

222000

1443000

-54489000

12697000

6000

1665000

18000

12697000

50000

162000

12517000

432000

4035000

8000000

9550000

50000

1500000

8000000

10000

0.0001

15000

9550000

50000

1500000

8000000

11390000

3000264

100000000

3.39

21984272

0.0001

10000000

21984272

0.0001

2745000

48047000

47000

285000

1002000

-46882000

9189000

2000

1334000

18000

9189000

50000

183000

8988000

442000

8496000

4050000

50000

4000000

1578

10000

1578

0.0001

1578000

5110

0.0001

15000

5110

5110000

4050000

50000

4000000

100000

200000

9200000

10400000 26000000 Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the "Overallotment Purchase Rights") and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the "Warrants").

400000

182000

-6163000

-0.69

19735374

1.0701

0.0000

0.0160

2.46

0.0273

1.0150

0.9791

14726417

86000

-6496000

-10164000

15000

57000

207000

-6520000

9000

24000

10000

3000000

5000000

3668000

1402000

447000

30000

-57000

-6260000

6577000

-2074000

3000000

1977000

4118000

1947000

12000

-837000

2459000

3582000

-26000

68000

71000

770000

632000

2987264

4615

16743495

P10Y

P5Y2M12D

209

3416

1612000

8326721

268

166

2056000

405720

-5735000

81667

<div> Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="46%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices In Active Markets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other Significant Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Short-term investments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,550</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,550</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices In Active Markets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other Significant Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

35000

2015

<div> 2. Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 9, 2015, the FASB voted to delay the effective date of the new revenue standard by one year but to permit entities to choose to adopt the standard as of the original effective date. The new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact the update may have on its financial position and results of operations. </div>

<div> 1. Nature of Business and Basis of Presentation RXi Pharmaceuticals Corporation (“RXi,” “we,” “our” or the “Company”) is a biotechnology company focused on discovering and developing innovative therapies, primarily in the areas of dermatology and ophthalmology, that address high unmet medical needs. Our development programs are based on our siRNA technology and immunotherapy agents. Our clinical development programs include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and ocular scarring and an immunomodulating agent, Samcyprone™, for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. In addition to these clinical programs, we have a pipeline of discovery and preclinical product candidates in our core therapeutic areas, as well as in other areas of interest. The Company’s pipeline, coupled with our extensive patent portfolio, provides support to further discover and develop innovative therapies either on our own or in collaboration with strategic partners. Basis of Presentation The accompanying condensed financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed financial statements have been included. Interim results are not necessarily indicative of results for a full year. Uses of Estimates in Preparation of Financial Statements The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit. Restricted Cash Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards. Short-term Investments Short-term investments consist of certificates of deposit with original maturities ranging from 3 months to 1 year. Revenue Recognition The principal source of revenue consists of government research grants. Revenue is recognized provided there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured, and no contingencies remain outstanding. Payments received prior to the recognition of revenue are recorded as deferred revenue. Research and Development Expenses Research and development costs are charged to expense as incurred and relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and our clinical trials. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed us with respect to services provided and/or materials that we have received. Preclinical and clinical trial expenses relate to third-party services, subject-related fees at the sites where our clinical trials are being conducted, laboratory costs, analysis costs, toxicology studies and investigator fees. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that we have adequately provided for preclinical and clinical expenses during the proper period, we maintain an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the number of subjects and clinical trial sites and length of the study. Actual results may differ from these estimates and could have a material impact on our reported results. Our historical accrual estimates have not been materially different from our actual costs.   Stock-based Compensation The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers and non-employee directors, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.” Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the requisite service period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. Net Loss per Share The Company accounts for and discloses net loss per share attributable to common stockholders in accordance with FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares. Comprehensive Loss The Company’s net loss is equal to its comprehensive loss for all periods presented. </div>

false

<div> Revenue Recognition The principal source of revenue consists of government research grants. Revenue is recognized provided there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured, and no contingencies remain outstanding. Payments received prior to the recognition of revenue are recorded as deferred revenue. </div>

-0.18

29278376

<div> Restricted Cash Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards. </div>

10-Q 0001533040

<div> The following table sets forth the potential common shares excluded from the calculation of net loss per common share attributable to common stockholders because their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,308,761</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,987,264</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Common stock underlying Series A and Series A-1 convertible preferred stock </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,743,495</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,969,615</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,615</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,278,376</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,735,374</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P7Y4M21D

P7Y

<div> Comprehensive Loss The Company’s net loss is equal to its comprehensive loss for all periods presented. </div>

Smaller Reporting Company

<div> Research and Development Expenses Research and development costs are charged to expense as incurred and relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and our clinical trials. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed us with respect to services provided and/or materials that we have received. Preclinical and clinical trial expenses relate to third-party services, subject-related fees at the sites where our clinical trials are being conducted, laboratory costs, analysis costs, toxicology studies and investigator fees. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that we have adequately provided for preclinical and clinical expenses during the proper period, we maintain an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the number of subjects and clinical trial sites and length of the study. Actual results may differ from these estimates and could have a material impact on our reported results. Our historical accrual estimates have not been materially different from our actual costs. </div>

<div> Basis of Presentation The accompanying condensed financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed financial statements have been included. Interim results are not necessarily indicative of results for a full year. </div>

3.07

<div> 4. Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows: Level 1 — quoted prices in active markets for identical assets or liabilities. Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.   The Company categorized its restricted cash, cash equivalents and short-term investments as Level 2 hierarchy. The assets classified as Level 2 have initially been valued at the applicable transaction price and subsequently valued, at the end of each reporting period, using other market observable data. Observable market data points include quoted prices, interest rates, reportable trades and other industry and economic events. Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="46%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices In Active Markets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other Significant Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,500</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Short-term investments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,550</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,550</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Description </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Quoted Prices In Active Markets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other Significant Observable Inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Restricted cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">50</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,050</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for restricted cash, cash equivalents, short-term investments, accounts payable and accrued expenses approximate their fair values due to their short-term nature. </div>

1.1681

0.00

0.55

--12-31 RXi Pharmaceuticals Corp

<div> Short-term Investments Short-term investments consist of certificates of deposit with original maturities ranging from 3 months to 1 year. </div>

<div> The following table summarizes the activity of the Company’s stock option plan for the period from January 1, 2015 to September 30, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price Per Share</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,000,264</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.39</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">390,164</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.55</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(81,667</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.07</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at September 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,308,761</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.06</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.39 years</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Exercisable at September 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,376,045</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.33</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.00 years</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

390164

0.0147

0.41

<div> Stock-based Compensation The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers and non-employee directors, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.” Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the requisite service period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. </div>

2015-09-30

0.0243

<div> 6. Stockholders’ Equity The Company currently has authorized for issuance 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. Series A-1 Preferred Stock As of September 30, 2015, the Company had authorized for issuance a total of 10,000 shares of Series A-1 convertible preferred stock (“Series A-1 Preferred Stock”), $0.0001 par value per share. There were no shares of Series A-1 Preferred Stock outstanding at September 30, 2015. As described in Note 8, on November 6, 2015, the Company filed a Certificate Eliminating the Series A-1 Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, in order to eliminate from the Charter all matters set forth in the Charter, including the related certificates of designation and increase, relating to the Series A-1 Preferred Stock. Dividends On May 22, 2015, the Company entered into the Acceleration and Conversion Agreement with TCP pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A-1 Preferred Shares outstanding after such date. There were no dividends paid on the Series A-1 Preferred Stock during the three months ended September 30, 2015, as all outstanding shares of Series A-1 Preferred Stock were converted into common stock on May 27, 2015. The Company paid dividends in additional shares of Series A-1 Preferred Stock of 57 shares for the three months ended September 30, 2014. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A-1 Preferred Stock dividends was $279,000 for the three months ended September 30, 2014. The Company paid dividends in additional shares of Series A-1 Preferred Stock of 21 and 209 shares for the nine months ended September 30, 2015 and 2014, respectively. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A-1 Preferred Stock dividends was $37,000 and $1,612,000 for the nine months ended September 30, 2015 and 2014, respectively. Conversion There were no conversions of the Series A-1 Preferred Stock during the three months ended September 30, 2015, as all remaining outstanding shares of Series A-1 Preferred Stock were converted into common stock on May 27, 2015. During the three months ended September 30, 2014, 2,557 shares of Series A-1 Preferred Stock were converted into 6,232,862 shares of common stock. During the nine months ended September 30, 2015, 3,599 shares of Series A-1 Preferred Stock were converted into 8,772,903 shares of common stock and during the nine months ended September 30, 2014, 3,416 shares of Series A-1 Preferred Stock were converted into 8,326,721 shares of common stock. Common Stock Hapten License Agreement On December 17, 2014, the Company entered into an assignment and exclusive license agreement, (the “Hapten Assignment and License Agreement”) with Hapten Pharmaceuticals, LLC (“Hapten”) under which Hapten agreed, effective at a closing that occurred on February 4, 2015, to sell and assign to us certain patent rights and related assets and rights, including an investigational new drug application and clinical data, for Hapten’s Samcyprone™ products for therapeutic and prophylactic use. Upon the closing of the Hapten Assignment and License Agreement on February 4, 2015, the Company paid to Hapten a one-time upfront cash payment of $100,000 and issued 200,000 shares of common stock, the fair value of which was determined using the quoted market price of the Company’s common stock on the date of issuance. Accordingly, the cash payment of $100,000 and the fair value of the common stock of $228,000 were recorded as research and development expense during the quarter ended March 31, 2015.   Lincoln Park Capital Equity Line During the nine months ended September 30, 2015, the Company sold a total of 50,000 shares of common stock for net proceeds of approximately $64,000 to Lincoln Park Capital Fund, LLC (“LPC”) pursuant to and subject to the limitations and conditions set forth in that certain purchase agreement (the “LPC Purchase Agreement”) between the Company and LPC dated December 18, 2014. There were no sales made under the LPC Purchase Agreement during the three months ended September 30, 2015. Per the terms of the public offering (see below), the Company cannot access the equity line until the expiration of the 13-month Overallotment Purchase Rights (defined below). June 2015 Public Offering On June 2, 2015, the Company sold a total of 26,000,000 units at a price of $0.40 per unit in a public offering (the “Offering”). Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the “Overallotment Purchase Rights”) and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the “Warrants”). As a result of the Offering, the Company received gross proceeds of approximately $10,400,000 and net proceeds of approximately $9,200,000 after placement agent fees and estimated Offering expenses, and assuming the Overallotment Purchase Rights and Warrants are not exercised. The Company first assessed the Overallotment Purchase Rights and the Warrants under FASB ASC Topic 480 (“ASC 480”), “Distinguishing Liabilities and Equity” and determined that the Overallotment Purchase Rights and the Warrants were outside the scope of ASC 480. The Company next assessed the Overallotment Purchase Rights and Warrants under FASB ASC Topic 815 (“ASC 815”), “Derivatives and Hedging.” Under the related guidance, a reporting entity shall not consider a contract to be a derivative instrument if the contract is both (1) indexed to the entity’s own stock and (2) classified in stockholders’ equity. The Company determined that the warrant contracts are indexed to the Company’s stock, as the agreements do not contain any exercise contingencies and the warrants’ settlement amount equals the difference between the fair value of the Company’s common stock price and the warrant contract strike price, and the only variables which could affect the settlement amount would be inputs to the fair value for a fixed-for-fixed option on equity shares. The Company also assessed the classification in stockholders’ equity and determined the warrant contracts meet all of the criteria for classification as equity under ASC 815. Based on this analysis, the Company determined that the Overallotment Purchase Rights and the Warrants should be classified as equity. No warrants were exercised during the three months ended September 30, 2015. During the nine months ended September 30, 2015, 35,000 warrants were exercised for gross proceeds of $16,000. Refer to the Series A Preferred Stock and Series A-1 Preferred Stock conversions described above in this Note and Note 5 for shares issued as a result of the conversions of Series A and Series A-1 Preferred Stock during the three and nine months ended September 30, 2015 and 2014, respectively. </div>

<div> Uses of Estimates in Preparation of Financial Statements The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. </div>

0.8943

<div> Cash and Cash Equivalents The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit. </div>

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> 7. Stock-based Compensation <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Stock-based Compensation <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2015 and 2014, the following assumptions were used: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="46%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> For the Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"> For the Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.82 – 2.43%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.52 %</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.47 – 2.43%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.60 – 2.73%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> 85.29 – 116.81%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">103.47%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> 85.29 – 116.81%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> 97.91 – 107.01%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Weighted average expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">107.49%</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">103.47%</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">89.43%</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">101.50%</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Expected lives (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.25 – 10.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.20 – 10.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.20 – 10.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The weighted average fair value of options granted during the three month periods ended September 30, 2015 and 2014 was $0.44 and $2.71, respectively. The weighted average fair value of options granted during the nine month periods ended September 30, 2015 and 2014 was $0.41 and $2.46, respectively. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the volatility of a composition of comparable companies. The expected life assumption for employee grants was based upon the simplified method provided for under ASC 718 and the expected life assumption for non-employees was based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends. <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The following table summarizes the activity of the Company’s stock option plan for the period from January 1, 2015 to September 30, 2015: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Total Number of Shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price Per Share</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Balance at January 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,000,264</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.39</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">390,164</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.55</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Cancelled </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(81,667</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.07</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Balance at September 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,308,761</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.06</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.39 years</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Exercisable at September 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,376,045</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.33</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.00 years</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Stock-based compensation expense for the three months ended September 30, 2015 and 2014 was approximately $385,000 and $454,000, respectively. Of this, the Company recognized approximately $3,100 and $24,000 of expense related to non-employee stock options for the same respective periods. <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Stock-based compensation expense for the nine months ended September 30, 2015 and 2014 was approximately $1,243,000 and $1,402,000 respectively. Of this, the Company recognized approximately $18,700 of income and $71,000 of expense related to non-employee stock options for the same respective periods. </div>

<div> Net Loss per Share The Company accounts for and discloses net loss per share attributable to common stockholders in accordance with FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares. </div>

RXII

0.8529

44451927

<div> The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2015 and 2014, the following assumptions were used:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="46%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> For the Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> For the Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.82 – 2.43%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.52 %</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.47 – 2.43%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.60 – 2.73%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> 85.29 – 116.81%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right">103.47%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> 85.29 – 116.81%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> 97.91 – 107.01%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted average expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">107.49%</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">103.47%</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">89.43%</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">101.50%</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected lives (in years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.25 – 10.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.20 – 10.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.20 – 10.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00%</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.00%</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> 3. Net Loss per Share Attributable to Common Stockholders The following table sets forth the potential common shares excluded from the calculation of net loss per common share attributable to common stockholders because their inclusion would be anti-dilutive:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="74%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">September 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Options to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,308,761</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,987,264</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Common stock underlying Series A and Series A-1 convertible preferred stock </td> <td valign="bottom">  </td> <td nowrap="nowrap" valign="bottom"> </td> <td nowrap="nowrap" valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,743,495</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Warrants to purchase common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25,969,615</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,615</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,278,376</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,735,374</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 8. Subsequent Events Subsequent to September 30, 2015, 400,000 Overallotment Purchase Rights were exercised for gross proceeds of $182,000. On November 6, 2015, the Company filed a Certificate Eliminating the Series A Convertible Preferred Stock from the Certificate of Incorporation of the Company and a Certificate Eliminating the Series A-1 Convertible Preferred Stock from the Certificate of Incorporation of the Company (together, the “Certificates of Elimination”) with the Secretary of State of the State of Delaware, in order to eliminate from the Charter all matters set forth in the Charter, including the related certificates of designation and increase, relating to the previously issued series of preferred stock of the Company. As a result, the 15,000 shares of unissued Series A Preferred Stock and 10,000 shares of unissued Series A-1 Preferred Stock were returned to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series or preferences or rights. The foregoing summary of the Certificates of Elimination is qualified in its entirety by reference to the full text of the Certificates of Elimination, which are attached hereto as Exhibits 3.1 and 3.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference. </div>

39000

-7607000

-7816000

10000

34000

-10000

-7615000

-2000

8000

2000000

8000000

209000

1243000

126000

31000

-47000

-4461000

7649000

-8039000

228000

9313000

16000

5202000

9266000

441000

2447000

6814000

-63000

60000

<div> 5. Convertible Preferred Stock As of September 30, 2015, the Company had authorized for issuance a total of 15,000 shares of Series A convertible preferred stock (“Series A Preferred Stock”), $0.0001 par value per share. There were no shares of Series A Preferred Stock outstanding at September 30, 2015. As described in Note 8, on November 6, 2015, the Company filed a Certificate Eliminating the Series A Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, in order to eliminate from the Amended and Restated Certificate of Incorporation of the Company, as amended (the “Charter”) all matters set forth in the Charter, including the related certificate of designation, relating to the Series A Preferred Stock. Dividends On May 22, 2015, the Company entered into an agreement (the “Acceleration and Conversion Agreement”) with Tang Capital Partners, L.P. (“TCP”) pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A Preferred Shares outstanding after such date. There were no dividends paid on the Series A Preferred Stock during the three months ended September 30, 2015, as all outstanding shares of Series A Preferred Stock were converted into common stock on May 27, 2015. The Company paid dividends in additional shares of Series A Preferred Stock of 87 shares for the three months ended September 30, 2014. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A Preferred Stock dividends was $421,000 for the three months ended September 30, 2014. The Company paid dividends in additional shares of Series A Preferred Stock of 105 and 268 shares for the nine months ended September 30, 2015 and 2014, respectively. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A Preferred Stock dividends was $172,000 and $2,056,000 for the nine months ended September 30, 2015 and 2014, respectively. Conversion   There were no conversions of the Series A Preferred Stock during the three months ended September 30, 2015, as all remaining outstanding shares of Series A Preferred Stock were converted into common stock on May 27, 2015. During the three months ended September 30, 2014, there were no shares of Series A Preferred Stock converted into shares of common stock. During the nine months ended September 30, 2015, 3,215 shares of Series A Preferred Stock were converted into 7,837,400 shares of common stock and during the nine months ended September 30, 2014, 166 shares of Series A Preferred Stock were converted into 405,720 shares of common stock. </div> -18700

50000

64000

On May 22, 2015, the Company entered into an agreement (the “Acceleration and Conversion Agreement”) with Tang Capital Partners, L.P. (“TCP”) pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A Preferred Shares outstanding after the completion of the Acceleration and Conversion Agreement.

691000

552000

3308761

25969615

P10Y

P5Y2M12D

3599

37000

2015-05-27

8772903

105

3215

172000

2015-05-27

7837400

3 months to 1 year

Three months or less

228000

100000

P10Y

0.0252

-0.17

1.0347

0.0000

2.71

1.0347

17494109

-2206000

-2906000

4000

16000

-2209000

-1000

3000

700000

454000

2225000

1459000

766000

24000

238000

216000

2557

279000

6232862

421000

-0.04

1.1681

0.0000

0.0182

0.44

0.0243

1.0749

0.8529

64949121

-2496000

8000

-2504000

8000

385000

2504000

1734000

770000

3100

211000

174000

P10Y

P6Y3M

0001533040 us-gaap:SeriesAPreferredStockMember 2015-07-01 2015-09-30 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember 2015-07-01 2015-09-30 0001533040 us-gaap:MinimumMember 2015-07-01 2015-09-30 0001533040 us-gaap:MaximumMember 2015-07-01 2015-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001533040 rxii:LpcMember us-gaap:CommonStockMember 2015-07-01 2015-09-30 0001533040 2015-07-01 2015-09-30 0001533040 us-gaap:SeriesAPreferredStockMember 2014-07-01 2014-09-30 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2014-07-01 2014-09-30 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember 2014-07-01 2014-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0001533040 2014-07-01 2014-09-30 0001533040 rxii:HaptenPharmaceuticalsMember 2015-01-01 2015-03-31 0001533040 us-gaap:CashAndCashEquivalentsMember 2015-01-01 2015-09-30 0001533040 us-gaap:MoneyMarketFundsMember 2015-01-01 2015-09-30 0001533040 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001533040 us-gaap:SeriesAPreferredStockMember 2015-01-01 2015-09-30 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember 2015-01-01 2015-09-30 0001533040 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001533040 us-gaap:MaximumMember 2015-01-01 2015-09-30 0001533040 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001533040 us-gaap:StockCompensationPlanMember 2015-01-01 2015-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001533040 rxii:TangCapitalPartnersLpMember 2015-01-01 2015-09-30 0001533040 rxii:LpcMember us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001533040 2015-01-01 2015-09-30 0001533040 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2014-01-01 2014-09-30 0001533040 us-gaap:SeriesAPreferredStockMember 2014-01-01 2014-09-30 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2014-01-01 2014-09-30 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember 2014-01-01 2014-09-30 0001533040 us-gaap:MinimumMember 2014-01-01 2014-09-30 0001533040 us-gaap:MaximumMember 2014-01-01 2014-09-30 0001533040 us-gaap:ConvertiblePreferredStockMember 2014-01-01 2014-09-30 0001533040 us-gaap:WarrantMember 2014-01-01 2014-09-30 0001533040 us-gaap:StockCompensationPlanMember 2014-01-01 2014-09-30 0001533040 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0001533040 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0001533040 2014-01-01 2014-09-30 0001533040 rxii:OverAllotmentPurchaseRightMember us-gaap:SubsequentEventMember 2015-10-01 2015-10-01 0001533040 2015-06-02 2015-06-02 0001533040 rxii:HaptenPharmaceuticalsMember us-gaap:CommonStockMember 2015-02-04 2015-02-04 0001533040 rxii:HaptenPharmaceuticalsMember 2015-02-04 2015-02-04 0001533040 us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001533040 us-gaap:SeriesAPreferredStockMember 2014-12-31 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember 2014-12-31 0001533040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001533040 2014-12-31 0001533040 2013-12-31 0001533040 us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001533040 us-gaap:SeriesAPreferredStockMember 2015-09-30 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember 2015-09-30 0001533040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001533040 2015-09-30 0001533040 2014-09-30 0001533040 rxii:OverAllotmentPurchaseRightMember 2015-06-02 0001533040 us-gaap:WarrantMember 2015-06-02 0001533040 2015-06-02 0001533040 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2015-11-12 0001533040 us-gaap:NonredeemableConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2015-11-12 0001533040 2015-11-06 shares iso4217:USD shares iso4217:USD pure Non-cash stock-based compensation expenses included in operating expenses are as follows: Research and development $ 204 $ 206 $ 378 $ 416 General and administrative 244 251 481 532

Stock-based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant date fair value per share of options granted	$ 0.44	$ 2.71	$ 0.41	$ 2.46
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Stock-based compensation expense	$ 385,000	$ 454,000	$ 1,243,000	$ 1,402,000
Nonemployee share based compensation expense (income)	$ 3,100	$ 24,000	$ (18,700)	$ 71,000

EX-101.SCH 7 rxii-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Statements of Operations (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Nature of Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Net Loss per Share Attributable to Common Stockholders link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Convertible Preferred Stock link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Stockholder's Equity link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stock-based Compensation link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Nature of Business and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Stock-based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Common Shares Excluded from Calculation of Net Loss per Common Share Attributable to Common Stockholders (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Fair Value Measurements - Fair Value Measurements (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Convertible Preferred Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Stockholder's Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Determine Fair Value of Option Grants (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Stock-based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Stock-based Compensation - Summary of Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 rxii-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 rxii-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 rxii-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses and other current liabilities Additional Paid in Capital Additional paid-in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allocated Share-based Compensation Expense Non-cash stock-based compensation expenses Amendment Flag Amendment Flag Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total amount of anti-dilutive securities excluded from computation of earnings per share Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Assets, Fair Value Disclosure Total Assets, Fair Value Disclosure [Abstract] Assets: Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at the end of period Cash and cash equivalents at the beginning of period Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Cash and Cash Equivalents [Member] Cash and Cash Equivalents [Member] Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash investing and financing activities: Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Class of Warrant or Right, Exercise Price of Warrants or Rights Sale of stock, price per share Commitments and Contingencies Commitments and contingencies Common Stock [Member] Common Stock [Member] Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $0.0001 par value, 100,000,000 shares authorized; 64,949,121 and 21,984,272 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Conversion of Stock, Amount Converted Conversion of Series A and Series A-1 convertible preferred stock into common stock Conversion of Stock, Shares Converted Conversion of preferred stock into common shares Conversions of preferred stock into common shares Convertible Preferred Stock [Member] Common Stock Underlying Series A and Series A-1 Convertible Preferred Stock [Member] Current Fiscal Year End Date Current Fiscal Year End Date Deferred Revenue, Current Deferred revenue Depreciation, Depletion and Amortization Depreciation and amortization Description Of Business And Basis Of Presentation [Line Items] Description Of Business And Basis Of Presentation [Line Items] Description of Business and Basis of Presentation [Line Items] Description Of Business And Basis Of Presentation [Table] Description Of Business And Basis Of Presentation [Table] Description Of Business And Basis Of Presentation [Table] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-based Compensation Dividends, Preferred Stock Series A and Series A-1 convertible preferred stock dividends Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Net loss per common share applicable to common stockholders: Earnings Per Share, Basic and Diluted Basic and diluted Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Attributable to Common Stockholders Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value Measurements Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value, Inputs, Level 2 [Member] Other Significant Observable Inputs (Level 2) [Member] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Gain on disposal of equipment General and Administrative Expense General and administrative General and Administrative Expense [Member] General and Administrative [Member] The gross cash inflow from issuance of common stock of the company. Gross Proceeds From Issuance Of Common Stock Gross proceeds from public offering Hapten pharmaceuticals. Hapten Pharmaceuticals [Member] Hapten Pharmaceuticals, LLC [Member] Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses and other current liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Interest Income (Expense), Nonoperating, Net Interest income, net Investment, Policy [Policy Text Block] Short-term Investments Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Legal Entity [Axis] Legal Entity [Axis] Liabilities and Equity Total liabilities, convertible preferred stock and stockholders' equity Liabilities and Equity [Abstract] LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Lpc [Member] Lpc [Member] Lincoln Park Capital Fund, LLC [Member] Maturities of Time Deposits, Description Liquid instrument maturity period Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Money Market Funds [Member] Short-term Investments [Member] Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Income (Loss) Attributable to Parent Net loss Net loss Net Income (Loss) Available to Common Stockholders, Basic Net loss applicable to common stockholders New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Recent Accounting Pronouncements The aggregate amount of noncash, equity-based nonemployee remuneration. This may include the value of stock or unit options and amortization of restricted stock or units. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Nonemployee Share Based Compensation Expense Income Nonemployee share based compensation expense (income) Nonoperating Income (Expense) Total other income Nonoperating Income (Expense) [Abstract] Other income Nonredeemable Convertible Preferred Stock [Member] Series A-1 Convertible Preferred Stock [Member] Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Operating loss Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Nature of Business and Basis of Presentation Other Assets, Noncurrent Other assets Other Nonoperating Income (Expense) Other income (expense), net Upon payment of a specified amount, the holder has the right to purchase shares of common stock in accordance with the terms of the security instrument. Over Allotment Purchase Right [Member] Overallotment Purchase Rights [Member] Payments to Acquire Property, Plant, and Equipment Cash paid for purchase of property and equipment Payments to Acquire Short-term Investments Purchase of short-term investments Acceleration of the preferred stock dividend payment date from June 30th to May 27th. Preferred Stock Dividend Payment Date Preferred stock, accelerated dividend payment date Preferred Stock, Dividend Payment Terms Dividend payment terms Preferred Stock Dividends, Income Statement Impact Fair value of Series A and Series A-1 convertible preferred stock dividends Fair value of Series A and Series A-1 Preferred Stock dividends Series A and Series A-1 convertible preferred stock dividends Preferred Stock Dividends, Shares Dividends issued on Preferred Stock Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Series A-1 Preferred Stock, shares issued Preferred Stock, Shares Outstanding Series A-1 Preferred Stock, shares outstanding Preferred Stock, Value, Issued Preferred stock Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Proceeds from Issuance of Common Stock Net proceeds from the issuance of common stock Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options Proceeds from the issuance of common stock in connection with the employee stock purchase plan Proceeds from Sale, Maturity and Collection of Investments Maturities of short-term investments Proceeds from Sale of Property, Plant, and Equipment Proceeds from disposal of property and equipment Proceeds from Warrant Exercises Proceeds from the issuance of common stock upon the exercise of warrants Gross proceeds from purchase rights exercised Gross proceeds from warrants exercised Property, Plant and Equipment, Net Property and equipment, net Range [Axis] Range [Axis] Range [Domain] Range [Domain] Reclassifications of Temporary to Permanent Equity Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock Research and Development Asset Acquired Other than Through Business Combination, Written-off Fair value of common stock issued in exchange for patent and technology rights Research and development expenses Research and Development Expense Research and development Research and Development Expense [Member] Research and Development [Member] Research and development expense during the period related to the costs associated with the acquisition of a patent and related assets from a third party other than through a business combination. Research And Development Expense Patent License License fee Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses Restricted Cash and Cash Equivalents Restricted cash Retained Earnings (Accumulated Deficit) Accumulated deficit Revenue from Grants Revenue Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Description of unit transaction which may include details of the offering (IPO, private placement), a description of the stock sold, units issued, conversion and price per unit. Sale Of Unit Description Of Transaction Description of transaction Number of units issued or sold by the company per stock transaction. Sale Of Unit Number of Shares Units issued, shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Common Shares Excluded from the Calculation of Net Loss per Common Share Attributable to Common Stockholders Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Stock Option Activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Assumptions Used to Determine Fair Value of Option Grants Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Series A Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Share-based Compensation Non-cash stock-based compensation Stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected lives (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, Maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Weighted average expected volatility Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Total Number of Shares, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Total Number of Shares, Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Total Number of Shares, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value per share of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Total Number of Shares, Ending Balance Total Number of Shares, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Ending Balance Weighted-Average Exercise Price Per Share, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term, Ending Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Cancelled Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Granted Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-based Compensation Shares Issued, Price Per Share Sale of units, price per unit Short-term Investments Short-term investments Class of Stock [Axis] Class of Stock [Axis] Equity Components [Axis] Equity Components [Axis] Statement [Line Items] Statement [Line Items] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] EX-101.PRE 11 rxii-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`&B,;$W-/B,M*4-REVD`5E$);Q7VXM4MB M>+;B2R!L-!J33%<>*C_TL4ZCK4 M12$RR'6V5F%)ZH,U7`0]&2RX]4]/XJ26\A?O`WS[?XVOA;TER/. MM;G^:>B-Z$ASZA$2)^5@2')<(LEQA23'-9(<8R0Y;I#DN$62XPY)#CK"$@0+ M42D6I%(L3*58H$JQ4)5BP2K%PE6*!:P4"UD9%K(R+&1E6,C*L)"582$KPT)6 MAH6L[).LI/D3:_8.4$L#!!0````(`&B,;$=(=07NQ0```"L"```+````7W)E M;',O+G)E;'.MDLMNPD`,17\EFGUQ2B46$6'%AAU"_(`[XSR4S'CD,2+]^X[8 M@,)#K<32KWN/KKP.J:P.-*+V'%+7QU1,?@RIROW:=*JQ`DBV(X]IP9%"GC8L M'C67TD)$.V!+L"S+%4EK0VTPAGEN&;>5ADZ3SX MB?078VZ:WM*6[13@2=&AXD7U(V8# M$NTIO8+Z>@"%,;X[)9J4@B,WHX*[O]C\`E!+`P04````"`!HC&Q';;-OU%X! M``!^$0``&@```'AL+U]R96QS+W=OOI1#11>/>HCT74!@:?P__638MS[; M/\/:15"OS/&YY4TUL^Z7MIAM>A<8\/PZ$K3V_QJ M2S&<92OCIG/2X_[G[.1\.:3N?*$T>;&NE'!(WSIW]95(\&:\T6S88%B^]_*? M[;NBJ',Y=?EK(VWXH\)\;9":>!#'@Q@2-(\'S2%!BWC0`A*TC`-`* M$K2.!ZTA09MXT`82M(T';2%!E"DR9I@D#6N,UJ1P31BO20&;,&*30C9AS"8% M;<*H30K;A'&;%+@)(SK.C-&+U9T9M!9VWML(W1FQ6]&:,W M*WHS1F]6]&:,WJSHS1B]6=&;,7KS1&]?62>7Y^#JMO2/KODV7"V:X.W#_2:/ M3QFGJI_8$ZW#L).8\?IP%,>IGR'FUZ^6XP=02P,$%`````@`:(QL1[0[L!!^ M`@``K@@``!````!D;V-0&ULO59-4]LP$/TK&E_*)3BD+9UF M@F=""-/.0&&:0,^*O(XUR)+1RAGHK^]*!M"J5Q3,Z3*'>N', M#8?',3PXT"FD@[()&B43GV5:EDH*[J31R:44UJ#)')L_"%"3^"4@,"CR`D1E MI7M,AC6F[0J8A>`*9I0KR;A"J%%_G0$S,T7)]6-7W-I,9ELW'@#PAG[-*:-VW=*J1%^Z'B[I/HP8BN.X,V3:,.MY-I%#.5O M>AQ%==K:&VQ5HK/)+V/O,`=P.(D;9S#;V+8M/R6C+P%!UC8R;CI+GF3;ZMM[ MEM(IP*OLFEOWGZ0(/35"?(E:W3^'8%RG;*X=K2/[KNM4-+RV)(TU,_1>:(24 MG7+%M0"V"/JQ@QO-JW0/SL=_=5B@U(`8%3SE*S^WD_`3AE9X*82I26J\9S4N3+4+.[CS@V(6AZ%0_ M"^\KFSIGY:IR?*6@DW-.R\9NN:J`70)'JC.TM*OWC;_<*!95`QE8&W0PXJX3 M'TYRHU*P'Y#-[RM:F-W`@=_!E/EKBP3>O5&+:H5P7WEUYIN=M;ZI^5'W;-_4 M[^BXCW[L8.DE[ZYM5[M/I#WZ^=J_G]&P5S\#%D[Z[@7QIN_>#0].4[E[\KMT M&[`%77]].3Y7[SQ54;QO*UO-<,5>?2[:]_Z+6S[>_G>2_`%02P,$%`````@` M:(QL1\MH73\^`0``:0,``!$```!D;V-0OXZ10 M7B@7X#$X#P$-Q(M]7=DHE)]G&T0O&(MJ`[6,HU1A4W+E0BTQA6'-O%1;N08V M&8^O6`THM43)#L#<]\2L++02*H!$%SJ\5CW>[T)%,*T85%"#Q"7;X?)OOD;#-?=$/_6\621A'^_1S80 MRY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ M4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1 M;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2/'K^!?F< M-0HACA*FNVB<5@$_9Y> MPTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ?JH M,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0]H=*W-R-] M9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9W MH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y M?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD M+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=<7^/1DN/; MIF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U# MKG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J*@!&K8KZZ MKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*M MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQ MF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0````(`&B,;$?Q79446P(``'0+ M```-````>&PO56E+\-,=8@891 M7D5PKE3YS?.J=(X9JD:BQ%ROY$(RI/14%EY52HRRR@0QZHU]?^(Q1#B,0UZS M*5,52$7-502_=A!P\?)NB)_;A0L(',>/ M+(+!Y`IZ;R<=^?K9RFQ7!_23/>E?(Q]07^^K_%7A`_(;0^ZUYQ^'N>#]-8RA M`^*P>@$+1+5_8-Q3084$2M^S5F$1CAAV'O>(DD02`^:($;IT\-@`MC1:/T:X MD#:WRS#,,_+[3+)((NBWS]O3)3V['DX`P[L0Z:BG:VBS[80A^':,4*YD*2%^UO"B'5 M`)80++!4)%U'_DI4SG"CV@KVFGR;PD.W_)Z:CG]JO1I=@A]]/`IZ:.(NWF5*5=WOZG M,J_M66N-<:,M=BA(:D(5X2L)R/S(/!C9=*-C]2U1R*+) M,IRCFJI'LA#*+D:PMW\:^<&D\YIU%!'L[5\X(S6[M0KZ_^SX'U!+`P04```` M"`!HC&Q'1K!L@#T#```C"@``#P```'AL+W=OFL>6GDQ$ M">>Z]#4HURK:[5[+@.1.:&6GHK'9DF8_0[.-`5[9*8"KY0)6PR![D1F3W+IA)1Q4@ZR#MWH.*P^,;TZ]D.&FV^YFK0![F^JM M8:6N8`&[GPK[9_DB8Q5,N)?N'H-]&W>0Y46G*'H+1OCL0<#<4F!XP'CIQ`SN M^7B0M3/&O=,70CHPY]S!#Z-](]0CLC(V$<:Z49AN_+(62M3B-<2-=W:JYS^U M$:]:.2Y'I=%2QE[A1>R$(]C_3S!&)\J5#QT?WX5*#+)>&X$S8<582.'^#K+8 MEA!FTOHPE9C^]Q93,3EO)69<56RH'%+8I5H4#U,38L"/+ZLXL.D+;)C+*E^D MBH+.M*I`6:C8*9==<3ME%Y*`>@346P==<^<-A*ZGW@H%UL;Z MG7(K`I"`]@EH?QUT!V4H_DE9:H_%5X_LUFB%[3)&1T`'!'20B`A;OS3&@3G! M@G&,[L0Y(\8>;44AWT&'!'2X#KK@PK`'+CVP*^`6IQG31$5L4Q/;R33/PJK! M<7$Z,`%C8LIU^40Q*T(GC(X=IEI68+Y9-GSVN#9H?^IQGA`Y]M\=\U#O,UWC MMFC7UA15.$\X//)C"\\^U&@X^Y@'JFV>\':K)3GU-J?BY@ESMY8W[U$453=/ MN+NAP&SG/HBR,D$J;YZP=U.&ERR*HOKF*7^WYNJ0HJC`><+@K;DJVG0GI"87 M"9,WY6J7Q3<416TNTOOSID6!N!.*6MF@-XG]86$$1H4_YU6_"^IWD?)[4P5W MV0C/$Q1%;2\2MF]!A<@HBMI>)&S?%I6O:XJBMA<)V]<6,$D4ERL5I+87^\M? M^/M?&P\NZ&45SC0V#H.'@C(<=/"RV(\ZW>!FN+_"P\\@"R<4/(QX*<_PV8WZ MI7G\CR_(;T>;XW]02P,$%`````@`:(QL1]6,#!Y2`@``]`<``!@```!X;"]W M;W)KU5A]N]`2MKN?.CW`Q_%+1=J`&0I&'R7HB(U+VCM,7+=^7NX/<)(2;3B M=T%:;KU[*OD3I9^J\_.R\P.5`RG)6:@06#8/F?\*<'&GYI[B(7&8;^-Z%7/&]%!^T?2/='&(5\$Q+KI_>^6/9JW1[T],O;(LL?C_(SB8"N2>4#L`&++OIH$V(KU/"!Q`(EE MWTP";`4,Y@DKA["R_7",B`W"2&JSS0&,YR%K![*V(M7_N+;[O5 M(N@]J$)MVSY%UAW>5*J*HL_45?X])?VHV0?B\VOV+T.[G?V7K%&I+G[EN_;8 MN0T6WD[MLW/1_M"7KVKJ0?0)M[IHAE]O>VY:75Y#%EZ9O8_'O!J.E_$?&4QA M=`!,`7`+8/R?`>$4$%H!_NALZ.MSUF;K9:TO7G/*^J?-'CMYW2?I,GO-D*T> MAZOKK.GNOJV!+_VW/L\D@4&R,224(C44XB;QN_JD";B:&"^?`,=']^/#:SP? MXT,<'YL6X[&)45(-$AZ$@A*E6"1YXN"$6TXX=B+-(F)TPE$1$5"2=$8RZT)8 M+@1VD9`N!&XU"!R*1%:1"!4)R3XV$1[T$,A>#0V'^SYBRT>,?3#21XQJ,!`L M)IU@E4RDO&]%6E8DMD*VNY'82D0/B:&1X7T?B>4CP3Y"TD=BU"!MS$AF7;#` MLM%3],,')WU,FNNSB1+ZV1BRA,G$PB%Y*AM&`8:XYR<"JFI"@*'=Y#9W&,8?"$]GQC&&H\=JMA< M8QAL84*"G@GC#8MHTINJ$$W.>31\VN1A&%Y]!!@83^1*FAL1A/,!&%V!T<4'Z M`,RD2`A&RE)#QF7@,O.!V7XPNSA-GDDS%OHD.)?DIS\U=3R2TF6$;!8"9B&G M^0,8T0.=>P%&&#Z")>Y).U>Y7_R"VQN0'*77RD8 M"QH1VTL:'^V<3ME!?<_J0UXUWHMNNTW8L&/::]VJ+E?PT(W?L=L,H,U+F@(``#D+```8 M````>&PO=V]R:W-H965T&ULG9;=CILP$(5?!?$``1LP$!&D MAJIJ+RJM]J*]=A(GH`5,L1.V;U\;2-9QS4^;BX"=<-UO'8<><5)AM:$-J\'-:T!)]Z4U4ZT'614^&BMM.D MGWMITX1>>5G4Y*6UV+6JBTO.Y823)L[#=RHJ4K."UE9+ MSCO[$]AF()227O&C(!U3[BT)?Z#T30Z^G7:V*QE(28Y'WX5K4_;4;?D%HM)D-<#3`AP'XLP9O-'B:P1G(^G5]QARG M24L[BS58/FVP%?)6!A&1+=9':X=RB94Q,7M+`R]Q;C+.*(&]9*]*H$F1/2F" MA\01^8T0\`[A#Q!0A?"?4T0#Q""I>XF[<5T7F&39C&R2QM-H/)4F>$X3##2> MD@:XP\8"S2LGF9#& MA%2FR,B$E$S(C_T80&!$4H40Q)$/0[A,%&I$H4H4&XG"M43A?Q%%&E&D$/GQ MLC_6_+'B1ZYQ%\;K=N&,;)(&N!J.[-$?/,;"[4?-N+V"J4TX(YOF`3J/V@41 M-/,`=>5F%E42`+`&1>^G0&VHR#.CP&44^.\H>C,%3]UTQ:X%>O,#_O+;`:QL M?W.Z:2*]`8)@^0T!_FILYA)/RZ9Y].8'U.Z'?#,/6G[P>"C3Z0,``#`1```8 M````>&PO=V]R:W-H965T&ULC9A-DYLX$(;_"L4]`Q)"$BZ/ MJW8P5'+8JE0.FS-CRS850%[`X^R_7P$R(REMFSD,()YN]=OZ:.3U5;:_NI,0 MO?>[KIKNU3_U_7D5!-WN).JB>Y%GT:@W!]G61:\>VV/0G5M1[$>CN@IP&-*@ M+LK&WZS'MN_M9BTO?54VXGOK=9>Z+MK_WD0EKZ\^\F\-/\KCJ1\:@LTZF.WV M92V:KI2-UXK#J_\76N5X1$;BGU)<.^/>&X)_E_+7\/!M_^J'0PRB$KM^<%&H MRX=(154-GE3/_VJGGWT.AN;]S7L^RE7AOQ>=2&7UL]SW)Q5MZ'M[<2@N5?]# M7K\*K2$>'.YDU8W_O=VEZV5],_&]NO@]7@BF9(VIWA9]L5FW\NIUYV*8@&BE M\'9PHCQ[W>BMG490);M3K1\;2M?!Q^!'(WA$4@MA$)*9")J)0/4/!H%]NP=L MF&.H@ZU)4`[&\-1)?L?)W3"C6YC1E*O(M$^>VY.;/9GLB6'/0CM$-NF:"Q(S0V`UTPGM012DU[9RPFY,U"(DA%2LU<,%=J/"7, M@DB<0%!F0C$.,03E)D006C`_F".;F9H(*)L]D#W%D3(C#N9.$ZW:8MQEJT6; M#":$@:)M*%XPJ;DCFIN*8E`1-SN)0W@@+0ACT%/&+=T$'.W9A2!P'>0V$R_0@UT]9E%@X/AL-:-3C^!H+0;>82QF MP5)#D1NL68$XF))4,P^3;R+@)I0]]Y);""8+Y+CU$)D%D8-Y31&Q\DH2<#EN M'0R'\)YH8XR&\*YH8]3L]+ZZV%5G5E$.SHBM9F[QA."09C9U9Q?);2JB2[YP MD%NYD5F7.5R7$7T\)/I3QL$2=TCTYXR-,0Y_]>0VAD)$E\RXN4+?]C^S_O(E M'MQRA\QZQYV=.M$),BO0E_#%+0Z)3I"#(09AV1\8A[#9:_.I.,! M\B!E+Y30\$6-QTD4^_FA$H=^N&7#0$T'^NFAE^?;[Q/SCR2;_P%02P,$%``` M``@`:(QL1_H-5O@@`@``>`8``!@```!X;"]W;W)KK#[K.3.`'5QJSMA.[?KR^$.,C= M]`7CX9PS,P<\E#WC'Z+&6`:?E+1B&=92=@L`Q+[&%(DGUN%6/3DR3I%46WX" MHN,8'0R)$@"C*`<4-6U8E2;VQJN2G25I6OS&`W&F%/&_*TQ8OPSC\!IX;TZU MU`%0E6#D'1J*6]&P-N#XN`R?X\4VUP@#^-7@7CCW@:Y]Q]B'WOPX+,-(EX`) MWDNM@-1RP6M,B!92B?\,FK>4FNC>7]5?3+>J^AT2>,W([^8@:U5L%`8'?$1G M(M]9_XJ'%C(MN&=$F&NP/PO)Z)42!A1]VK5IS=K;)[-HH/D)<"#`D3#F\1.2 M@9#<".E_">E`2+^;(1L(V20#L+T;YS9(HJKDK`]$A_3G%"\4G&L1I1P(H\;M M"U'>"16]5+-9"2Y:9X!``UFYD+SP038N)!X10.7W%@'#^PS0H4-?@K6+R+UE M;AZ*;+\0^;+,Y%IF:KU*7*_FC_GIA)\Z_'ET7V)AG;"0UAI9I#[,VL7`./=A M-BXFRZ`/LW4Q>0(?]Y--^LG3T6XDZZYS M?OS95/\`4$L#!!0````(`&B,;$<"N6R[`00``*`2```8````>&PO=V]R:W-H M965T&ULC9A=CYLZ$(;_"LK]%F8,!E;92`M5U7-1J>K%.==L MXB2H@%,@FYY_7[Z2];@3Q3=)(.]XWC'V8^/U1;<_NZ-2O?>[KIKN977L^].S M[W?;HZJ+[I,^J6;X9Z_;NNB'R_;@=Z=6%;LIJ*Y\#`+IUT79K#;KZ=[W=K/6 MY[XJ&_6]];IS71?M_YFJ].5E!:OKC1_EX=B/-_S-VK_%[I_Z,M7M=00C0UN M==5-G][VW/6ZOH:LO+KX/7^7S?1]F?])@B6,#\`E`&\!MSQ\@%@"Q$?`U'7^ M[&RJZW/1%YMUJR]>=RK&IPW/@[P=&QE:]KJIM7;NKJ&R;KC[ODEQ[;^/[2P2 MG"29*8&;PA\:9S/@BH:C$ID031H41,J[ M(:+$84B9Q\]M!/JT[U2--O8T]%A(*`?)6S#U4*H!?O8@*TMCE`=A$0T(T/E&&!%5A*.]T M#I%)E"[]8Q,-"=&`)5J&)M&2\,XND:B&VE(7/S;XD(`/>/"AR;0PN+.*$54$ M+L-'V#LY0=#G,AF$C35!L`8\UH3)*[RWAA&5V\HB[,V<(%`#?M,BS(V:3/AA MD1.5B!('Z`L;D((`$GA`"D%ZAT<^$0GI]')J\U&0UTL+%LOKI2!X1,F)CDX]F-NM3<5#? MBO90-IWWIOM>U],9PE[K7@WN@D]#EQU5L;M=5&K?CS_CL2_G`Y3YHM>GZWG0 M[5!J\P=02P,$%`````@`:(QL1S7AH^&@`0``L0,``!@```!X;"]W;W)KWQI0HNJW7V)9R;GG#GC2SFA>;4]@"/O2FJ[I;USPX8Q6_>@N+W" M`;3_TZ)1W/G4=,P.!G@324JR/,M^,,6%IE49:X^F*G%T4FAX-,2.2G'SL0.) MTY:NZ%QX$EWO0H%5)5MXC5"@K4!-#+1;>K?:[(J`B(!G`9,]B4GPOD=\#B(293= M&69!,*]^L45.S^GY"3W_-WT]T]?)X?K,X7_T+V:!(@D4?QLQ87;GF.\NV M*C!=O#J6U#AJE[9TJ2ZW\RZ/9_(%K\J!=_"'FTYH2_;H_,G&8V@1'7@3V=4U M);U_/TLBH74AO/&Q256CG-"\ MV![`D5U#9=^8XD+3 MJHRU)U.5.#HI-#P98D>EN/EW!(G3@6[H4G@67>]"@54E6WF-4*"M0$T,M`=Z MN]D?BX"(@-\")GL1D^#]A/@2DH?F0+-@`234+BAPOYSA#J0,0K[QWUGSK64@ M7L:+^L\XK7=_XA;N4/X1C>N]V8R2!EH^2O>,TR^81]@%P1JEC5]2C]:A6BB4 M*/Z:5J'C.J4_NWRF?4S(9T*^$GYDT7AJ%&W><\>KTN!$[,##V6WV'FZ"B%V=*VNM_,V'B)[@U?E MP#MXY*83VI(3.G^R\1A:1`?>1':SHZ3W[V=-)+0NA-]];-*52HG#87D@ZRNM M_@-02P,$%`````@`:(QL1V@=1=NY4&!EP69>+11H*U`3`\V6/BTVNU5`1,`?`:.]B$GP?D`\AN17O:59 ML``2*A<4N%].L`.75(-UJ"8*)8J_IU7HN([ISWJBW2;D9T(^$QZS:#PU MBC:?N>-E87`DMN?A[!8;#S=!Q"L3&]5,FMX;M;YZ*A?Y?<%.0>B,293=%69& M,*]^LT5.K^GY!3W_GKZ;Q4Q-VL:<* M3!NOCB45#MJE+9VK\^U\RN.9?,#+HN&PO=V]R:W-H965T+F"@?HW9\&M>+6I;IE9M#`ZT!2DJ5)V/N4<$P"\!D]G$Q'L_(;[ZY*D^T,1;``F5]0K<+6>X`RF]D&O\-FM^M/3$ M;;RH/X1IG?L3-W"'\K>H;>?,)I34T/!1VA><'F$>X=H+5BA-^))J-!;50J%$ M\?>XBCZL4_R3Y3/M6UX6&B=B!N[/;K=W<.U%G#(Q M04W'Z9U1XZKG8%8$<^J?MDCI)3W=T-.OZ=E"SZ+#;-L] M2[X6R!>!/`KD_QLQ8HX7F.S?(=EF3Q7H-EP=0RH<>QNW=*VNM_,V#6?R`2^+ M@;?PD^M6](:J9A8')8'LK[2 M\B]02P,$%`````@`:(QL1Y9Y[,*A`0``L0,``!D```!X;"]W;W)K&ULA5/;;IPP$/T5RQ\0LT!Z6;%(V415^U`IRD/[[(4!K-@> M8ILE_?OZ`F2WBIH7/#.<<^:,+]6,YMD.`(Z\*JGM@0[.C7O&;#.`XO8&1]#^ M3X=&<>=3TS,[&N!M)"G)\BS[Q!07FM95K#V:NL+)2:'AT1`[*<7-GR-(G`]T M1]?"D^@'%PJLKMC&:X4";05J8J`[T+O=_E@&1`3\$C#;BY@$[R?$YY#\:`\T M"Q9`0N."`O?+&>Y!RB#D&[\LFF\M`_$R7M6_Q6F]^Q.W<(_RMVC=X,UFE+30 M\4FZ)YR_PS+";1!L4-KX))(?%E(TI_VG"+O94 M@>GCU;&DP4F[M*5;=;N==WD\DS=X78V\AY_<]$);0X?HP)O(;FXI M&?S[V1()G0OA9Q^;=*52XG!<'\CV2NN_4$L#!!0````(`&B,;$<&(4T4H@$` M`+$#```9````>&PO=V]R:W-H965T6CG-"\ MV![`D3U# MY_OC-B`BX+>`R5[$)'@_(;Z$Y&=SH%FP`!)J%Q2X7\[P`%(&(=_X==9\;QF( ME_&B_ABG]>Y/W,(#RC^B<;TWFU'20,M'Z9YQ^@'S"+L@6*.T\4OJT3I4"X42 MQ=_2*G19W[GA5&IR('7@XNWSOX2:(>&5B MHYI)TWNCUE?/5;[9E>P?5/6Q3TFEY+5L:3&4;NTI6MUO9WW13R3=WA5 M#KR#7]QT0EMR0N=/-AY#B^C`F\AN=I3T_OVLB836A?#.QR9=J90X')8'LK[2 MZA]02P,$%`````@`:(QL1^!IBN>C`0``L0,``!D```!X;"]W;W)K&ULA5/;;IPP$/T5RQ\0LRQITA6+E$U5)0^5HCRDSUX8P(KM MH;99TK^/+T!VJZAYP3/#.6?.^%).:%YM#^#(FY+:[FGOW+!CS-8]*&ZO<`#M M_[1H%'<^-1VS@P'>1)*2+,^R;TQQH6E5QMJ3J4H#\BOH;DL=G3 M+%@`";4+"MPO)[@'*8.0;_QGUOQH&8CG\:+^,T[KW1^YA7N4OT7C>F\VHZ2! MEH_2/>/T`/,(UT&P1FGCE]2C=:@6"B6*OZ55Z+A.Z<]-,=,^)^0S(5\)MUDT MGAI%FS^XXU5I<")VX.'L-CL/-T'$*Q,;U4R:WANUOGJJ-MO;DIV"T(Q)E,,% M9D4PK_YIBYQ>TO,S>OXU?;O0M\GA]L+A]Z\%BD6@2`+%_T9,F,,%ILC^:<+. M]E2!Z>+5L:3&4;NTI6MUO9UW>3R3#WA5#KR#7]QT0EMR1.=/-AY#B^C`F\BN MKBGI_?M9$PFM"^&-CTVZ4BEQ."P/9'VEU3M02P,$%`````@`:(QL1Y&4O">A M`0``L0,``!D```!X;"]W;W)K&ULC5/;;IPP$/T5 MRQ\0`TMZ6;%(V415^U`IRD/[[(4!K-@>8ILE_?OZ`F2WBMJ^X)GAG#-G?*EF M-,]V`'#D54EM#W1P;MPS9IL!%+Z7,]R#E$'(-WY9--]: M!N)EO*I_B=-Z]R=NX1[E3]&ZP9O-*&FAXY-T3SA_A66$VR#8H+3Q2YK).E0K MA1+%7],J=%SG]*?XO-#>)Q0+H=@(G[)H/#6*-A^XXW5E<"9VY.'L\KV'FR#B ME8F-:B9-[XU:7SW7>9E7[!R$%DRB'*\P&X)Y]7=;%/2:7ES0BW_3=RM]EQSN MKAS^AT"Y"I1)H/S;B`ESO,;L_FC"+O94@>GCU;&DP4F[M*5;=;N==T4\DS=X M78V\A^_<]$);0X?HP)O(;FXI&?S[V1()G0OA1Q^;=*52XG!<'\CV M2NO?4$L#!!0````(`&B,;$?C[*8^(@(``$L'```9````>&PO=V]R:W-H965T MMRI?\Z,4R35E%]BT7.,3L9$29PF21E3U'9179FU=UY7["I)V^%W#L254L3_ M[3%APRZ"T;CPT5X:J1?BNHHGWZFEN!,MZP#'YUWT#+=[F&F)4?QN\2!F8Z"+ M/S#VJ2<_3[LHT35@@H]21R#UN>$73(A.4N2_]]!OIC;.QV/ZJ]FN*O^`!'YA MY$][DHVJ-HG`"9_1E<@/-KSA^QX*'7AD1)A?<+P*R>AHB0!%7_;;=N8[V'^* MU=T6-J1W0SH9UHDIW(),F3^01'7%V0!$C_3AP:V2Q3<==-=8R][13(I8I0<1:>3:TYD]?6S/1GMF*\SF]'0!/Q\#)1]-6?182/WA,M.'L(?8YS#;-U MF..(BLT"3NISYO<5EDF8XXH6W$J8^1SG8I=IF..*,H\3SYH=Q?QB>KH`1W;M MI.UUT^KT;CRGIEE^R^NJ1Q?\"_%+VPEP8%*U7-,?SXQ)K*I(GM3-;=3+-DT( M/DL]7*DQM[W>3B3KQZ=K>C_K_U!+`P04````"`!HC&Q'JU9!-:,!``"Q`P`` M&0```'AL+W=OV$`*S9#;;.D?U]?@$`4*2]X9CCGS!E?\A'UJVD!+'E3 MLC-GVEK;GQ@S90N*FSOLH7-_:M2*6Y?JAIE>`Z\"24F6)LF1*2XZ6N2A]JR+ M'`*8[.A=>1--:7V!%SA9>)11T1F!'--1G^K`[73*/ M"(#?`D:SBHGW?D5\]9%K'(GIN3^[W5V/J3A3-[A1=[S!GYQ MW8C.D"M:=[+A&&I$"\Y$@I'7O9TDDU-:']R[6\4K%Q&(_/Y#EE1;_`5!+ M`P04````"`!HC&Q'`2RM#:*ED6H/>NRP-&*7L&S)F:4DNN_)Q`X'>F.+H67 MONVL+["R8"NO[B4HTZ,B&IHC?=@=3KE'!,#O'B:SB8GW?D9\]&P6; MW[GE9:%Q(F;@_NQV!P?77L0I$Q/4=)S>&36N>BEW^[N"7;S0C(F4TQ5F13"G M_FF+E%[3TPT]_9J>+?0L.LRVW;/D:X%\$3F MEI+.O9\U$=!8']ZY6,&ULC53;;J,P$/T5 MRQ]0$TB:-B)(35>KW8>5JCZTSPX,8-47UC:A^_?U!2A4D;HOV#,^Y\P9C4T^ M*/UF6@"+W@67YHA;:[L#(:9L05!SHSJ0[J166E#K0MT0TVF@52`)3M(DN26" M,HF+/.2>=)&KWG(FX4DCTPM!];\3<#4<\09/B6?6M-8G2)&3F5_JB!-O`3B4UBM0MUS@$3CW0J[PWU'S MLZ0G+O>3^L_0K7-_I@8>%7]EE6V=V02C"FK:<_NLAE\PMA`;@X-J+ M.&5D@IJ.W3NCQF4OQ>;V/B<7+S1B(N6TPLP(XM2OEDCQFIXNZ.GW]&RB9]%A MMJR>W7\OL)T$ME%@NQ38)^L6(^:TQOQ'D[LO178K@?1JD34F^U*$+`8G0#?A M?AI4JE[:.+Y!UMX`_5#9,&G95UUR?,NE;*@C.1W#@7K7ND M<\"AMGZ[=WL=[VT,K.JF5SC_"HH/4$L#!!0````(`&B,;$>D3(HWRP$``-D$ M```9````>&PO=V]R:W-H965T\'N=E5UM;&=]D*^J1I` MHW?.&G4*:JW;(\8JKX$3=2=::,Q**20GVH2RPJJ50`I'X@Q'87C`G-`FR%*7 M>Y)9*CK-:`-/$JF.70*"H:)*$\!0^; MXSFQ"`=XH="KFSFRWB]"O-G@=W$*0FL!&.3:*A`S7.$1&+-"IO#?0?.KI"7> MSD?UGZY;X_Y"%#P*]DH+71NS88`**$G']+/H?\'0PMX*YH(I]T5YI[3@(R5` MG+S[D39N[/U*?#_0OB=$`R&:")$W[@LYFS^()EDJ18]42^R_VQP-7%H1HXR4 M4Y.^>V-4F>PUV\2[%%^MT(#QE/,,,R&P4?^V1!3,Z=$-/5JG;T?ZSCO,@*W?%%,I%UVA_]*;L=(L?(G=VO^!9VI(*_A!9T4:A MB]#F!KCC6@JAP9@([\QFU^:=F0(&I;;3V,REOWH^T*(='Y+I-KKAJQ=0LIVXWGB6-!:R+>6$L;]>3,>$VD M.O*+)UI.R#> M+S[*2R'UA9>EWL`[E35M1,D:A]/SUMV!30Z0AAC$[Y)V8K1WM/D#8Y_Z\/.T M=7WM@5;T*+4$4^ MZYSHF5PK^<&Z'[3/(=2"1U8)\^LA,!D:IV9O+X12;*4L\X1+=%O&VP4G&L1I>P(H\9MN51F0MW> M,A"#U+MIH1X##68_P0P(3ZDOAH#NE`Y'=+@4(!\CHOAY!'2/8(\[-$D"/A<( M[@*!%0@F`FAJ,K1I6$QCTT@@CA&.EH#Y&`@2C$*$@^>6PIFE<&)IA4`T*TKT M:E'PS`%>410\RA4A/\816*P)GA0OQC!:D5$\,Q1/#(7/!9)929)72P+\F07= M&)X5)>]!_1<0X0`%R0JW`,R#3?^_Z;LEFHJ3<<*GJ6>HNU?SL'[$&R]C[6AMF: M_0=02P,$%`````@`:(QL1W+7FCA=`@``+PD``!D```!X;"]W;W)K&ULE5;;CILP$/T5Q`R$- MKL6?,Z$5XF)(+PYK*$:GSJ@J'1>`P*E04=MITLV]TS0A5UX6-7ZG%KM6%:)_ M][@D[<-''N=J>BPC4K2&U1?-[9KW";P4!".L2O`K=L\&U) M\0="/N7@QVEG`ZD!E_C()042KQO.<%E*)N'YCR;][U,:#K][]F]=N$+^`3&< MD?)W<>*Y4`MLZX3/Z%KR#])^QSH&7Q(>2((`9,JW%Z%&KZZ(Q718X)- M3^`I@LU00#36&*HH%*3N(#Z8@F0SD%D5GJ'"&ZJ(QRY\I<(;N(@`6.'$-YSX MHUS%CPD"(]G!L\D.#07A0K)UF.%"LA4DFX',JH@,%=$PC'C2QSX:^(`^F!8R M!'FKEB0VI,2/USU^>MTA,+S(36D0,9STHT'*4>S/Y'Z$\L":]$-HRAEM';&[ M@L)L>_ATWT.S\>%2Y_FLJ:IJ@Q,/\%25>J]5X/FJE)OOR/41%4Z@Z.M01?\$]%+43/K0+@X);LC[4P( MQX(+O(C0&ULE5== MW1YQ@^@#.>&6?[,G78,8?^P.'CUU M&.UZ4E-[T/=CKT%5ZQ9YO_;<%3DYL[IJ\7/GT'/3H.[?$Z[)9>D"][KP4AV. M3"QX1>Z-O%W5X)96I'4ZO%^ZCV"Q`9F`](C?%;Y0Y=X1YE\)>1,//W=+UQ<> M<(VW3$@@?GG'*US70HE'_BM%/V,*HGI_5=_TZ7+[KXCB%:G_5#MVY&Y]U]GA M/3K7[(5S/5-&FBO%=1KT,5RKMK]>AF\2*&EV`I0$.!+& M.'9"(`G!)R&\2P@E(1P)J7^7$$E"-#="+`FQ0?"&8O6E+A%#1=Z1BT-/2!Q` ML.#P3HAP98?V:MVP@[S8E*^^%R`+!<)!(-0$(MUD M-)1KP+0]QKVK?#SB] M'Y.04H,$$-S8#Q4%XGA&3H&9D][`,SU.*-VH(#BK=F:;!Z$F,>-W"\8&+1LL MB+[;84%LNM";M+6JI00-54W2(`GM'72M`4,_X@=PAB>S[8-$JPR<(9&:E4F_ M71FS*X),Y^U.^R$_H@'^A[E"UU'DEC`^0_;2W)X1A[MI_X-MUY.\:XT.-]TS< M)F(?A^E[>&#D='V9&-]HBO]02P,$%`````@`:(QL1W>B"(*U!```\AD``!D` M``!X;"]W;W)K&ULE5E=<]HZ$/TK'GY`;7U8LC.$ MF88TA(<[T^G#[;,31&!J8VH[H???7W\(HMW*9NE#`^3L[M%*YZQ,YJ>R^E7O MC&F"/T5^J.]GNZ8YWH5A_;HS159_*8_FT/YF6U9%UK1OJ[>P/E8FV_1!11[R M*%)AD>T/L\6\_^Q[M9B7[TV^/YCO55"_%T56_?=@\O)T/V.S\P<_]F^[IOL@ M7,S#2]QF7YA#O2\/066V][.O[&XM=0?I$?_NS:EV7@<=^9>R_-6]66_N9U'' MP>3FM>E29.V/#[,T>=YE:BO_MDD_:W:![NMS]J=^N2W]EZPVRS+_N=\TNY9M M-`LV9IN]Y\V/\O1L[!KB+N%KF=?]_\'K>]V4Q3ED%A39G^'G_M#_/`V_T=R& M^0.X#>"7@"2:#!`V0%P"F)P,D#9`4@-B&Q!3`Y0-4-0`;0,T==&)#4BH%5(; MD**`<-B_?ODS1S4?;9J.%3M_M?MIQ\+'L7S M\*-+9#&\QSQ`C/)AEA"C?9A'@/$AOL$LB0_SY&*4%[*Z6NCY>I(U2/+9F+!M MJK>S_-Q9,726._$LE=<3B',".2003H)80H[)T-$!0H>XW8:Z#W%);2@]ZU4TI[&`VPE0MK4XW`GEV8 M4"HAT4X0[01(VW_*$W=SO=UV$2(F$4D1D=3M'_,W)G4;PVD+9A$JU%T;/I?L MWZD'"QI*I7S\G"&@4F.[!8"MB6H:>X;9`R]GS$?JP8)LHQ3U2#..BW%0#,V? MU!;C0/N$Z<#P>&`"U!&PCK1U((A2!SLZDR!%[-]Z:,&2VCSLP2P&Q93W1#/7 M.)FB5<+&R8!SD8&/4OQE/"[`0FVGH"-W\FPCW'7QY2?-H^N6O=UR!I`6*P3`EOL6YR!$Z;\ M=-DU+D\`XK\EK`"&>RWR&6*<*3"^).R.'+CCR,CGKCMR/3;,5P`G]-@4`3"F M&*>='6RX''JI_[+%Q?7=<"$\'ML/%R7B-/7O"$!)QS#'UX4-GDMPRE`A:>F` M*4#J'_9V#KP](E@NOYCV^9E*W6JY'%\Y.;QS>L?F"H$H=;"U\P2<%HK\4[S: M]-;5"NQW(@(LO');B@@[JU='WZ9PXY2PJ0EX&1LI!9R&>&L5V&P$,!M.22'0 M'@AQ\QY@?0FH+^_0>1+N!4IQP1/%O;X`@(G6/,5GV%H#!`JN-"<,>H%5*X!J M22FP:L7-JA58M<(59)SX%KP4\!&0>#RQ;@70+2>XE,"Z%3?K5F+=RNCJ>E?2 ME6-,6Z[$:I3@BN&?QX]RXHIA1S&`*$DC@_4JH5X%(076J[Q9K_*OK[#`J./H M5MX]DG9//-*55_L$%Q.^(I187-(5%TL(TUMB<6K!]8I4:K/>O M)Z;0^=[YF+V9?[+J;7^H@Y>R:_B3Q/"F*8_GO[!<_LRS^!]02P,$%`````@`:(QL1[U,E,7?`@``GPP``!D` M``!X;"]W;W)K&ULE9?1;ILP%(9?!?$`!0,&$A&D M0IBVBTE5+[9K-W$25,"9[33=V\\&0K!E&N\F8.<[OW\?C@XFNQ+ZSDX8<^>S M;3JV<4^>QW8GW"+V1,ZX$_\<"&T1%T-Z]-B98K3O@]K&"WP_]EI4=VZ> M]7,O-,_(A3=UAU^HPRYMB^C?`C?DNG&!>YMXK8\G+B>\//.FN'W=XH[5I',H M/FS<9["N0"J1GOA5XRN;W3O2_!LA[W+P8[]Q?>D!-WC'I002EP]47!UV1K*>P%K@5(H(98?U:G1X(")W3,Q^ MY$$`,^]#"HU,T#/%G(D3$[*=(V`B/&'`Z")PU16"N0O3`N6E-/'(V#)*#5I9K!/HZR@=%AI+H=`@8]LH M;:"M#50M0LO;"O5M*6T=!A824U\?7PQ`;<@6;P:@=UL`'S_$0H7@0MFID+'* MJT5HV;'>FKQ?38 MGWN9LR.7C@_GB6EV.EL_!_+TILT78%T"P_Q6GL7[T]Y=/L_.Z(A_(GJL.^:\ M$2[.C/T![T`(Q\*U_R22=Q)?"].@P0'\/`PX.=\^!Z9ODOP?4$L# M!!0````(`&B,;$&PO=V]R:W-H965TV$[=O7 MQD`,-4TN`9MO_IE_`IZX)?2#Y1ASZ[,J:[:U<\Z;C>.P8XXKQ%:DP;5X"\N.9<;3A([8]RIJ'#-"E);%)^W]JNWV4>2Z("?!6Z9=F_)V@^$?,C% M]]/6=F4)N,1'+A60N-QPBLM2"HG$OWO->TH9J-\/ZE\[MZ+Z`V(X)>6OXL1S M4:QK6R=\1M>2OY/V&^XM!%+P2$K6_5K'*^.D&D)LJT*?ZEK4W;553R+8AYD# M0!\`QH`QCSG`[P/\>\#_,\`^`#Z;(>@#@ED&1WGO.IS"LIF2$=I/E6#XV%0P,Q5,3+G3+(K931G/Q*1/,-D3S'Z) M6304S@R%$X'9RQ8I0Z'6-G\=N*YKPE(=@P%]', M7C2Q]V*T%^GVO`5S.@06O>G4%V\=+5C3L&ULE991;YLP M$,>_"N)]P<:`(2)(3:=I>YA4]6%[=A(GH`+.;*?IOOUL0ZAMT8:]`#9W_]\= MG,\NKXR_B)I2&;QU;2\V82WE>1U%8E_3CH@5.]->O3DRWA&IAOP4B3.GY&"< MNC:*`L(_[NE+;MN0AC>)IZ;4RWU1%25 MT>1W:#K:BX;U`:?'3?@`UUM8:!-C\:NA5V$]!SKX'6,O>O#CL`F!CH&V="^U M!%&W5_I(VU8K*?*?4?2=J1WMYYOZ-Y.N"G]'!'UD[>_F(&L5+0B#`SV22RN? MV?4['7-(M>">M<)<@_U%2-;=7,*@(V_#O>G-_3J\P"V$TR':(<;'IC@P`` M<9;*'5`:!:4VJ`"P"69Y606!]Q'8`^!'40ZB\`6XDL.LPS? MY^0>)W4D6%!RH<$)X%%18H1C@#27H?!(%'TLW`0N4NJA@7 M%;"36BTI:PA]D+MZ"Q<$X4B"=B6LTB4IQ3[)6<08S'Z]T6AQR4'D4Y!#@1_D M@YPO!Q84'?0[`G1:`HX_("4N*5M`\EL"='H"1O/%D+K%@!:`_)X`G::`O::0 MC"#7:$DI^(T!.IT!9_,S9I9?#?CO-3F>7A]ALV._F57DF)_J3\%/3BV#'I-KVS1Y] M9$Q2%8-:MV%0J]/5-&CI4>I'K%??<-X8!I*=;\>GZ0Q7_0-02P,$%`````@` M:(QL1SOC;RDM`@``\0<``!D```!X;"]W;W)K&UL ME579CILP%/T5Q`>,;9:01`2I6:KVH=)H'MIG)W$"&L#4=L+T[^L%,MBE@KP$ M[)SEGIM<.VTI>^Z\L2^E-E$5-7IG';U6%V9\M*6F[\9'?;[P5UURH M#9"EX,$[%Q6I>4%KCY'+QO^"U@<4*8A&_"Q(RP?OGBK^2.F[6GP_;WRH:B`E M.0DE@>7C3G:D+)62=/[=B7YZ*N+PO5?_JN/*\H^8DQTM?Q5GD^=R07? M2O%&VV^DRQ`KP1,MN?[T3CX'("(260&17:2@[@ZDU!HXA]D-$&$,(IPN)G$(BJY#8MDF,332P08M9 M-K%C$ULVBVF!A=/QQ;,=3YP*$DL@&>OG(1D&G=?/I6.SM&R6TP(K)^CJV:`( M.B6H4VLR:@?JLL)961%RG>Q!6LV0<"<)/3U*R)TE-&.8MF@X*Q&<&=B=%C1C M7+;(FI=E\*\5&!R=#;Z2'YA=BYI[1RKD*:R/S`NE@D@U^")+R>7]^UB4Y"+4 M:Z)J-#>260C:]!?LXY;/_@)02P,$%`````@`:(QL1W]__+W`'@``[I0``!0` M``!X;"]S:&%R9613=')I;F=S+GAM;.U=_7+Y1]DFNNP&0 M(`%R*-E)-CFE:IT1B8]&H]']ZT8#_#K/"UXFT0^E.$O+I/C-H\G)^!'_M(V3 M_#>/-D6Q>_KD21YNQ#;(1^E.)/!FG6;;H(`_L^LG^2X3P2K?"%%LXR>3\7CQ M9!M$R:-OOLZC;[XNOGF>AN56)`4/DA4_3XJHN.4O$]E"E";\B.>;(!/YUT^* M;[Y^@G5DO1/^.DV*30YU5F+5?GLI=B,^'7M\,O;G[9=OTIL1'R_<+RMZ3MWT M?'=ZE1=9$!;_UEGS_>U.M%_ZXZ/?MY^=0ND5U7@1!]?MM^L@SJUFJCXN1!:E M2."*/P\*JYP>/_O5KWH'^2+*PR#F_RJ"C+^`AQ:;VR55O\ZROY^VG[S/@E64 M7//+V^U5&K??OOOCRY?M9XKC[\1UA&R&CM\$6VMX[_X8\0L0BVT0BK*(@+"< MGZ79KJ.U,QA`!L2_!%'YQ/]9W+;+G959UF9'%VN/COS)T=3OZ.I%%(N,GT&] MZS2S^KGX]?TD+@;\LB+V"U M0'5K'"F,,,G%BC\+XB`)!=2!A9?SPP])4*ZB0JP>PXKZR0!H\GHF@7?4M=]G7E?J>9&4?!511'121LCIZ&(:K? MG.^"V^`JML02WF>EZ.6!T;P]UVL!A58\$S?<,M&4#IWZ3Q2F3YKVD&BEN+/2`":@0Y M%G>1!0LIEPOI8#P:C\<^L#+C()>E\+@_'GMC^9\R.#PH"Y"^Z$>Q^B>^F'DG MLQ//G_@TJHGOG1S/O,ERH@M'>8[<)Z;7ZY,'!0=57(CM%JI6 MF`>\SW: M&&39V;-N`BRQJ#KJH=HM#_,N41C3*.>>[X__4I//#P-<9,"ZE00=1-3CKL$= M^??EXWYC<7@1X)+?"+*R:#P.^),.2';1YFO%S[TE+3[W+^#.AIO%[MAJ8S8' M%4V[37$E>:WIZ"&^N\K>@>RMZA[4WFH#!@C2=[].>RKV=%M+[64!.DY:FG3- MWX*1IL5R/[`S'>Q.6%#H91*F6U&3T^,BO'-;5T4[J`QMO2U%!C@)0&DH0=4* MFHE3PB'M85 M8#F`<>IU#XJ2!?BAHN&QLZ@BN*?#-Z)P$EE)/G+%D,@^Z[:*;B*0/5MX="<\ MV.UBT)-8N4BAK5IE*(/867.'.$V5QS6PORE+1)X%>11*^8CBLK"E^`\BNMX@ M+`A@B,&U:'28/^57^QIXDR9'!.B)CB,HC[`=/!B8(6FH*O0)LQ&7L))PT=D" MQ6F$.5^G<9Q^A*Z[_]UI^KD`C1!&DGTD1%OTXG^D!Q8;`VPV@:64[](7]SM_+X9,A?[1$,&!_;,WT4)*PA8BRS+!P467@=%F5%CP^L0:<0"8KO1 MY\X927#$&T(A5FI@IO@,JV_QT\6;??Q<1PEX!'OXB3WM&M3"-)/\D3?1$LS^ M=Z#1)T.V"9Q^C8B-[V>[B]%8( M5:J:PAUX29W0X[69O=P"#U'F??#=5])?%FZB6J-EG91XE(I=:%@$@*:H+ M#*;![+@LAXHCXEQGP M-__?_V'N!M^#,`9A*(LAT6&%-910422K0AT(+$L--9!0M@&T"VM"),A?\+VE M4L0VLQ5I!5KW0U&-H49.-.9=LYQSK(YA4,<9+FAT MH[=!`C"?<"((ZS;X'A9V10P!&-",VYV$J<4&UGZP7H,V9#C"C/8H!*&<4@$Z M-P90+H.A!U@5]BTZZTA%LP):L&7\70V2F1.*@*6#'!6LEH4JP+$"DYU<&V.@ M225--N*G85$"%X$[90R-P*3'2#L,.ZL,1BY8Q:81JW0E_3BO=27-DQ9@&'`> MH5O&05SX!F`5"(T,X<$\P>HJY7"DL"4L!>05831W*R'&K61"!E9G*P,1`!YB M(>'JE;`4M:++5-U$0HXF&4C/HIB:U-R2^ICDEX6H<-8@K$IT5\"E/"I&S-B, MP=99:W-&]T"5.AKA&Q&C#62UQ.+PHZ*44A8@G3%&I]''0(14U%S\^:?_RD%T MI+J`,<-:C="\9BL8K[$5]+)&7\R]0U0QHX=2G`IK'E`T`59IU$E:)2F@-7*2@W"3B4C#9X=YV"SD]H76;*L6/7!&9& M7+<-NC"3S?\([*_0!0)I>@D"#:@F1[=,D)D(!T^N*T$UUM$G M:``XOA+(+A@U&AVY21/'$@0QM10S(3<0@`0!`H8%B:`@3[':+6D.F!Z/ZBQ-M1[!SF`V<<=KQ;"B9`F6`#@>9+074B'% M*S`4ZZB`1^L@1!5W>Z18R+1>\GB.N(GJ=3KEFN](AVH[9Y+%R5'U!"4]C6]J M:V2LGTJBR/@9HP5J/\&\HZSC3EL4(B'2,:L]+L411'\@HAL1K)A!$EKLK(N9 M*S188J^-?1$"Q-=[3A*$$(8H%'ML62\ M>@<*"D"&(5[;8"50`1E$4NYNB$SB2JGP[X^;",@&R5^E8&H( MVF@BH+D8ZI7*QJC]))R#:E3MT=0C(>,/F(Q:U,,9L0MS$E!1-+A>3UZ]-HI- ME*V.4!)N62UF>7GU)R!&KPG42!4"`%4,?WPDO6;.+),S2]RY$AKZE6B-/!X' M5V@CTNQ6BAKJH2"^100I_V9%^BD*I<#E!K!;026O$@3'?@,-Y%`_FH5I94] M"8"$+Z03)6BIU!"VJQ9\]49)1%#W@8U5/;"7H$VA65*ST!7"L\9CT!#P3)%JT?:5:%;Z)4S?GIYUNB)__S3?ZI=ZL9C++?TC]D+D$3I"Z=J8@DF22B@(;>L@D); M*3H8-;R@8`QK6$[/-) MPU&?4_H#.LM`3&6B8"5@Q/>\LO`8#'JEMX$HS:LQ!X'._<%!&LX6&BIS`XDV M?_LR0MDR`EB,(BL2; M)!,2J6B#)8M:AE1`5$AFUW6I"(R,H>F5-,L2S'^`(HUE*+5'069("SO[Q45[6M0`C*9@Y8&\E,%XXUJ M]>+XL$/G5P8,3B\_(+,U^,<%"QQ.B!QET,]*F,$M3MZAG*'%>/$8*OW9%5EL M"A,_;8F$F5?8L3-93?M%U4HW@Z8C/KA79O9*,B-5#!D3*DKQ`A`(M=QV*>Y< M1*2WC/U*W-Z@+496!7I!08:8^:1\B*1[<[5)&7,MD2L1!F6.YE)$F=S/I'CA M1PH97,$Z`Z*.:*<4I/@I:Z3Z,$KU06%@;W5$:TCR8TH]-2;CH^]Y<+G$^_D M>.E-%C-VU@A_HS*+*?HU((S(6F%$ACK67WC+V=2;G=+G@_HFWG,[AIY4,05'/?Z&HYVOP%LO,O2B-8L^K MP%'?$IR->$?3`ZU52TD?3Y2&[FA5>I,U:1[JO%?H*G"?K-8/95I('S842I_2 M'NDVR+Y7\LO1+2^DV99!,(SIU,!_I!J<4(/2%BV*QUR)>4AJ<)H6Z!P-]O6HZ4HG*9F2M28=)2) M30F!2!`TC!NP.LY(>O\*$SPT0*&M&BRL2$#7(,(@"47#"!+1*DLE*XWAM;BE M_06;[D8<3F9>4]`DHF!#(X3E.78\P$UV[^PAR-`S!'@Z0Y?QEN"JGH`PAA_` M)@E(JK*(R"*,91`.(UQ&&P$KS7LSN0,68Q[('2C)`4JB+('C/Y1`!30@ZWK- MO1DF`.1;`4Z/8XS^6@F38KDQ>R@`(_:V?F`*QBZ-9*B0]&I3PCW<\*#4'8:Q MN=Q37>LQK!H[O1$X:L!WM5,)RBG=PII#XX:XLP:-:J+5E!)[UL:V"2PJQ&C@ M_."8%/8'A`,X'R.@NY/H%ZWTJ MU^]KM7X/U6)_S&4^TJ6Q(`S^O93+096>/.8?S,72?#M]S$YENKP563T`U,@/ M2%77/^T0K^_-QV.IT/6OK@#H,>:O4M'JE]+C!_S$FQO=&7\UF&8EJ?Y]\FQ6 M,6)F,0*>&&T8?S'#+#2V:5[6L7S2.R%84[+,.M!>>7#*4[]2N;5T`DI'G]0X MF%LE>1V9!E[M"*@`!+GF@97YOP/3]TEJ7XE>ZD6%?KL*U,`+4_$EM,]GP>V> MS&(K&P_<++`ZL.R5VU/;SQ[+/A_U92_#[,OMT_8";GIRFV!E9,>2-U'M^@N^[@.7V'-8UCZO<;RDW?&=N+>7G=938IM'FF(R=&/P8()(MU5+7 M,"D;,8,2:^J6WO%TZ?>@[=_3I7]MP*$4DKWVW:%Z-&B`E6LFJIZ;+)4X4Q6O&\ M9<6KW#WF.*#78JEQLJ8^T24R:23D1K7O:L,Z#F8UPZK@ZHAUGUZY-U2I$Q0# M5D.5-IG#DL98`ZPXB+P/3,$7;5#"G*"$@@V`3#"RA&.BQ".Y166VCG.!^(7` M#ZGJ0#LKWIF-`*T M+O5X:?@6_C%48#V9YD*W#DKQ8(WCEP/3<9'!Z-`A*:L^U=UC7O88%;LG(I'U M($3;K+0A#1L.:1PCA;=S-T;L&3-S8L3AJ(6Y,.)^U-*4`ALE`E19GNQ!B0Z[ M^UDHT4$3O-5GI<)/IQ#M>3+XD:)R?G#A`XUX& M28J.O25X'2?CJ='$0-C8J:.0*#P%=^]9._:FDP6`1[^33>9^(OMM`!0D_)5, M\ZK!`0*.*J;H+PV\WQT?ZMD@"$7*YZ*\`G[RMY@N M@DL=YDF^=`'#]H`FBPI2ETE4Y`RSR-5.!KP&!#T;TP8LOB5+`MB0^DM5?W7@ M2U/`W]Y0HE5:R+N.%/'L'9U6XWH'L[GS%V5Y4><-(<[5#?\;P#WQU[,_9F[0Z@207C3Z;U%B?0VQO4_,-L8VPHF4@LXL" ME*/K#',R#$D"XT1SA2FS:Z$3;[O=VM86X;.O.C)SV>##92=NQEFES;'FS;AMG<)W29C\#:3A=8D>ZE'5, MM'$BJI'7]$ZAO#.9LT@@7K58)0=UN]-+Y4Z[4K8&Y7*5N9!;X\_B`$I?A@"& M4`O1?L\1KEGDX#9="4S583I/7#@0$H(#W%^5=;G.7L>$+2Q#B*&5LO4E)JAH MI(N8&7_D0^"1QZ>4-88%WU,OYKT.+>NH"[Y!(GK*5!?EWQ^ML0.] M,_5'Q[B?_Q]\,II-OX)_YQ/^%3R=+8VG_F@Q5G\NIU^Q)-B]@JF MC[/C^6AR0F5\?S$Z]J'2>`JM?&6_82?+T8DOGXR7HS$\L8[Z"[L+*CP[J1KF MQR>2N+$_FH\-JF)8#SD_A$6-QQ_RQWPQFLQ5=Z.Q_`=H&M>/&G_5#57N\&V$ MIT0PN/*5_2^)[,?V`)KBMT^V9&R_RB;;&XN6GA/8JAG9A0.8%[_M>`PGBSG( MJ@5]+U7,HLI70>C1;-'V$)"JK$,62VT+*%>`B*(FI9K0IVJ9G`WXXT>1I4=A M2B\^C"YAR!GMS(/5QUUXF88A3S!QVC/,HVT4!YEVHD0M,>O*C]*>K>1-PW6G M\SY5)77:EI"#(:7U(L<\PA;I1CE42I19B(=[5`88G1O,R`V41P@CE6])B8^<&VHMBDJV;ZM,02*HVU.L/6Y$_=*2/@R5/F`E$B)W)<,9B9C6RO,&!<4QNEU\'"-^<>4S],,4Z([C>G:%`R@/>K: M[\41J13-^)91V92$+]&=[0)Y7+-1;^3.]]/I'-(XJ=,>MUJ`3&$QDX'I/';E M9JN,>,H%_%V0E+@-[5?Q08=5>:JR`-Y4Z>`JIJ9UYQ$_58O\7!\[I\P'(R/2 M+OI..\S\S)BN]SA=I]>`O:]Q7;Z$-U&"EZU0A@'3]V_!%+1)GQ*ZGBQF>*O) M:'K"OE6J97HR]GQX/![-YTP3N*+0AL`5*Z#,^Q@-B?GJ:W8WZX)K7;DAJ_:'MC4\ZM=0>F,X=4>BG(CCF?K\;NRR+RC0V7/\_,:5?FH5Z$'=QX"ZV\69\83N(+`]M)ERBAM. M*&L[H5U^&V_Z;<<3Z;B!9_X&_"OJ:N'RSM<1+OF`G]5G7OEY'.%AST)'``== MOECE5)LMI6N&EYW5Q_F;&EJ>R^GJFVS-P"L+[]7[89%>"]R`D2Q!I]VH3J&T MBAS;:[O+-0?\4%^=8-W)..@.AG^TJP[:X[OOS0=?JIV'&Q1^23<&;^/:AF&E_A:7.W1]3"@R,-U$'^C MZR`&7YQXWG']X<-U$@_723Q<)_%PG<3#=1(/UTD\7"=QA^LDAFZ7/MPN\5>^ M76+__0#[2_S2KZ-P?*VA=3O%_A)_I?LK[G<]`S]\CV_M@),N*_4NS]\]I"I]9"I]?>5J65_JH_T.86_ M)>Y6J^!4I70,`A`/V2#_K[)!/FLC%EA='TPR/]-["'HYB&(;+G?M*75^W,:T MI,.(^@Z/#?"7P(G<:NU5>V.JWH9R?VSAO6-G:MCN2>>([%V/+^2C'/$^;^1+ M>B+5_'9^'_H4`+[&]R"75?IBBR;0)F51T>2Z]*YG,M4W76FCCTRMZ528.9.B MT6G8[%28'FWN\L<-+Z1*(#&9TO-A)J/0A_V>R'T^(VFZ)'>CKLO=..J\E,V8 M]6&?D#IU?YZX;M]K=.#A'I[R4CIYNN?[+"04G],A__<[HNXA'TIMS^9>Q5FS MV&H6+SVK37S?`JFMJ>L3592!&C:^Q&*>;*]UI'W"HCJ9*EM*DWUW$W5\C:7S M9&?W!V-<=P8TCRP/^SBJ>0+<>=+=_A@5'9;L^*3[G3ZI"R(V:(6^#Q"ZJ*-E M%T%6),`#C[\:78SXX:/W9Q>/NJ7O>7M,:)_LCT7>_ZXD#`<.NBKIYY_^_%C= M3-`W'F@.1D2%!]U>P.][>P&_U^T%_'-O+[#/U=_Q]@+^.;<7F++8=7>!S'+? M[F)AYO<-FN-!%YA\CM:#.1OQL1)32[N(*W@Y<[]\'60C'7JQ:P[Z2M1@-=69 MF]#UM4=,[M-JU.M079>!#'_0^4Y/G=#01SKWP&7C>DO[AF&@DTZ%FLDPN.6H M`KW6_2X!]Z='\@Q-VCC;685"Z7N&C>`H-GBT">*U;MS9-K=/K<[G-,9U&<=U MG68ETD*/>H^9@H*46;%K@(1'B+7UH4VDTO@\X/VHG$]J(COJ2"(U2GOTV%HI MWS83CDE#M8[H#JE2G46MTIG[/[IV=Q.J#G:WOB]&IYT[K9`^]KT67=\*MRSC M9W]6W=WL?:CO:JO_Z'=G<_T'HKMJZ>6O;T>JEK_35^D,L![Q+Q)*[?3LS<.T MS>W>.@$./\[H.'3+3S_B3G(?DNT((@*:CY)H6V[M#^<=3[ZR'\Z6CH>+L?6P MN[O@DZL["E;:#Y?VPXZ6[;ISFWY']+.3`13[M%J@^.?`=MTC59%4Z[$,IPYH MV:XY=4W+D+BLBXB9/6@9K;4+4_"VD^)V+->N+U]T-M",X;:+40#7@BIR+CM5 MP4(%[G0$R;K+5;V?Z`B3/P'0>.OXKNZGWGYZE,B]`9PUH?(\K$3E-0JK%)OC MF'$?F:X4#\L=!LM>G7#:U"E'SO200WERRM9S/0JV#K^W`N_=6E/L1I4KHCAW MP)\H"^RVP^Y(N<>?51^>56'EH16_=;.WJ_AY%\#HJE"%OP?W(+V2.P[#"(9W M"=_1ODT$!Q?!WMJU;MUV2VM2[=EZ=RR7!E&UL4$L!`A0# M%`````@`:(QL1TAU!>[%````*P(```L``````````````(`!S@$``%]R96QS M+RYR96QS4$L!`A0#%`````@`:(QL1VVS;]1>`0``?A$``!H````````````` M`(`!O`(``'AL+U]R96QS+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+ M`0(4`Q0````(`&B,;$?Q79446P(``'0+```-``````````````"``:P.``!X M;"]S='EL97,N>&UL4$L!`A0#%`````@`:(QL1T:P;(`]`P``(PH```\````` M`````````(`!,A$``'AL+W=O4@(``/0'```8``````````````"``9P4``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M:(QL1XR@S4N:`@``.0L``!@``````````````(`!RAH``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`:(QL1P*Y;+L!!```H!(` M`!@``````````````(`!#R0``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`:(QL1V@&UL4$L!`A0#%`````@`:(QL1Y9Y[,*A`0``L0,``!D````````` M`````(`!I2\``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`:(QL1Y&4O">A`0``L0,``!D``````````````(`!,#4``'AL M+W=O&PO=V]R:W-H965TK5D$UHP$``+$#```9``````````````"` M`6$Y``!X;"]W;W)K&UL4$L!`A0#%`````@`:(QL M1P$LK0VG`0``L0,``!D``````````````(`!.SL``'AL+W=O&PO=V]R:W-H965TD3(HWRP$``-D$```9``````````````"``0,_``!X;"]W;W)K M&UL4$L!`A0#%`````@`:(QL1]25B%1&`@``9P<` M`!D``````````````(`!!4$``'AL+W=O:.%T"```O"0``&0``````````````@`&"0P`` M>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`:(QL1W>B"(*U!```\AD``!D````````````` M`(`!7DD``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`:(QL1W=I<3R?`@``SPD``!D``````````````(`!]E,``'AL+W=O M&PO=V]R:W-H965T v3.3.0.814

Stock-based Compensation - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Weighted average grant date fair value per share of options granted $ 0.44 $ 2.71 $ 0.41 $ 2.46

Expected dividend yield 0.00% 0.00% 0.00% 0.00%

Stock-based compensation expense $ 385,000 $ 454,000 $ 1,243,000 $ 1,402,000

Nonemployee share based compensation expense (income) $ 3,100 $ 24,000 $ (18,700) $ 71,000

X

- Definition
The aggregate amount of noncash, equity-based nonemployee remuneration. This may include the value of stock or unit options and amortization of restricted stock or units. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
No definition available.
+ Details

Name: rxii_NonemployeeShareBasedCompensationExpenseIncome

Namespace Prefix: rxii_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 15 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share Attributable to Common Stockholders
9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Net Loss per Share Attributable to Common Stockholders

3. Net Loss per Share Attributable to Common Stockholders

The following table sets forth the potential common shares excluded from the calculation of net loss per common share attributable to common stockholders because their inclusion would be anti-dilutive:

 September 30,

 2015 2014

Options to purchase common stock
 3,308,761 2,987,264

Common stock underlying Series A and Series A-1 convertible preferred stock
 — 16,743,495

Warrants to purchase common stock
 25,969,615 4,615





Total
 29,278,376 19,735,374





X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 16 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Recent Accounting Pronouncements
9 Months Ended

Sep. 30, 2015

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

2. Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 9, 2015, the FASB voted to delay the effective date of the new revenue standard by one year but to permit entities to choose to adopt the standard as of the original effective date. The new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact the update may have on its financial position and results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Direct Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Indirect Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.10-01.(b)(6))

-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Accounting Change

-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Retrospective Application

-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 4,035 $ 8,496

Restricted cash 50 50

Short-term investments 8,000

Prepaid expenses and other current assets 432 442

Total current assets 12,517 8,988

Property and equipment, net 162 183

Other assets 18 18

Total assets 12,697 9,189

Current liabilities:

Accounts payable 222 285

Accrued expenses and other current liabilities 1,443 1,002

Deferred revenue 47

Total current liabilities $ 1,665 $ 1,334

Commitments and contingencies

Stockholders' equity:

Preferred stock $ 0 $ 0

Common stock, $0.0001 par value, 100,000,000 shares authorized; 64,949,121 and 21,984,272 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively 6 2

Additional paid-in capital 65,515 48,047

Accumulated deficit (54,489) (46,882)

Total stockholders' equity 11,032 2,745

Total liabilities, convertible preferred stock and stockholders' equity $ 12,697 9,189

Series A Convertible Preferred Stock [Member]

Convertible preferred stock:

Series A convertible preferred stock, $0.0001 par value, 15,000 shares authorized; 0 and 5,110 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively (at liquidation value) 5,110

Series A-1 Convertible Preferred Stock [Member]

Stockholders' equity:

Preferred stock $ 1,578

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Cash flows from operating activities:

Net loss $ (7,607) $ (6,496)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 60 68

Gain on disposal of equipment (10)

Non-cash stock-based compensation 1,243 1,402

Fair value of common stock issued in exchange for patent and technology rights 228

Changes in operating assets and liabilities:

Prepaid expenses and other assets 10 (207)

Accounts payable (63) (26)

Accrued expenses and other current liabilities 441 (837)

Deferred revenue (47) (57)

Net cash used in operating activities (5,735) (6,163)

Cash flows from investing activities:

Purchase of short-term investments (8,000) (5,000)

Maturities of short-term investments 3,000

Cash paid for purchase of property and equipment (39) (86)

Proceeds from disposal of property and equipment 12

Net cash used in investing activities (8,039) (2,074)

Cash flows from financing activities:

Net proceeds from the issuance of common stock 9,266 1,947

Proceeds from the issuance of common stock upon the exercise of warrants 16

Proceeds from the issuance of common stock in connection with the employee stock purchase plan 31 30

Net cash provided by financing activities 9,313 1,977

Net decrease in cash and cash equivalents (4,461) (6,260)

Cash and cash equivalents at the beginning of period 8,496 11,390

Cash and cash equivalents at the end of period 4,035 5,130

Supplemental disclosure of non-cash investing and financing activities:

Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock 2,000 3,000

Conversion of Series A and Series A-1 convertible preferred stock into common stock 6,814 3,582

Fair value of Series A and Series A-1 convertible preferred stock dividends 209 3,668

Series A and Series A-1 convertible preferred stock dividends $ 126 $ 447

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

+ Details

Name: us-gaap_GainLossOnDispositionOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards other than stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 3A

-URI http://asc.fasb.org/extlink&oid=27011957&loc=SL6540498-122764

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 40

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6445032&loc=d3e90193-114008

+ Details

Name: us-gaap_ReclassificationsOfTemporaryToPermanentEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Preferred Stock - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Class of Stock [Line Items]

Number of common stock issued upon conversion of convertible instrument 0 35,000

Series A Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Series A Preferred Stock, shares authorized 15,000 15,000 15,000

Series A Preferred Stock, par value $ 0.0001 $ 0.0001 $ 0.0001

Series A Preferred Stock, shares outstanding 0 0 5,110

Dividends issued on Preferred Stock 0 87 105 268

Fair value of Series A Preferred Stock dividends $ 421,000 $ 172,000 $ 2,056,000

Conversions of preferred stock into common shares 0 0 3,215 166

Preferred stock, accelerated dividend payment date May 27, 2015

Series A Convertible Preferred Stock [Member] | Common Stock [Member]

Class of Stock [Line Items]

Number of common stock issued upon conversion of convertible instrument 7,837,400 405,720

Tang Capital Partners, L.P. ("TCP") [Member]

Class of Stock [Line Items]

Dividend payment terms On May 22, 2015, the Company entered into an agreement (the “Acceleration and Conversion Agreement”) with Tang Capital Partners, L.P. (“TCP”) pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A Preferred Shares outstanding after the completion of the Acceleration and Conversion Agreement.

X

- Definition
Acceleration of the preferred stock dividend payment date from June 30th to May 27th.
+ References
No definition available.
+ Details

Name: rxii_PreferredStockDividendPaymentDate

Namespace Prefix: rxii_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockDividendPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_PreferredStockDividendsShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityDividendsAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (27)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=rxii_TangCapitalPartnersLpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-based Compensation - Schedule of Assumptions Used to Determine Fair Value of Option Grants (Detail)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Risk-free interest rate, Minimum 1.82% 1.47% 1.60%

Risk-free interest rate, Maximum 2.43% 2.43% 2.73%

Risk-free interest rate 2.52%

Expected volatility, Minimum 85.29% 85.29% 97.91%

Expected volatility, Maximum 116.81% 116.81% 107.01%

Expected volatility 103.47%

Weighted average expected volatility 107.49% 103.47% 89.43% 101.50%

Expected lives (in years) 10 years

Expected dividend yield 0.00% 0.00% 0.00% 0.00%

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected lives (in years) 6 years 3 months 5 years 2 months 12 days 5 years 2 months 12 days

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected lives (in years) 10 years 10 years 10 years

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average expected volatility rate of share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 22 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

Nature of Business and Basis of Presentation
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Nature of Business and Basis of Presentation

1. Nature of Business and Basis of Presentation

RXi Pharmaceuticals Corporation (“RXi,” “we,” “our” or the “Company”) is a biotechnology company focused on discovering and developing innovative therapies, primarily in the areas of dermatology and ophthalmology, that address high unmet medical needs. Our development programs are based on our siRNA technology and immunotherapy agents. Our clinical development programs include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA^®) compounds for the treatment of dermal and ocular scarring and an immunomodulating agent, Samcyprone™, for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. In addition to these clinical programs, we have a pipeline of discovery and preclinical product candidates in our core therapeutic areas, as well as in other areas of interest. The Company’s pipeline, coupled with our extensive patent portfolio, provides support to further discover and develop innovative therapies either on our own or in collaboration with strategic partners.

Basis of Presentation

The accompanying condensed financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed financial statements have been included. Interim results are not necessarily indicative of results for a full year.

Uses of Estimates in Preparation of Financial Statements

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit.

Restricted Cash

Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.

Short-term Investments

Short-term investments consist of certificates of deposit with original maturities ranging from 3 months to 1 year.

Revenue Recognition

The principal source of revenue consists of government research grants. Revenue is recognized provided there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured, and no contingencies remain outstanding. Payments received prior to the recognition of revenue are recorded as deferred revenue.

Research and Development Expenses

Research and development costs are charged to expense as incurred and relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and our clinical trials. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed us with respect to services provided and/or materials that we have received.

Preclinical and clinical trial expenses relate to third-party services, subject-related fees at the sites where our clinical trials are being conducted, laboratory costs, analysis costs, toxicology studies and investigator fees. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that we have adequately provided for preclinical and clinical expenses during the proper period, we maintain an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the number of subjects and clinical trial sites and length of the study. Actual results may differ from these estimates and could have a material impact on our reported results. Our historical accrual estimates have not been materially different from our actual costs.

Stock-based Compensation

The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers and non-employee directors, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.

For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.” Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the requisite service period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.

Net Loss per Share

The Company accounts for and discloses net loss per share attributable to common stockholders in accordance with FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

Comprehensive Loss

The Company’s net loss is equal to its comprehensive loss for all periods presented.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.
+ References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares

Sep. 30, 2015

Dec. 31, 2014

Preferred stock, par value $ 0.0001 $ 0.0001

Preferred stock, shares authorized 10,000,000 10,000,000

Common stock, par value $ 0.0001 $ 0.0001

Common stock, shares authorized 100,000,000 100,000,000

Common stock, shares issued 64,949,121 21,984,272

Common stock, shares outstanding 64,949,121 21,984,272

Series A Convertible Preferred Stock [Member]

Series A Preferred Stock, par value $ 0.0001 $ 0.0001

Series A Preferred Stock, shares authorized 15,000 15,000

Series A Preferred Stock, shares issued 0 5,110

Series A Preferred Stock, shares outstanding 0 5,110

Series A-1 Convertible Preferred Stock [Member]

Preferred stock, par value $ 0.0001 $ 0.0001

Preferred stock, shares authorized 10,000 10,000

Series A-1 Preferred Stock, shares issued 0 1,578

Series A-1 Preferred Stock, shares outstanding 0 1,578

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (27)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements

Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:

Description
 September 30, 2015 Quoted Prices
In Active Markets
(Level 1) Other Significant
Observable Inputs
(Level 2) Unobservable
Inputs
(Level 3)

Assets:


Restricted cash
 $ 50 $ — $ 50 $ —

Cash equivalents
 1,500 — 1,500 —

Short-term investments
 8,000 — 8,000 —









Total
 $ 9,550 $ — $ 9,550 $ —









Description
 December 31, 2014 Quoted Prices
In Active Markets
(Level 1) Other Significant
Observable Inputs
(Level 2) Unobservable
Inputs
(Level 3)



Assets:


Restricted cash
 $ 50 $ — $ 50 $ —

Cash equivalents
 4,000 — 4,000 —









Total
 $ 4,050 $ — $ 4,050 $ —









X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2015

Nov. 06, 2015

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

Trading Symbol RXII

Entity Registrant Name RXi Pharmaceuticals Corp

Entity Central Index Key 0001533040

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 65,349,121

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Document and entity information.
+ References
No definition available.
+ Details

Name: rxii_DocumentAndEntityInformationAbstract

Namespace Prefix: rxii_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-based Compensation (Tables)
9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Assumptions Used to Determine Fair Value of Option Grants

The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2015 and 2014, the following assumptions were used:

 For the Three Months Ended
September 30, For the Nine Months Ended
September 30,

 2015 2014 2015 2014

Risk-free interest rate
 1.82 – 2.43% 2.52 % 1.47 – 2.43% 1.60 – 2.73%

Expected volatility
 85.29 – 116.81% 103.47% 85.29 – 116.81% 97.91 – 107.01%

Weighted average expected volatility
 107.49% 103.47% 89.43% 101.50%

Expected lives (in years)
 6.25 – 10.0 10.0 5.20 – 10.0 5.20 – 10.0

Expected dividend yield
 0.00% 0.00% 0.00% 0.00%

Summary of Stock Option Activity

The following table summarizes the activity of the Company’s stock option plan for the period from January 1, 2015 to September 30, 2015:

 Total Number
of Shares Weighted-
Average
Exercise
Price
Per Share Weighted-
Average
Remaining
Contractual
Term Aggregate
Intrinsic
Value

Balance at January 1, 2015
 3,000,264 $ 3.39

Granted
 390,164 0.55

Exercised
 — —

Cancelled
 (81,667 ) 3.07





Balance at September 30, 2015
 3,308,761 $ 3.06 7.39 years $ —





Exercisable at September 30, 2015
 2,376,045 $ 3.33 7.00 years $ —





X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Income Statement [Abstract]

Revenue $ 16 $ 34 $ 57

Operating expenses:

Research and development ^[1] $ 1,734 1,459 5,202 4,118

General and administrative ^[1] 770 766 2,447 2,459

Total operating expenses 2,504 2,225 7,649 6,577

Operating loss (2,504) (2,209) (7,615) (6,520)

Other income

Interest income, net 8 4 10 15

Other income (expense), net (1) (2) 9

Total other income 8 3 8 24

Net loss (2,496) (2,206) (7,607) (6,496)

Series A and Series A-1 convertible preferred stock dividends (700) (209) (3,668)

Net loss applicable to common stockholders $ (2,496) $ (2,906) $ (7,816) $ (10,164)

Net loss per common share applicable to common stockholders:

Basic and diluted $ (0.04) $ (0.17) $ (0.18) $ (0.69)

Weighted average common shares: basic and diluted 64,949,121 17,494,109 44,451,927 14,726,417

[1] Non-cash stock-based compensation expenses included in operating expenses are as follows: Research and development $ 204 $ 206 $ 378 $ 416 General and administrative 244 251 481 532

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net amount of nonoperating interest income (expense).
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeExpenseNonoperatingNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RevenueFromGrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholder's Equity
9 Months Ended

Sep. 30, 2015

Equity [Abstract]

Stockholder's Equity

6. Stockholders’ Equity

The Company currently has authorized for issuance 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share.

Series A-1 Preferred Stock

As of September 30, 2015, the Company had authorized for issuance a total of 10,000 shares of Series A-1 convertible preferred stock (“Series A-1 Preferred Stock”), $0.0001 par value per share. There were no shares of Series A-1 Preferred Stock outstanding at September 30, 2015. As described in Note 8, on November 6, 2015, the Company filed a Certificate Eliminating the Series A-1 Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, in order to eliminate from the Charter all matters set forth in the Charter, including the related certificates of designation and increase, relating to the Series A-1 Preferred Stock.

Dividends

On May 22, 2015, the Company entered into the Acceleration and Conversion Agreement with TCP pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A-1 Preferred Shares outstanding after such date.

There were no dividends paid on the Series A-1 Preferred Stock during the three months ended September 30, 2015, as all outstanding shares of Series A-1 Preferred Stock were converted into common stock on May 27, 2015. The Company paid dividends in additional shares of Series A-1 Preferred Stock of 57 shares for the three months ended September 30, 2014. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A-1 Preferred Stock dividends was $279,000 for the three months ended September 30, 2014.

The Company paid dividends in additional shares of Series A-1 Preferred Stock of 21 and 209 shares for the nine months ended September 30, 2015 and 2014, respectively. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A-1 Preferred Stock dividends was $37,000 and $1,612,000 for the nine months ended September 30, 2015 and 2014, respectively.

Conversion

There were no conversions of the Series A-1 Preferred Stock during the three months ended September 30, 2015, as all remaining outstanding shares of Series A-1 Preferred Stock were converted into common stock on May 27, 2015. During the three months ended September 30, 2014, 2,557 shares of Series A-1 Preferred Stock were converted into 6,232,862 shares of common stock.

During the nine months ended September 30, 2015, 3,599 shares of Series A-1 Preferred Stock were converted into 8,772,903 shares of common stock and during the nine months ended September 30, 2014, 3,416 shares of Series A-1 Preferred Stock were converted into 8,326,721 shares of common stock.

Common Stock

Hapten License Agreement

On December 17, 2014, the Company entered into an assignment and exclusive license agreement, (the “Hapten Assignment and License Agreement”) with Hapten Pharmaceuticals, LLC (“Hapten”) under which Hapten agreed, effective at a closing that occurred on February 4, 2015, to sell and assign to us certain patent rights and related assets and rights, including an investigational new drug application and clinical data, for Hapten’s Samcyprone™ products for therapeutic and prophylactic use. Upon the closing of the Hapten Assignment and License Agreement on February 4, 2015, the Company paid to Hapten a one-time upfront cash payment of $100,000 and issued 200,000 shares of common stock, the fair value of which was determined using the quoted market price of the Company’s common stock on the date of issuance. Accordingly, the cash payment of $100,000 and the fair value of the common stock of $228,000 were recorded as research and development expense during the quarter ended March 31, 2015.

Lincoln Park Capital Equity Line

During the nine months ended September 30, 2015, the Company sold a total of 50,000 shares of common stock for net proceeds of approximately $64,000 to Lincoln Park Capital Fund, LLC (“LPC”) pursuant to and subject to the limitations and conditions set forth in that certain purchase agreement (the “LPC Purchase Agreement”) between the Company and LPC dated December 18, 2014. There were no sales made under the LPC Purchase Agreement during the three months ended September 30, 2015. Per the terms of the public offering (see below), the Company cannot access the equity line until the expiration of the 13-month Overallotment Purchase Rights (defined below).

June 2015 Public Offering

On June 2, 2015, the Company sold a total of 26,000,000 units at a price of $0.40 per unit in a public offering (the “Offering”). Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the “Overallotment Purchase Rights”) and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the “Warrants”). As a result of the Offering, the Company received gross proceeds of approximately $10,400,000 and net proceeds of approximately $9,200,000 after placement agent fees and estimated Offering expenses, and assuming the Overallotment Purchase Rights and Warrants are not exercised.

The Company first assessed the Overallotment Purchase Rights and the Warrants under FASB ASC Topic 480 (“ASC 480”), “Distinguishing Liabilities and Equity” and determined that the Overallotment Purchase Rights and the Warrants were outside the scope of ASC 480. The Company next assessed the Overallotment Purchase Rights and Warrants under FASB ASC Topic 815 (“ASC 815”), “Derivatives and Hedging.” Under the related guidance, a reporting entity shall not consider a contract to be a derivative instrument if the contract is both (1) indexed to the entity’s own stock and (2) classified in stockholders’ equity. The Company determined that the warrant contracts are indexed to the Company’s stock, as the agreements do not contain any exercise contingencies and the warrants’ settlement amount equals the difference between the fair value of the Company’s common stock price and the warrant contract strike price, and the only variables which could affect the settlement amount would be inputs to the fair value for a fixed-for-fixed option on equity shares. The Company also assessed the classification in stockholders’ equity and determined the warrant contracts meet all of the criteria for classification as equity under ASC 815. Based on this analysis, the Company determined that the Overallotment Purchase Rights and the Warrants should be classified as equity.

No warrants were exercised during the three months ended September 30, 2015. During the nine months ended September 30, 2015, 35,000 warrants were exercised for gross proceeds of $16,000.

Refer to the Series A Preferred Stock and Series A-1 Preferred Stock conversions described above in this Note and Note 5 for shares issued as a result of the conversions of Series A and Series A-1 Preferred Stock during the three and nine months ended September 30, 2015 and 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Preferred Stock
9 Months Ended

Sep. 30, 2015

Temporary Equity Disclosure [Abstract]

Convertible Preferred Stock

5. Convertible Preferred Stock

As of September 30, 2015, the Company had authorized for issuance a total of 15,000 shares of Series A convertible preferred stock (“Series A Preferred Stock”), $0.0001 par value per share. There were no shares of Series A Preferred Stock outstanding at September 30, 2015. As described in Note 8, on November 6, 2015, the Company filed a Certificate Eliminating the Series A Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, in order to eliminate from the Amended and Restated Certificate of Incorporation of the Company, as amended (the “Charter”) all matters set forth in the Charter, including the related certificate of designation, relating to the Series A Preferred Stock.

Dividends

On May 22, 2015, the Company entered into an agreement (the “Acceleration and Conversion Agreement”) with Tang Capital Partners, L.P. (“TCP”) pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A Preferred Shares outstanding after such date.

There were no dividends paid on the Series A Preferred Stock during the three months ended September 30, 2015, as all outstanding shares of Series A Preferred Stock were converted into common stock on May 27, 2015. The Company paid dividends in additional shares of Series A Preferred Stock of 87 shares for the three months ended September 30, 2014. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A Preferred Stock dividends was $421,000 for the three months ended September 30, 2014.

The Company paid dividends in additional shares of Series A Preferred Stock of 105 and 268 shares for the nine months ended September 30, 2015 and 2014, respectively. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A Preferred Stock dividends was $172,000 and $2,056,000 for the nine months ended September 30, 2015 and 2014, respectively.

Conversion

There were no conversions of the Series A Preferred Stock during the three months ended September 30, 2015, as all remaining outstanding shares of Series A Preferred Stock were converted into common stock on May 27, 2015. During the three months ended September 30, 2014, there were no shares of Series A Preferred Stock converted into shares of common stock.

During the nine months ended September 30, 2015, 3,215 shares of Series A Preferred Stock were converted into 7,837,400 shares of common stock and during the nine months ended September 30, 2014, 166 shares of Series A Preferred Stock were converted into 405,720 shares of common stock.

X

- Definition
The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to temporary equity.
+ References
No definition available.
+ Details

Name: rxii_TemporaryEquityTextBlock

Namespace Prefix: rxii_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stockholder's Equity - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended

Jun. 02, 2015

Feb. 04, 2015

Sep. 30, 2015

Mar. 31, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Dec. 31, 2014

Class of Stock [Line Items]

Preferred stock, par value $ 0.0001 $ 0.0001 $ 0.0001

Preferred stock, shares authorized 10,000,000 10,000,000 10,000,000

Common stock, par value $ 0.0001 $ 0.0001 $ 0.0001

Common stock, shares authorized 100,000,000 100,000,000 100,000,000

Fair value of Series A and Series A-1 Preferred Stock dividends $ 700,000 $ 209,000 $ 3,668,000

Number of common stock issued upon conversion of convertible instrument 0 35,000

Research and development expenses $ 228,000

Net proceeds from the issuance of common stock $ 9,200,000 9,266,000 $ 1,947,000

Units issued, shares 26,000,000

Sale of units, price per unit $ 0.40

Description of transaction Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the "Overallotment Purchase Rights") and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the "Warrants").

Gross proceeds from public offering $ 10,400,000

Gross proceeds from warrants exercised $ 16,000

Series A-1 Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock, par value $ 0.0001 $ 0.0001 $ 0.0001

Preferred stock, shares authorized 10,000 10,000 10,000

Series A-1 Preferred Stock, shares outstanding 0 0 1,578

Dividends issued on Preferred Stock 0 57 21 209

Fair value of Series A and Series A-1 Preferred Stock dividends $ 279,000 $ 37,000 $ 1,612,000

Conversion of preferred stock into common shares 0 2,557 3,599 3,416

Preferred stock, accelerated dividend payment date May 27, 2015

Tang Capital Partners, L.P. ("TCP") [Member]

Class of Stock [Line Items]

Dividend payment terms On May 22, 2015, the Company entered into an agreement (the “Acceleration and Conversion Agreement”) with Tang Capital Partners, L.P. (“TCP”) pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A Preferred Shares outstanding after the completion of the Acceleration and Conversion Agreement.

Hapten Pharmaceuticals, LLC [Member]

Class of Stock [Line Items]

License fee $ 100,000 $ 100,000

Research and development expenses $ 228,000

Common Stock [Member] | Series A-1 Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Number of common stock issued upon conversion of convertible instrument 6,232,862 8,772,903 8,326,721

Common Stock [Member] | Hapten Pharmaceuticals, LLC [Member]

Class of Stock [Line Items]

Common stock, shares issued 200,000

Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]

Class of Stock [Line Items]

Common stock, shares issued 50,000

Net proceeds from the issuance of common stock $ 0 $ 64,000

Overallotment Purchase Rights [Member]

Class of Stock [Line Items]

Sale of stock, price per share $ 0.455

Warrants to Purchase Common Stock [Member]

Class of Stock [Line Items]

Sale of stock, price per share $ 0.52

X

- Definition
The gross cash inflow from issuance of common stock of the company.
+ References
No definition available.
+ Details

Name: rxii_GrossProceedsFromIssuanceOfCommonStock

Namespace Prefix: rxii_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Acceleration of the preferred stock dividend payment date from June 30th to May 27th.
+ References
No definition available.
+ Details

Name: rxii_PreferredStockDividendPaymentDate

Namespace Prefix: rxii_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Research and development expense during the period related to the costs associated with the acquisition of a patent and related assets from a third party other than through a business combination.
+ References
No definition available.
+ Details

Name: rxii_ResearchAndDevelopmentExpensePatentLicense

Namespace Prefix: rxii_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Description of unit transaction which may include details of the offering (IPO, private placement), a description of the stock sold, units issued, conversion and price per unit.
+ References
No definition available.
+ Details

Name: rxii_SaleOfUnitDescriptionOfTransaction

Namespace Prefix: rxii_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of units issued or sold by the company per stock transaction.
+ References
No definition available.
+ Details

Name: rxii_SaleOfUnitNumberOfShares

Namespace Prefix: rxii_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockDividendPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_PreferredStockDividendsShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=rxii_TangCapitalPartnersLpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=rxii_HaptenPharmaceuticalsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=rxii_LpcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=rxii_OverAllotmentPurchaseRightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Nature of Business and Basis of Presentation - Additional Information (Detail)
9 Months Ended

Sep. 30, 2015

Cash and Cash Equivalents [Member]

Description of Business and Basis of Presentation [Line Items]

Liquid instrument maturity period Three months or less

Short-term Investments [Member]

Description of Business and Basis of Presentation [Line Items]

Liquid instrument maturity period 3 months to 1 year

X

- Definition
Description Of Business And Basis Of Presentation [Line Items]
+ References
No definition available.
+ Details

Name: rxii_DescriptionOfBusinessAndBasisOfPresentationLineItems

Namespace Prefix: rxii_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the maturities of time deposits (including certificates of deposits, individual retirement accounts and open accounts) held by the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

+ Details

Name: us-gaap_MaturitiesOfTimeDepositsDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Nature of Business and Basis of Presentation (Policies)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying condensed financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed financial statements have been included. Interim results are not necessarily indicative of results for a full year.

Uses of Estimates in Preparation of Financial Statements

Uses of Estimates in Preparation of Financial Statements

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit.

Restricted Cash

Restricted Cash

Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards.

Short-term Investments

Short-term Investments

Short-term investments consist of certificates of deposit with original maturities ranging from 3 months to 1 year.

Revenue Recognition

Revenue Recognition

The principal source of revenue consists of government research grants. Revenue is recognized provided there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured, and no contingencies remain outstanding. Payments received prior to the recognition of revenue are recorded as deferred revenue.

Research and Development Expenses

Research and Development Expenses

Research and development costs are charged to expense as incurred and relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and our clinical trials. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed us with respect to services provided and/or materials that we have received.

Preclinical and clinical trial expenses relate to third-party services, subject-related fees at the sites where our clinical trials are being conducted, laboratory costs, analysis costs, toxicology studies and investigator fees. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that we have adequately provided for preclinical and clinical expenses during the proper period, we maintain an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the number of subjects and clinical trial sites and length of the study. Actual results may differ from these estimates and could have a material impact on our reported results. Our historical accrual estimates have not been materially different from our actual costs.

Stock-based Compensation

Stock-based Compensation

The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers and non-employee directors, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period.

For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.” Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the requisite service period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.

Net Loss per Share

Net Loss per Share

The Company accounts for and discloses net loss per share attributable to common stockholders in accordance with FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

Comprehensive Loss

Comprehensive Loss

The Company’s net loss is equal to its comprehensive loss for all periods presented.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2,12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 325

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6872867&loc=d3e40691-111596

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section M

+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-based Compensation
9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-based Compensation

7. Stock-based Compensation

Stock-based Compensation

The Company uses the Black-Scholes option-pricing model to determine the fair value of all its option grants. For valuing options granted during the three and nine months ended September 30, 2015 and 2014, the following assumptions were used:

 For the Three Months Ended
September 30, For the Nine Months Ended
September 30,

 2015 2014 2015 2014

Risk-free interest rate
 1.82 – 2.43% 2.52 % 1.47 – 2.43% 1.60 – 2.73%

Expected volatility
 85.29 – 116.81% 103.47% 85.29 – 116.81% 97.91 – 107.01%

Weighted average expected volatility
 107.49% 103.47% 89.43% 101.50%

Expected lives (in years)
 6.25 – 10.0 10.0 5.20 – 10.0 5.20 – 10.0

Expected dividend yield
 0.00% 0.00% 0.00% 0.00%

The weighted average fair value of options granted during the three month periods ended September 30, 2015 and 2014 was $0.44 and $2.71, respectively. The weighted average fair value of options granted during the nine month periods ended September 30, 2015 and 2014 was $0.41 and $2.46, respectively.

The risk-free interest rate used for each grant was based upon the yield on zero-coupon U.S. Treasury securities with a term similar to the expected life of the related option. The Company’s expected stock price volatility assumption is based upon the volatility of a composition of comparable companies. The expected life assumption for employee grants was based upon the simplified method provided for under ASC 718 and the expected life assumption for non-employees was based upon the contractual term of the option. The dividend yield assumption of zero is based upon the fact that the Company has never paid cash dividends and presently has no intention of paying cash dividends.

The following table summarizes the activity of the Company’s stock option plan for the period from January 1, 2015 to September 30, 2015:

 Total Number
of Shares Weighted-
Average
Exercise
Price
Per Share Weighted-
Average
Remaining
Contractual
Term Aggregate
Intrinsic
Value

Balance at January 1, 2015
 3,000,264 $ 3.39

Granted
 390,164 0.55

Exercised
 — —

Cancelled
 (81,667 ) 3.07





Balance at September 30, 2015
 3,308,761 $ 3.06 7.39 years $ —





Exercisable at September 30, 2015
 2,376,045 $ 3.33 7.00 years $ —





Stock-based compensation expense for the three months ended September 30, 2015 and 2014 was approximately $385,000 and $454,000, respectively. Of this, the Company recognized approximately $3,100 and $24,000 of expense related to non-employee stock options for the same respective periods.

Stock-based compensation expense for the nine months ended September 30, 2015 and 2014 was approximately $1,243,000 and $1,402,000 respectively. Of this, the Company recognized approximately $18,700 of income and $71,000 of expense related to non-employee stock options for the same respective periods.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events
9 Months Ended

Sep. 30, 2015

Subsequent Events [Abstract]

Subsequent Events

8. Subsequent Events

Subsequent to September 30, 2015, 400,000 Overallotment Purchase Rights were exercised for gross proceeds of $182,000.

On November 6, 2015, the Company filed a Certificate Eliminating the Series A Convertible Preferred Stock from the Certificate of Incorporation of the Company and a Certificate Eliminating the Series A-1 Convertible Preferred Stock from the Certificate of Incorporation of the Company (together, the “Certificates of Elimination”) with the Secretary of State of the State of Delaware, in order to eliminate from the Charter all matters set forth in the Charter, including the related certificates of designation and increase, relating to the previously issued series of preferred stock of the Company. As a result, the 15,000 shares of unissued Series A Preferred Stock and 10,000 shares of unissued Series A-1 Preferred Stock were returned to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series or preferences or rights. The foregoing summary of the Certificates of Elimination is qualified in its entirety by reference to the full text of the Certificates of Elimination, which are attached hereto as Exhibits 3.1 and 3.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share Attributable to Common Stockholders (Tables)
9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Common Shares Excluded from the Calculation of Net Loss per Common Share Attributable to Common Stockholders

The following table sets forth the potential common shares excluded from the calculation of net loss per common share attributable to common stockholders because their inclusion would be anti-dilutive:

 September 30,

 2015 2014

Options to purchase common stock
 3,308,761 2,987,264

Common stock underlying Series A and Series A-1 convertible preferred stock
 — 16,743,495

Warrants to purchase common stock
 25,969,615 4,615





Total
 29,278,376 19,735,374





X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements - Fair Value Measurements (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Assets:

Restricted cash $ 50 $ 50

Short-term investments 8,000

Fair Value, Measurements, Recurring [Member]

Assets:

Restricted cash 50 50

Cash equivalents 1,500 4,000

Short-term investments 8,000

Total 9,550 4,050

Fair Value, Measurements, Recurring [Member] | Other Significant Observable Inputs (Level 2) [Member]

Assets:

Restricted cash 50 50

Cash equivalents 1,500 4,000

Short-term investments 8,000

Total $ 9,550 $ 4,050

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-based Compensation - Summary of Option Activity (Detail)
9 Months Ended

Sep. 30, 2015

USD ($)

$ / shares

shares

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Total Number of Shares, Beginning Balance 3,000,264

Total Number of Shares, Granted 390,164

Total Number of Shares, Exercised 0

Total Number of Shares, Cancelled (81,667)

Total Number of Shares, Ending Balance 3,308,761

Total Number of Shares, Exercisable 2,376,045

Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares $ 3.39

Weighted-Average Exercise Price Per Share, Granted | $ / shares 0.55

Weighted-Average Exercise Price Per Share, Exercised | $ / shares 0

Weighted-Average Exercise Price Per Share, Cancelled | $ / shares 3.07

Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares 3.06

Weighted-Average Exercise Price Per Share, Exercisable | $ / shares $ 3.33

Weighted-Average Remaining Contractual Term, Ending Balance 7 years 4 months 21 days

Weighted-Average Remaining Contractual Term, Exercisable 7 years

Aggregate Intrinsic Value, Ending Balance | $ $ 0

Aggregate Intrinsic Value, Exercisable | $ $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

ZIP 38 0001193125-15-375630-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-15-375630-xbrl.zip M4$L#!!0````(`+B`;$?&$UX;3&L``(`T!``1`!P`+GK*NZ;W\^KT@)5ND"(F224F] MV2=;)$#B'%Q<7``'X$]_>I[$TA/+\BA-/H[PB3R26!*FXRCY^G'TRPVR;ISS M\Y&4%T$R#N(T81]'+RP?27_Z])__\=-_(21=7TMNFB0LCMF+]&O(8I8%!9/. M$YXE9'`SG$U84OPHW0BF)Z=GG[[]NTDR\:+QYR$ MZ>140FCQBK]4Q3N3).V$D!.Z=.LZG27C,TE;NN1D+"@@N32&\G(A&2,%OV:;91G4EBC?_"[/2.L9QRQJ MSP,W6I*SY_"Q/3V_H9LN1Z"_+XL__Q&2\W#'0XL;\U3WFG+5&1K:@3N+A+R&^.&Z<[3::?5 MS5K2HC6I6B4MEI/&:\PNCI+?N/-Z3<\OU-)_4\K4V#3-T_+N:](\:DL(C\6G MOW[Y?!,^LDF`7MT!.!!)*EU(?):7]Z[9@U0^\2S(0FZ;W6BS`Q,**&0Y%M$PVI'O%\ MVU8=;V(`;LOS3:1=X!R2"8EFAO1#!&RHW MKU4BU"V)F+O,L^KN>9[/V/@*7#^[8EEY;5L69$TFFRT?&JU-L"\CU[+!\BU' M11:A%O*P8UFZZ_B69:Y6][RCO?OEQKV;LNQN@5H^H0!Z(Y0Z8B<.\OSRX:]! ME@5)<9F5@9/WS+(PREF9[_5F/K^;X]W8X#:@4+5L#+JN;K2!3NR4-D`[L:.2 M-W9V@GT$S)DZ_*?TPIS"F5.ZV96J]DM=D#]:R9C_X:WR*8AA#));A0/97L!- M_R6(9]LV.@PS#=1!02I!-57`NCJ-2WW!='7N\Q9$[ MHK53,_JD8J5RM%O!:7$T-A]S\5$+2_)R5&1QUKXR/B*S7]Z27`4O_)+U+<+E/NYA-[EFVM6&ML-5F2+JK:)YB&TCS77##GFTCR\#`GH9=5<VY M(;7USHHB&[J&&SZI3]0-LVKV_-:L>$RSZ%_;]V+=Z%$0)7.;>&8[?!&H?MO>W)2" M^Y@=A^=N,Q,",;M,U?Z:U@KJ.JE7,!AF6<;&Q^>\21L_>,5WKT>PP6544?IA M&T_K\'JSMZB*/E@3.=[N21`>-KHG11FD#77OGNIV>91^FW3IZ9M^NQNNAEWR MI(]I/&997LT&O!]WRQBC:XLS10,,C&6%U+S+:LGKR*SQ..(V$L17030^3YQ@ M&A5!?%!XN@B>IJKS"9H-Q6]@#,NUEAQ:!F\"3KF`4AP2(B8BB(34ZZ^]["OX M,G"EGZ/@/HJ!#I8?`T1!3`5&2JG2Q-A>_CK,:U8$4<+&7I`E$&+FD&TVF<6\ MZ;KL(0JC@^)5#!%>I%)JF#7$FZ'4H2]18R7CX_)&5!96--%,O89[$PYAM+/+ MO$Z_U2MLL9IH)-XR>-Y4F11DD=A^9KM)Z-7N%FU7!D;KB]K"C(,0T'4]2QD8\M&MFRX!K5M MC^CS)0UA4VPN8@R"O<[Q9?'(,BO/69%?I$EX^$8A[(:P46L1K05OQ!7EW4." M$0>Z*UU+5=AFQ)!#U870J[9/M!^T0Q$N$LB-4&$]AJ8?2V'L4[Q[3LMQ[0W5M4IG M`1=+]8"F::7V1L-X@XG9CFJZEFH@SW%L1'65(%OQ#(1M0_=4SR>N8G`*%;$W M,=5&]R=$N(^>?F]\"%W,NX*!]C3?G[6(9Y+4YCIX5\1#.>&]<=*GGVY;@7KW M6O2V`L9N_5.I/&I3,&Y84!,N30^Q?C@<=&**EA1W6T]L2_N>)<4!*[U-K;D! M==L*XY"K6@/6NV!4W_M"5ZOFM4]?T$G#VXF84K])R'JSV(1G+?K!K*-G$K!@ MFF2M=73$VL$\>G27?5O'&HEW1T@=\/?D,/O&OJ&77`-EZ#'&$!'1FAF*HQM3 M#(/_>QU##,/&]S5F&(:#/L<(0\S2*9@HN!_A?>7RQ.N!6#&[U/I1*^_I*ET[ MZS>%.\&X,H-H]#M4WG>DIUL/^N^BO&\A;4=I8^?-9LJ)8O[?4=[W;'6MDFIL M&I3H9(W1[5%YWS/@O2CO>YWDZ9>`HQ6)]US/;2+Q#H:]MRF M=?&0K!$F$YW6A]W[T27WBTXH8J"&3!L+_5UTR>Z\OJ_9$TMF.^J2>X6(A4.& M!K[VH@\@N^X7GEAV;31TY7N47?<+43SPA<"^B?$@LNM^&Z58=DTUPZ@C/K#L MNE?@8MFUB1MJ\[VJKONM77&#%8W"!E5=OX+;L7$>2'7=KX<1S[(H"A49WD"J MZUZ1]:.Z[D,1W"NL0RN">P4CC#!7O-X>!,']^KIC%P3WBE8L"#;JF\/V(PCN M%9M0$&R8AM%BHWO2`_>*4:P'ID>H!^ZWFQ!6+S4;F\&V7V3H:[5UCOB=>C1% M-1W=<71$B.(B*GLJLF5+1ZKNJ:ZGNU0W[`UZ-"H?Q>KKOOGXOE9C]\V.L*^C M*^LKNZW.]BMI?*-G$'T7:9=M-284X)`:#6-,86J*(GF60XU5R#H^]+3CHT#C:>HE&PL5`Q)KPU0ZK@%#T?E;P%8_;%.QHYS'F M.C)V'GB5#40XF<4)66<.FZ$./1`;(I1>(_([NH'7,/B_UX'6,&P,-K`J3T3G M'T4)LI#G<]D3B]-R(FX^M7,%/4Y2?(Y"_J,[+;A2PA*95N-/1=7-9VSP8:B^ M?LV:#;K&%D^"9UHJKZIE^G$$1&)04G#9KHA79F`#AD; MYWZ63OA]_D&,RX>E!;NMB5DY(+^EQ70['U\\4VLVH6^$L=1,?L[2/-\#[I9- M[-U@BU?P9+K<(KH!64)^`U[D\N$7>':E];U\J&SC_5AW_PA"ZW<>B"8O`Q65 MNQ6:R_(PBTKYZ>7#;18D>1"67Z;:$>1NJ,CHDQ>$CR4T_N8\RJ%O3A^D-&&2 M5.+DO\*RGJ2<5]2/4B!A!<'OXE%*N4HVCM-R75R:SL#Q!>"WJX]F%>G;%?Y` M]!C$#XN'MSY;"@IX^K24(,.M_RZ/_I=@V"(]S.+X+4\]TQ^*1R:-+FM%N5J\ MN/H`P.B/$@SPX-D/T1-#+^"AI6_5-P)X*=^*N6,I5?)62$&>JI"+#Q.,_GBR M8C0BB]BBGW#29/ZY-MZV^/]%!+'I#0LA:;&54J&RKJKC:_N:RE;?@W!M0W5D M%\F8V(A2JB'#4BG?>^)Y+OSV#'FUCUVT,KI-_[&1`7&_,J^;A>)[#URU--O. M3`G/#\'&REE(0HAU,BY8P0,YR/`4C=G8?ODE9^/SY'+*O]K'!SU@CD^5#J-4 MO\S@VOPF__Y=9[J(KO3\Q8QUHCRD04W4&'D?SCIG"Q'88G[$#O(HY+%?%,^V M^GJ1F)35K12R0709;`O,PC`1Q3Y&-CP4N<3155?5B.X[=U2HPZS-`R'Y1%O: M2;$!3V-T"^R,^0UPJF\MS'L.XQGPR@V.;\>`\7'ETYK/K@;1?5#4YG1\QR$& M-CVD:WP'$R'0E&S518[E.I[E:IJO6PW!Q.N4D*DKJJ(O[5_J!6E/6WE>1U
$Q<52\7,-0XTOP'$UFDZ$8-F1*%,7$R+=U&9R5YR%3 M]@CBRW^6K/DJT9T[O3:W`!TM`WY/9%WNX[LL6U.QARIP(^Y5DC%_ZX&9Q_(* M]>6T;Q]'3'6E8$#&KZ/\-S]C_&A-!NVV*.LY2@YN\MI=*^]8&XKW-43TNWWP MYS)X/4^JB*NQ5:Z\Z<*K7XLX3._G$,6C&!O(HBI!5'8),CP($!S3,SR;.KZ! M*?1^@NF:6N='3FB/W^_9DIU]MXRCZ`QP6\N`-^VS90S>%32JOMX3]5$!=%?Z MM;:^&*M#.::U1.P_'#J*OD%I:0&F;NXY'&KK'1JU59O$6EHC'V"(TS(0[CC$ M:=L1BJE.-(KU-T9W0]:8*JB(SF]3*_SG+,J84%-\X)&P6#A MA.F$?4[SH4;]7:M?N":#M*:,ME;L-8BLIR"*JQ7=I>GI^5:GTD(.C%D\TX$A MQJ1BT)N1U6E9=)K5$^9+6!=IDBXF2K92_P_!Q1JQ4XV&+DB:Z]?EEE0^LJ_" MNL,"%=JY6M]1NU+L9HV&&8->PV757XA5*V']8B=NJ\#^L/Y,J-4@LMZHY%W` M-;9=+0SB6#R<<)$-:2JI#^5;RMZRIVS9ZFO-X;`XA;5!`F76VRYL7H(]")1#ZC*,/JP!B(4BM'&8 M1'OI&^>=+-BHDW18B(JP;FGSS)/VXG>1.U4KW+\D$*Z#)8`!1$\\F&DGC0_B M#MSPB7"DHG2116T/=U.PVSAOYL!N46@R2-T4V#:`=%&=5I/2S4<=V$"$/0/2 M*FW5)J5I.RI!3#^/GPXK_>5@G>2:U0]Y;'+-<0'[L"P;F4.XQTX MQ8Z5*Z^^!`5?RW\I3W2)8Q;.PZ_C"9Z$G>=*%+D#MDX&Y4<)..0C-R@B/K'* M;#2K]\%8@5GL?UL^(/SB&&T>VK`4QF`Y[$"L0:_3-1AS649`L:ER7#\$Q7K`C<@VA17K9X!=V`.Q,L"AK(IMEH%TYAP80D7&@,_UG@2)5%><,_P M=!R32T(O2*A:GTG;`*-Y]MF;JK9L')6@;2ZP9>,M/N4[2+,7SJDIJM$\XVT# MD@ZVOGRFXV&!"W$CHFTV\V4/,>?.H9F*&6?I67%!KJWCA.0[X!?&W.73DH3XE13,IU\J9) M-YV`T,G_`7"ZI@,LX\#EK:R=`!Z(%$H(7\E_/RFD)$4H"M`:7][=B91#ZL`Y M9R:P,=]P07K1A9=G:;1N^3(-O?9EBP&4X4=#IZZK&T\@Z":S+T\@:-O;HV'U MWX-+$_.A?`]<*N4)!FVR)TVG"C6'Y;.\<;]9FW:_C3:-+_#L'$*6)"MRV9$H MFJSNILN#!J_=&:-/5UC^6V,]8A"TWQ&K5-$IWHU5PEG5@57U;^0+)N[^F16L MI&V[H7B%G.U.LM(Q[ID*H;_KRFBY'-C>N#"YO M-!8.=99W2+YGT+8M?-,Q=)/8)E)4V^,'L_C(A&$X5[!@V=`4U:]BMW;X"L7: MFO%;$]3^5X?7T;$:W;NFXFA0\8@:/OAX^`4^'H8['M%\S5%E55>-53+J$SG: MRE3.SLO%>]I-O)ZQ;<^CZ&101-1/&O`.G2SKK7O=4#RLO^ET*I2G@O/6=(P< MS05_8T`(87HV1H:I:[)#;&PJ]AI_HPD/#CRXO^D$7]--RS5-"^DF5A%UX`6V M9=I(\RR/$AVK1%;%\+&VN[MIG!;U2IL6G(Y/A,0SB,`2_5)I,WHCLRY ME$QMZUPZ68_0N5!PX*3GPPK&+#ISTW#&&?:C/`SBZB$^7-N>)G4Q!]4,Z!Q3 MAO&'CUS'TF'P`9&*+2L:4A39QY:I>K+AW_&3PC[]6?GI=&V9#GJL@-K?-"-> M)[97=:4N,N_S6('W;D6$B#B:/WBQ'[$/(G?^4JC:/&3NM3,&=ZLWA@7]XJX3 MNSQ\8$7^A07\=++Q97+-&UTVWP24WP)1=KS+>J:H>1%=)J;M:\C4L`EN1:/( MDGT580KC>E6Q-9\?Z@$9/_T0%Q_&T=,/7XL/4'3^:RKEQ4O,/HZ^6-<_GU\@ M^_+V]O++F21/BP^2?WEQBV[._^Z=2?CM@F]].?_\MS/I-IJ`*[U@WZ3K=!(D M'Z3Y(VXOK^;Y;[U?;]'YA>M=W)Y)]/>C^7OGR^%!+`65E'@RIXJ??O,`+$I/ MY1;?-)$"*5N0)]US]B2H(7@$C,\F0740:)!+#VDYFG^X/NT*-+)ZSNQ+,[3U_7_ M?_>^WWU:MY"LQ:2-318]6H\E2;]EP?3CJ/J[G'BZR]M>V\^B2?^N4C!)>%I( M>1I'XP_27\_=V_\YDQ3S1%UJS?#&>_[_T@E9)07WK]1,:\RLKZ,RTYN#J+N* M9MXYSDTE'ZV0!ZX!_$%2'F!0;_"+0I>EOV%3&)W?L^RM'(K\X]L/WJ,TL&X' M[WLCY,^S%,95;X4H/[R4^G^ES.<%FN79AZZ?W1S_*KK6P&_I&*YM)KNK35>RWZ^9.( MZY'OMJUC.\`;+ZXBHC3ET;^[UQ6>`E,]23P#DGCN>@_ZL`6_3+$[O@*TVT:N M4(@\T*6+/RU/&^%4QZ:GCIXZ=ECJ\U(VJ5:%"-;]7`C*%,N+8Y_60.H/R)D< MD)XZ>NIX&OM_]SV^.OQ MU^/O6/B[?!M?7:NJ?HXS+SRZ9OI(UY<]T'OOUW/30WM:N%1:>&Y:IPI"9!8O M;T+_6&+K\3.>I]SO,=ACL,?@<;7/>G0D0'%/+2[^]E(VNKEKY9DR-DF[D.?[ M@-=G$?`Z\J?->%>Y'N^J-4#=NU?SK/#1Q[N>#O<4[RKT8:['P?8S"7/=TJGS M["(#^S7W:_X^HD;[R.]^S=_?FB__SJ./!>_=W<_WZJ,GA/._][@<'>?BH[RU M/A#M;(Y&3QT]=7P_%\;/)\RIQU^/OQY_EXN_RS?9GU&8(J@F];YG`*<>@SV&.PQ>.D8K'/8GZBP:O4+7L.V+.Z[:^W=DU83W[+ZL:R; MCJ8.9='!CFV:,AF*0V7HB*XT&:JJHL+?-I7U;6EL42\??9A*X?_TO>0D=<)5 M+""/S9W6K*E9)_PK;TJ(P"=Q!'].J>ASBBV,[[$$=%HT+J1G@F@:+$+_`.6: M82>XE=T$D@N'TLTS1HOP+ M=H1_)F/I%A8LIL&__9_E\O.M-P_"AY_77![)\&@H!$7QU M_9\R+YIYR2P5?EO,O`P+2;\N%4BWC"=S/OU6@:YX8O3+CS2)*-D#@C.H_^[^ M\M'_XD=+7[A-XCE>A<#:$V^:I<+7(+L7W&4*8,-A$UY_CA?!5#`D@\64T4!7 M+4..?BE_%V!9^?PP>(K=5U*`U\L$+Q(`?T'V(*3W\3*<8=GL^"X"+,)?;$E9 M#/P&)LT00_`Z+"Q*;_U$B&^%!2PW2`%9=W$,V(E!I?63+Q@MBJ]-BV4'$<[D M4?,N'`*G3OQ;;`">$N+AC*3!C!>>QW>_W@?3>_J)K\^GADHT[@TN@[X.86H8 MV_\VI:,(>YY@(>_47UW0E7`="?]8A@^E_+`',`X>N,KF?\'05P9S"*1!"[B] M]2F:5<"]1[#QVPB(B:.(X90H1+AY$.+(%QZ`GP@WRPQ'6OC)/,C8@@..F?L8 M%PE_>;-XD6.V&,1+\UEB,%J"R`L;B[@2/O,E%.]\#<(0QKBIKI>APQ>P<+T7 MX`>!/V2&@;0<',?<#S#)=+J M<<=@$?33`M`'<'JXE("U,,*OEW1LX!0_"/?>%ZK0'L!>WA8%W1=Q&A0#@7!9 MAAGB`$:)BW8$5ZOJP8H\WP?#KHN`Z^3.BWA75CB6Y#2C#Z088(=J/X7AV5?+ M-(C\-*W$R&-?UW(R>'D:'$(VJ+JKV,90%\>&*HO:2!F+-O8^,,>:[EJ&8BK# MW62#<@#9(%\)[[T,]"LDG1Q7M..$2_RVBLWSD1,?_R<0/H#2,_>F_C(+0%]( MX:@DV'F&B+9=&,!;)0B#*FNN^1\J;WSU.UYH?SQ>)NW21F#GOFL:?LJ[)!4V M2Q!N`CC)T_LH#N.[!R!3QD!N444"_AA',/8,-*<8U#YD"[B),XQZ!O$$'X,H MBK]0[VY<1^(M@.@'("T";+X`#(7Z+>#Z/&S]C!L/O'_N96PV'"Q>W(.4".?T MS8`+J]DL08JY#^[N07<%-@0CS/T9;@@P0W\&+*+@:]?+)%\1-3D"4767>'-J M!"%0"S_D0H!"(0T^OG=0*I7PX@J"^7P9Q6SY\,T=\A`0(O#"-`PBFK,R/KQ? MS``"N"S`DX0F%)@?`Z MG8G)-_@3MRI=%E1?DK"E`T63Z@WK$X&+/S`^_CMS_29@)#FJ6Y M?""A[GNL&52^%R';ANDR!$D&*G)2[#-(3R#7Y&QX4XB@@;")V\^?0#8 MHCP909$5Y9=!(8IJ$Z5+D/%`1M1M`G8FA7&^>DD&M.(!7K%)-E%(Y@T`AY$X M)P`]>#G]$TEH.8\3QD"F2Y"#?KQ,B2(R#\1BZA-AS4&.PU*]*]3VL/M%KF'` M:K`KX-A*^($!)3GK`(%K`G$7&LG-X9>6`/[\J[LR5VZX,?4#KX2`,H MNY!8XB0_!,0[&,D/4,9_]4-L98*G@>BL/`T!IBKX:7:%-PZE7"[/J?U+6JQM M`',L%Z@*D;*(DP++\T&A`A`67L:I,TZR6Y`_,9Y#:@>4`OX7^#5BXW:9T!)R M(*LG&F5YRX$6_(!>X<.N"A2;N"S?P<(6,`.1[#?J_+\ M&%8*:<3=\B8X!WF#6^Y-.=/%8P=JP@Q[7,\J*E.:-U%D+&T9>"F1"F0+=DP&<#$U&+5WT8]FY2.H67LA MX2V]]_T,M7`/>%6*S!).Q8PL-R'?@K9=0BZ/`F$6`R`H$3@PP.K"&I`)QL#A M?H$M@<@CSL78-$I71!'R-2_R6/^I`8W@%1WOP$ID0^.N1C'Q\J(;$G+JZ30! M!*4_%E87S!6!T9ZF((R(4WNLG=*B:[9,\%/ M2,CG95H!BG)B,C!9;@7P]2P!1MR7$W*-W[A(&:<9*#*,RR,'@=-5H*CL454T M.4W/B[$LZ@MNW<,63H&4""-PXDPK](?B8^[]"89G@1=2$\IFR%Q]([N4S'_T M+J#D06Y%3@'"*^_JA2^'@7<3A,Q>)DE4G`]F%4ZI71VJ')UO,6`#".,(!EHU``)6/)-I5) M-U+"V2DR$A!-F2\1XO90IIA@I-TR56TQR(KS"K'L@`I&*`*GTR.^7QK%3P M?=.HX'L66]9>8;@X'VLVCML%S>.)O!M;:R)#)6:IYL<4CJ=M4IFC_=:G=VZ#;TSWGOE(/T`$V`:3 MK'DXK^C")C<3%]Z)CT>8+BC\@!+VV:*\-,87'TC?@#,[H!&BN*HD3(FH_#E: M&O$R(Y\Y_'`E\':M*1^50`N00\1SD?,JTMM>JKF\8IMVJG]S`SNY#AVA=SF-#=!%IE[+X`20.? M2<%&2\C7Z,\78?S@HR42^;G-%"^]1>8A MG%8Z_A84B&OAHZ=\!>B<*KY#1AB'7S98J4D%>+1R2_`'Y+Y)D"?FEU<#[B"* M\\;-.8K010?G]][W9D2MQ0K1(Y-TX7>&%@#CU`,^4A:394C*?=43&L+TI//6 M%&`X:S%(VHS[G,CY6;K#O**K-%M@U64*\AU,S\K)FWM@`I/\KMY4H0$R^T+6 M!TKL3DB*ZT:P)6&(!S\KF1,\^Q.\B^^CDDT3D\V)3Q4'OG&4&2@++RBA184> M+&:_85]4WZL@GJX?*Z1%\[/;3&`-,W18DH6<+P0&1-?=DJNL`"G><[+]**!K MPE3"0Y;55Y^-F0.U)?OINN/9P]'^4"4'Y.BU_2^14Q[=[#Y(9B+2Y4,%LC9[^&5A)Z55; M>`\DPF+&(1;P.EC3).L`H0*1C)];#RBV`-DP<1SQD;SI?>#C3N=L/9?01([, M/N4BC%FE!<_D/EJ:-?^%TZ=7SD*70/D<+%*"G/3$_"*RPVN4!X?X7TN`'D'+ M:14)O\(6.*LL**%A3;,5)ZCJ2R7N7^H6' MBZ$JA5_X=0]Z*6&=8.4GL%+>&#R:U>^$Z%:BZKT`B<.B#^B$9P0*$@K39J(E MU@YCUQE$JFD;Q3-2)2>%']VAF_Z6LSPDKX<5IP%>E:^X#!H>%G(LE'<5.5/( M+]ZY7[YP:_"AV1W6/>A_<9+O"T=K.7S!HLB1EX\LZ^T0:0R5;504`]O`<4^OPRM:J-P M8&%>..HDUPU'&^U&H08OT@O:\2(8\28UX%ICG,8I(OJ$YA.($_"YCZ ML%SD#_);HJJ=O15QY'I-<6&U1$R'#RUD[V0\Q)">]D'CJ7@1"\=^J405W@'2 M`J,[ME/L"+#ITAQ8=L4/\A4C*)BUB1%/3,\9AAX<[T_3^SA$IQB](,+@4WQ@ M'L_\<$`!?>B/3GR1\Y+Z&)73QSE[JYT)-#-'I88`YU<=G."XC[5FXA9'L:J5 M,>#S!;&;1F9]$]G!3* MZNT2(\<8PIFCO=Q@]EO[\:!5YU>M%9R5:"7*)C+)@I"K9-7SC$2(UX\/`G/K MG]"Y\QX0^C9.R=\F4!C^>6H@/*R`7]Z6]W=HJ`,(80X"Y1T@'66@)=\L*5^# M*?4QQ`TNEW,TG)UXFF)(@PYVYB41T&D%Z5"<)E M1K?CE47GB\-!*$X6@*:G;E`]!MN'[MWY&UL"=\-"C;]2]6GD=<#=T"!DQ@43 MF=5YT[H?\WF3IS02B+D=;# MD-_;=L!0W,+FQLLMCXM@"Z\%%M<&.>75*:`D\>]YI!6>R[,\C:M;1J0,VXTV M.QG30<;VOH2&'H'3BQ0$^\!$0)I'A+0QP=5@[(.&3I?910XP\!FE\H3>W;%S MBN27O]YZ8>JSI*+:4NIQY/PFI7)?1"`][#\67)=<_/5KG+Q@-5/W^Y`O#!3TC\DY@'%C/B`G$/ MR9C*RE&4+,643,,0QZYEBYH\D<4A#"J.%-?41[JAF!/W#_4/6:OD8@9IK"FR M^<=OGT9_`%G\D>=FBM*5;)7@;X"G#KP#&YF+TC)!<_R-Q>=-DGCNDN0G5GQ] MVQS;8?KV@?)5)\!F+=D>BZ8QKH]IK^$;V.MO_^7O[_``-Y%,S1F),C`:4;-<6.<0V(P^5L:3X41W M[*$$ZU1>_@K/RSHL7Y/8:EO7U2@",+WW9\O0O[Y](N_9OR9HPT\30Y)$'?0^ M$#_PSU":`(\U;=U5==<=CI1=F,:!52YV;T%>)])/**X7SE7N0LY-P(85Z7,$ MXTGE5V6%WXWK'=WV>\,XKUB7-?/+2S"V]JD?8LL3]"#^[260`GY>8+X3__PUF&7W?WMI&C^\ M%&[H+I>^KI?I<*_?OG4^?!K_G/^Q=N^:&]W6:B5?8ZWRT:Q8C?;#UA6-\G?4 M[E?V]?W)INZJ$+7E)E@K+=B>7,>V\<9N];&*+CQ&DS1RP!@EYO0N7TE2WM,G MKQ938)SNW3YA+E*C5Y`V-W': MD>YDJ9/PNLID^WJPY>+C%'QUP96!;YD`QM,,"_D2V>V;D[U:O72L7T)]\ MC$\6'/*RY1]$&57^O(+6"PI!90ZQ$F%'.#2[;>4C1MA?)2:.D30S9T61[K%KPO4;37!_.?VCM%'E50>WS0 M]XO[\3<_F08ITM"6"Y!/@'N%<+\_M#\"ZD9<2#5@\DT$IJ7/;MT/%=CG.JIM M:[HEFL.)+&ICW10=;6*(F@)HLBU7F=BCD\>`]$&Q&\(YMJ2:9FS$)`C]Q,42 MBBQO^:B1$=K+7S_-`60_$3X6Y:XX)JN!$K5%-N-?67`DAJB5"?P\>WG/P5*J MI`,[T6S1,,=#K(8\$6W#&8J**@W'X_%0UB8[Q3WTA3KZ0AU]H8Z^4$=?J*,O MU-$7ZN@+=3S30AUM.18;E;:ZELSB*R1(9NFA%E.:!&YJ@[6HVV( M0T,U[`F,I3CFR16]OMAX7VR\+S;^3(J-K_+([5A>B\=NN,9WE7+GU;#3>;4( M>%ND-Q'KRM=P8G'WEO\AP9(8!\EN&UKZ<#A21Z+J.I*H#5U+=&39$553-ZR1 M[#CCX>@/'7UWV^2WJ5>2V?#N'1%#]?TIVD*.RJ-R`.FEN_9D:$CBQ!Y:(+V4 ML>BHNBZ.;,U2QB-'&VN3C=*+]RX?7G_^?/WN9Z'L=KYS^W/JT2DWPI>)CVI7 M`F)$()0([RIE,RJ\ME.,[7F%)`IK_=EY$L&+;:M@-0KA6$IW%9P.L)G/IJ2- M6K.F4K1S7V&G\"A96D<1>U8W/V&9M$49&.Y+R:O59]6R)E[&RM@TJ])S0?0Q,CP15Q`>V6-!T;I+X3V#(,VP(`S9!S(NMAZA` M@E+[%O_[`FM1+99UX0M2S0E\Y.=%2!;D6H@AF M";4(Q&H]/J]*0E*$U;MA(@0SN+-<9V=;BT7FRYU=8_@?'3ZE#A]S8*7!7419 MD5AGYP:M?)8RSC8M3W9DL*&ND#3H-HF7=YAGF21QK1-07A:(5!HO[WQ8+99& M_0W/"#UJ'3U5Q"RC5=14>ULB9(7F5#_Z-UCW*C?CD"E]Q?ID MP(W')6L8271707X3]=SC\A2,?JMC%#_71(2R6VW&/?-_:4O^/V77$%1P(:`2 M!;42HB5DOLJQ$;+CJ43D'OOO(M=,ED-Z_ECXUZ&1O#_+-9_7,T+?9 M)@H&O(@8.^B6^9IH)E"A,_1=B09[9!G5NG;/(Y=CP+S51-EH2^2/V7V^:`VLH/ M*WE194IH+7JJ'@C#W]>,W;,V9>ET:9O]W(>:NRO8KD+2UB:*7A^*UPP,;#ND MN\Q6G)_\2/,`+1!S/`'P%^'W-Z//__FSH-I7>HLQ5*E0M<;ZV6O06SU)NW/E MJ_DVW8F0^:+79=66(NO<$CX/C9#_1T*M7`2Y"!K&[DTB_-2DC3>5"L0.F07E MYW?,/M@\R.N&PB#_^%WA_AHU@W(-GTI]>S/J2I6E'.`-Z>6[HUWYOM#^6\66 MV8;0'X=4=<](W4(`;=:I7JZFOK4OJBO/X2GVIXSY#S5S1H2O\FD<4GM7%=2# M1_N?ZKE^S?V:]W2JS^4,-XJ/'?TLO]K*9EA)V-&EK=YKT<]/D:+4MH[M`&]F M'NTM1_U,,=63Q#,@B>>N]S0;[AY?`7IJNN-`ER[^M#QMA%,=FYXZ>NK88:G/ M2]EL[\=\<>S3&DC]`3F3`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`+N?[:-7QYOUDM=F$ MI"FJ:LOB9&A*HJ:-QZ(MC1714#73D8R)KICN'WJM4\<"$/+R5_E*-BQYA\X< M>T/%$;9@%&`+M&B&LQX*\T-YK*B&.Q)US51%33>'XE!V;%$R3'GDZOK(U"1J M\]'$O'0E20?&>Q7^/;>H^7N"Y>LOH3N-LD5W&NE*U_?8G69[Y)1]@%UL"QAE M$V!67OA/WTO&T6ST)+I]7#-@]>6O,+(BJC)K_=NUKF8'XX_^79!B,?OLO3<_ M^JKEE[]^_)]`^`"[,O>F_I+:+:@?C^B+K1^)-(<8.U<].=^WAT!DJ MHH7\61N-'/A+T45C:"NF,1H.)6EX\GYVE1(S;QHE9LZBH5U["1S6?RS-4#7# M7IT4;,V[RLU`XTF#+&\(&BO;=G;S"?L?..[94>3P^=J>J37U`6*L':EC*NBWDC2!82RC>^_B! MMYIK;="$BB4B68@7K/L&*,)%[QO>5XD(XA]>M/22AY(4Y(&`Z&3=@=O+J],# M?>N)W5I/&,KNK2>TTW5@Z*<^R-2'S\([L./FT%DN[,ZJ6,-[ZGQ,*[DIGFM) M8P%62**FV=9O[[$R9X6L7/L6-R.(*^B;'\Q5^,U/DI*_Q6.UG@BX2?T>/7&/ M/OK8LQP$U.9'7="C$M8\>_/#GT'S_*XVQ[F[2_P[4*8WX^8-X#$`/7RZ^5%R M6>P7CYUJF1KIHG9QY$J6(0Y4`QM*U>/Y.;;/SQD;?VZI5J M7QJH)WONK-?\O&+UR6/ISRZ/?]C20+X\[O%4L-%??7$P]VSD.U1:O2+DHHD5AA>H"KVVY(%AF(\]2C]>E@:D7DF/!K77@,YI MS<\MBOKYY/Y<(C7U:SZ?4WO)=DO%V;KF@O_BE`1UH$K6P#3D2Y.=C_:W2L:E M@?K4/3;1QUP+6THO"047GR?VQ"NJ2])UGE.NR25*X7[-EZ3MG(MNPWVR%"KX MS/0;9:":QD#2+NYVY/'WR>JE@?IT_4:2>OVFUV]Z_:;7;_HU'T"_67KVRI[2/ULS[OZ>Q&EZJ(1/#@4'4MV1NZ$G`-F M/'\,TC\GB>^_P?A=/\THSSJ(3IYRKK4G/LN:>:#4YS6(."3':6P[_8A9LL42 M#Y,%[2KJ6)-E.`Z:KHB:-%)$:SQV1=<>6^.AYDXL6?M#K>U!=PJTMH\R`(_# MSC9;PT9VHMF;",/4@R_^A]"+4I9DN;=<2&LX&EFJ/1(UVQJ+FC%1@;L/57%D MF+(#(\F6/-DE1UX!-T-SC1Q/@T)U)N*B@6/ MC'[YL3)<.1@,[,8SEAN,&9_MHSJ?W*Y!/\>+8"J8LC6HF5KL9<)\;3^:.A]9 M90)M7]?&5::#*3H7B&OH6.1`^'H?3.^%!.NU)#P?=NY[6``%CRG68X&A$W\: MWP%30#Q@TG1E.7F5%DJ&]<*0I%]I@^;>C(JU^/-%&#_X?CJ` M\0#%?I)2Z9<0RU+HDM(J;:-3#$ M';(2889U$LKZ,0+P?:HL0T5NL")-,J/+/,P`;]`AC`'0MC`24XNX1W M=J9T21=UJ?-8C>'E[$$@H2!P>4,)^N]AJ>-\J>4YNFH M4%`,0&<"9NX+P7SNSP(@G_!!6"[R!Q&LQ"?XD]D.Q)%GDC-^!Z,L$=/A0PO9 M.QD-`5N!3_L>'.+;@CVRNDV,._(A%_!O@DC`9<,O;*>^Y"6JX$.:`XN5F6#' MO'"Z##U6V6F94O8\O#$,/3C>8-+%(59,H!=$&!S3O85Y//-#X"D!$$;A$_D MO*0^1N7TK4FY1YJ9`T89X,@=&$Z0X*C&5(VF*D=QMDSRF3CP^8*\V?\N4P81 M(SMX+GP`'A(@^15+FU._PG*%S>-!J?PUND=FD"YO_A?X%>)X>H^J3UXUZW:) M9:@8PEEEK7*#V6_MQX-6S?A>#6+(M01S'6#*2D(!"[I'*;C,[N.$N#2J%`$0"DI^ M>$>6)$KOE*KW-Y"IG(0L&H%?FO/`55D:39&3T+[#VGX>,%F6%7`PGE*,L M$O_63U!UZ1J("4SVRAH-;7_(9'>PR@];T$%ITP$7@\$<418^%!`1B32LNO,A M"8?P7]P>"_FE<5UAO/=F720B>#!*AL4L<""YN;,5E`!_^()5G?#&NK'AG5;2 M!HRV&4X%Y7E(>8R(2M+!,P#"]RO^$\7M"VW,A-;%,DO1_J0:G&LOVZ\0HS-J MQWW#3!=DEX(%]E1$*NP7AF>C#"6Q:^$<1C,07_,N.:$9G6Y4K>" MTL:J6=4C&KTR6GP+`X"J$">@B'JYW5A=0Z'K?_*GB9]Y"95?`NL[\TOMJ/@X M\D.T(.%L`Z14)(BL2+YFO[((0#1(&K1$X7VPZS(T+5-6K11FY"H9?VQ0,2N9 M0IXKO*MUP=+@+F*0('N!]Q+0P6!!]`X-$'-X$&U(\JM;?!2.TEV5-B_Q>&ZU M9Z\CX9U7*5"@*&U42^4FB-8YIIWIU`]S"Y4Y*ABAHK$N.'>@=I`/@TCML_M! M`'T'F0FIZ,SO41T?MQ6>0ML`7T4U'ZT$-@6S#B+0.X09QV+NW>`>!:!`>/4? MR\A?/:TX%'`!)"ZT_+PFO'8.+ZX!S4@40WQT(+YT"4LMIJV:G)S7T>**!QBS M(9$VB(5R7D%9Q+?BJ6%D<$`4=H M"DR@RVPV(\<@".:=5L6<:;JYHNWE5?6V1A2,A,Y2)&ZRE8MRU:U>A0AD08A7 MOMYB`<8K!;85V,AU2*YJYP(AY^VKCHL60.NT3M@M$89'Z95BVJ2^=$/Z8EVI M0.U\CD>-,K:FBU6.P&CP5E!D8H&*9'>2111$.^!*Y^/)&DKJ%$L=!U]\]/DT MB(6$QZ[DTDHLI*>N)9?%LM,M]E(XO5(!8_F]K!'O"#9!K[?N@!:=L'LV_2`->Q^U"ZI M8)1-JP?24@:Z;FY8)*GUJ\MDBS0&BJH,+$,1VDW_,^%\%21M>P[Y_JH#W;9+ M#6V7C608L@:FJ0QL2:T-LN(JG^V^0BY&<8V:;#R%U*R!JA@#4Y$W>7+.UL/B MLD6>MT^E6.U_>K"?D?`VF-*]06'YG!E3!3-OY$\;A">;.?/HM/7`7/)2-+_S MN^0(>X.`]$Y!A@DAA]K+H1X(KW&H5C\/QY33'*X==2V7^F1+\E$:!>0'PMNW M;J>'B;W3-2S=\W&;E(_.C-"!X-_>,FF-2\T$3T"'.#O;\#&>DH.5S)&)?Y/4 M*_UIA1T="ZD/`M"/]]&^'EQ_Q!B0>\IP.9?";\MN)V68XW+[Q5" MX*A9(81-B&WJP'0WF&\AO.R+&9P7,.IO`9B,-<>IF/:ON-^;.972=$E<5%GQ M7-?]WZO*)2,=ICG.?*QX#UQ_5KES_=+ZW/!*XIBT2O<=*W>I`-&?"\!:$G.^:#&Q@M" M9WYO6I%]_UJ2GZ_07M[ABQ6IQTMA[B*'OM7Y(WYNR)4R9Z$[(/\4I?`+>?$6 M#F\<`@,#8A!<;Q&@5YU'3[#0XD\4E@K[ND!&'B>BH MQ%-@Q"GS:5=:484/PBN#&KLC)VW%Z03X^GJQ\/9#9_Q8U5N)I%Z)+V#V*GJ_ M,X_?]"-SC2-F!IE0T!B3D#AL^Y*Z7&Q;&"Y@]7S@8R/C M+&R\Q?(&A!<&J/G^;?(TV$,MH+CVNZ;N0JZOIFO MX0-#W#5'W)FQ$U!#ZU[ZUMN&)K,`@R:_3\;XB337Q@I)^DJZTB2Z`<3?R0/6 MI"`Z9RU1:W22:MA:/5M7PAACO&ALWK^&"!4T#,;!&'^JZPE>25QQC;AR+L`4 M.F0I%;Z`2LN]%]XVAV]8F2O0ZSJ!CP%'N1]UY:UN3M-._3`0H_\NED,-`X5; MT(]%S.X$%2A).-,L@*P`Q,#;%B1=*2#J0O(:B'YG2^E:.EWA>JC.+,.,#8Q# MY72P$DKI`XPSX8[2E2I"J2Z2T'$H2P.MHG$UA%A3A-F#7-ND2QB\>0(%FD?_ MWN&_MQC@1D97$2J;+[+HTRC%V-*M8.2X*"!E@JP1T:I94G?\-HP`OW<&(E1?&P44W+D,TGO< MG;>!=X.M%`,_7PJ/%ZJ,P-7HPF0@;6$C9-S@JD%&FTWCAYR'3 M`$+M,@E&H.O4W;#9P",,TL"D!?*G.Q+>XF4*6O#8X,LCH.\O'MK=;-[_]&?8 M]:L6*RS\5B@EN:T,J*=89AS.*^-PT:&!Z@`P$6`EJ"KD\=5HT/.6$LBS,$@5 M=B.?FPSMO&6L$.3&$G\^2(6;&'C[:[E2D!%CPK\55U:D_F2U+4?S.OY:=1:^ M5BKO3T-T#]P&Y'UYP=M>M86>,0VG?D'81D><([,+2%HX.^[UA;;?ON1R+.6P M%"IKFD=AXYBHUY+7B+,.^A*P[D=33OG\]:\Y1Z["`;IR%G)^QZ)S`3)L",BN MQ)'3^1B`Q)7;/'#W$3',3+2L+*?<4.RE^Z?/GAL4!RR.,(#72P*\?$JYJ3^- MER'YR-_U00OK;UVOUAKMZ]\="*K.?#\=ZT++G-0@U%4JBLTKF73T M,T'L1[PIJ0>%"<[*!0J2S=I;LNK=8QGOY]V`/L]L>Z!B"OW#D>@/G9\([M=@ M3D6Z6"QUS5R.5*\UBS66:WK1&L6V2ABD9N[G7GZ;#(5M0\7K$>:_I?[U[9BK ML$_(^&^$D3N*9$PFBBXJYD@2-"V)+Z_.\X'\B'S'$<8U6.9 M#'@\Y]Z?91)@6IHQ/(6&V#\3LER39TH='JDYZUZ/-E5Y11+6=6[0('*ZS(U' MKIMDG6]E-5\[2>P<5%+("F!S#:%M28G_Q8^6N>7&S;1Z<$*IGO*41,&AQF:< M3Z1,R>`Z4!%C2T9Y@;!M#FS]Y+7D?;PA'L5$!DO183&"U^VQF4A&2R:291\L$VDM(NH;X'KI MO1/-\#\H7T!3QM-VJ$[?IJM88]MQ14V7QX`NRQ6',OREZ(KLF(XRD2WWY`($ M<4&=#]$7#\N>50SJE,D'#\W<9J=OW@VZHO:" MUAF2=Y^L=+KF]$L\7*'UT/BN:#0.!ATVG`YIT)Q'LTOSW,SN:$2^#7O=BESK M%%XJ2]>WU;/UD;DQW#C-TI6CE>Z?]C'1;N@.55&W)JJHJ9HN#B<&%M208$3% M'*JCS14TVK3ZW__SS>>Q^.F#XX)>'\4)\"JNJ7_^Z+S_-+G^^`Z_CWQX]/KC MB)Y\\_[O_(+7O7Y[_?%G(;F[>2T-X'\_,JN`60C"?S0(\#]@C#>CZ]\_P>]M M%R=OQY\_CS^64]26DQL.-*_XU;_Y,\".]7`:@$KC/WV1.BG3[ROA2B9/#.PJ M[_&(4*7SP)NQ-=J05VR/M2=71/F^4%;EJ,N45P?97`"`Q<`4+I26D`]DRD&6 MUHLK7%%!"GR&Q[TVLN[W;'72JJC<#`4Q551^'G,"$,]^/@]24'8B!>D@3*<[ MEH4J`&Y7B;@%"%[8$H!_ZWSX!*]-85.\1>KO@+D*(O8&MX"MG=*%AW1-=>;P M\P*S&OAGWN+>5GYHMD06;BA%$9^JHJE6[G26OZ\9/VQ=D#%_1^E^95_?]U,? M=>HMBN%:FT_3%L5R#U?TM;VW>,G-MFHO;K2U%Z_J/"`CRG4`#R\_?$:A4'Y\ M1T*A_#Q&Z5!7B]IZC;<+CX8ZM??"U1>%Z/=!=!EX[@\5VVNE;:^+G2AJ]S\K M^MX(L_8=PMSO\S%XRC9Z[X&[F;7HV3OT_,"B3>(MFE@!+]LD8.+_JBOJS)L_ MR%>6TE974ZV,K%QIZ@];#7\F+2'V@1@%(QN_.ZCE*\WLR:$5,8:T&3'FH1&S M+]9Z/HQT_`T#&WQ81'';=%0F>J2.[99^I=B;"$B6C2M+OJBS=0STR9(*;*E' M2T]5>T:?;5[9\D;T2>:5=&CT?0\JB%P!U:/8^J.,B M@-T7([X`8"U[3WKN!<`J2_*5+AT$V&>LL8:4^?(ZB`1JFOCCQ3$OXTK1-XN_ M*^F25(?]'(?O#V;0)#<:N#U>3H67[T$_+/AJ46/U(?##V<5Q52QZ?5'65@]T M#_19`;VA?>H%A!JRM+<#Q!I^;1K1]:C!30&!,`JK=<&R6;:H$%2$`[*ZO-*5 MIO%TU%?*E2DW2\9NO\87?VE;91FLN/T27_QE=9&L2"XL43.>5,[UF9-3TGZ- M28&=E$1*7;-85SA$+0L)7BZ*AG$DHC%7^-]^$HO3F'[Z[>H34$)"#9@>A-2? M8K8`IFVQ7`(J(22DP3P(J3$$3P#U2[OJMLCJRHL&,**IY5:7NA@KQE:\7\TD M+UU+E?A5J@K0A*3R)(;?4K\I3"^H-/3S$@KCI#^C($_USN=]\1>V\LH\A,&\ M31KOC[:*1D3%(J3<9SR??G9/SY; M+=/FB>.8SD9;4C25J&*[KHU5H8/'<==;L7E+Q1KRO/"R>0E6B\;>;E0(D!)$ MRJ+.K#RAGU(O'!B#GHZ),J-\PH5'G=[J;^Y8F^Y09WKQ;;VH(<@7P.:V MC\K>CP\#GLYQURC?_-P?8\W5-]0[+':-PX+`$5%H7'>0H^R/__A1?4Z MF'+1W^+%VKC[/HY^"R+NX^B?$D=OK(G1[@KKUDX74=Y/?9"I^Y#?;<(B/V-5 MPW(9[Y?$M<-L0\PV%@FA)/;ZH\\_C#2_W14WXXBGEV]^,$_^W_SD!U3VMWBL M*GAIG_IM>OHV?AY`Z@,HC28 M;G[TO]'WLE]4?@\W$D,O9'TULTZU?D5#/7?WK4HU>A5#V^KU,_);OWHDO%>J M?6F@GNRYLU[S\XLD^3OS?U\>#[&E@7QY'.3I-U^Z?G$P]ZSD.U5>BLII1V4O M1XK<+GVSV@F7VB.JYV+/@(N=#\]RT=P*PPM4B5Y;\L`PS,<>IQ\O2Q-2KZ1' M@]IK0N>TYFUX2+U`W.FPT>1$W`]'%Y$U)]PW[H1K(?5=>F]:B@@?RDO=[3K_G4>L_Y:#G<5TO!C<], MTU$&JFD,).WB;DX>?]^L7AJH3]=TI$J.;*_I])I.K^GTFDZ_YCUK.GTB+(>] MVIYD6FE/DO=P*Q)S=NW)6<\C;70!5RT];Q@.H[S2=(U"Z1H)L->WU'!RI35Y M?!<%_Z;YF\,.9-Z%_)5"(V(:4@Y(GOZ8Q;5TOA?U;*2T`#CUYGYE07D.;9_T MNC/I/+9K2AOER`-%4ZNT(P\T2:$OGD@\LC4P&<4$$8##&KZ\,N5N.H(QJI3T M%#IB_T]?K33<>F+WK'HKKK&78'AY^L%/Z)U#M9ES'4LQ-,.%UQ1+U#3=$&U7 MFX@C8ZR,%=>V5%,Z>9NY]WXFO(W3%/=$*',8SJZ_'+88I29N2%.5+I\^I@!G M0IB#0-TAD;*S+`ENEBS##_A=M2TX[V3;UKDT[VV/LU-W>\6`(UDJW:R[/6$G M)Z,2<[56]24:L0,VC,2[;@?A$H].;='YXNZI2SOU,%_04S%WPJ1,K:R`?Q=B2U8NR M0"0XX"P/"HC\*C[6@O+B+]WMVQ'*8J3U,.3=73M@*!+;`YAFFN5=L/*%"XN8 M$L&IPVMMD&TZ`&[@(8SAS/S@Y\^)AXOY]#"_BX<;XK*E+6%#G6T3J'U[P1WW@>R'1K6"AE>N MS8&S0XV!E7WMK##0]\KKIS[W7GEK+(]]W!OLY&YK3[7]/Q+]7]\F[SE@^7GW MR'M>A^E9M$W;*\"7T!NOW^$SVN''1:TTV3P[/I MB+>==G9\)MIWPRN_[?N6]=WP>JHZ'OHNO1O>Y:C*?2>\DQ>4>#*P?2>\9PGK MV77".WM-M>^"=X8JPWZ.PO<'\WET>^OQ\GWJA7T'O`L^(CW0/=`'XG0KB3^K MX:W[C;=;'WZ__[`\9ZB:0VEHBZJEV:*F#B>B8^NJ.#;&(U=5X'_VY)2!]W0) MJ%X)J['W@M.(['8I,/D%SS3AL=VT9^5-XHDC]%?:(?DL2C^[9]V,\C#K1J2V M_VT:+EE\'W4ZHA9B7CA=AE[>G:L[1KX1`/_B+^TA\/[46Z84KQ@DF-(2+E,< M^FN\#&?PZXM&+/N:X,`*;C`.L()=J?Q8(K?8[?JA7(T+W#*,SS1^J,;M->ZK MB_C`_(^U>]?::IC)=,6KJZ<+C#CYUER*YY298%7K9DY1YBDQ; M$XV5`\8H,:=W&018'B&1QTS4PQ].&59UZ9NP$ECRV$TXNZ";HX!\Z+";%>MO M1[J3I4["Z[(8N;0)_=N,<(!&8%66B_F7CQ#H7*=#U6.Q3*;WH/C51.O%&8_K M2^,U+[(.M_BC`ZX,;,OL[,RR-\"?R';/C/S="JFS-KDA-8C]Y"?8<-BA=)/\ M@RBCQ?+%3[(`5#EX>Y'XMWZ2^+,284PQM;/1@(I^L`V[($A'Y@RS@]R[?!`KQ4_C/(6WW[90K,_ M`CJ;QXAKL^1A0E7V6YLJV^U`.(,ICVL@?)\X?%X*%NN#>W$LW!XHIH6E)[\W M%B[;`U/5`?)3FA&7P\=5QA!8:;\C,:&]S'E6G/S98G'G>[C.N[)&>8SE3>K_ M:PG,>?RE5OAJ?[6L=,U59,45U='($#7=U41KXIJB/!Y9BJ-JUDBVCUWI0F[X M;,G)9UT))38$A@["[8;[LB-6X:BL#XR<-<4M!@)@GVJO76-D;QC&&=[`PA`? MR157B=BS?]Y0=4M:@X3H2 MWL=?"'3!R`&N5JJ[#4(,:A9<]+#`V;^DBR[$8XB*J/#=BE M["PO`Y/7%9Q6(&)(FODI,'.&(MP5>"_QX0`,V#LT0,SNFQ/_2Q`OT_!!"-)T M":.EM$,,D,)%EU!^PV%LQ90[X[1+H"`58V_@KM#X0OMX'TWN! M1PAX&,0BP-GQ830`;_SM/KC!*=4KF;9(O5*0B<14)5/X?TNB2:";CSX<1Y@R MP@)&TK)$+(E]2Q*&FCT7+!65@8HU& MICP&D2\;E2I@01IKBFS^\=NGT'J`Z(M[[V1NJ1DJA,H>!==N* M9U(7K*)I2&8-W-JRUT#D?/&"D,*E8G;[4(WT894C3PNST@VS)1O=,&\&K(Z5 M-SS/GXTP9J5FW\<1$@EQ>`R7.BDJS"Y,R%(-#=M`4H?]HP^L8.E/0(S^G;F_ M3PIH)YFK6@W0E64W=Y0)Z9'/_OLF`FFW\(+9B`LHCAHX^]>HXS@IQ8Z=E)U9 MG=2^LLF/`:Z.H.N<(,Z%P>EK^!O,5(6_9>T-X!#J*M77CL-IX>S>9:4.Y%H8 M&ES]/$&UNT"UZJQ[.R`_^M/02U.F@F&DR/7M9W^..E'R\#G^X"=@`Z)F`Z(< M5+J3GF2EL!K,I]5DY&Z":*BJ.\"T327ET^Y_)U.7%4VM MP=V^^CJ$!3;J2#HMB&KGULI*747M6'Z3IIG7#!6;-V!>8WUXG@J1_H9104`) M:+=^0>G>CC0T:DY\[I5.S5V5&^2^'W`W:7^Y9L35QA-SQ4Z2$;6Z);<1D#K< MKI?>`Y[P/R@POG@A,LT/U/*B.=2)":13,(B:9M1I9!>H.I19#QJ=F M#7*W`FQ)#;_-T^!LJH^I[R53I*01G)TP)G\/F49+T6I*]?[!GLK0IS`:]'TS`E14;MP M:*NRN@T=;@EFMX#G$8>\:>K!V-.V".G69(Q.H=T$89M#=Q;&::>&HBN2LL41 M:K51V]69B@_RQ#OF[FX'NJ;) M&Y2N55CJT/_=C_"2'`C$FLR_"7:8_&EFXZCGP6`4[ZU;HXDS,+ M=7(H"&!MB%,UVN7>FU7C&VYC[%,7<,$G>$*&T<,X(HO*J*19%<$/14Q&1VH6 MCXEXW1I)TQ70T1%$@Z$4K[!\AR0+"R]OAU2TOZ-@B<1G(1U1+*PN$B.Y&O$? MM09VV3K48;`*BXR9)L&-C^$)POLXJS3!L`88P[!5D!4,M";,::L@JQ=_Z0IR M6A_BE$6(4I>V,4!(Z'3`,)(H$[R[QZ0:`:.+%7]JI`@2Y'W+SDVBP5'$$ M)Q]A77@>IDMXL+6NMPB0[WT`.@'=,!T(;Z\^7'6PL,_NAZXQ%\L$.6G&"J:P M4*EFM".\SL"CV#,O!X'U?(LP$"LO)H9,E=T6";,B!/`?RVH3GJ))&_6;%I"> ML1^PUT2ZC8R4H1W7L%P`AO*QX4BF2UAH4<,LF,_]6<`:%G,>SP]M\0AGM+1= MU=3!*SCN^$Z$;8AC.GV)CY@>-$>H048MF`M,$&+JZS=SADS\'G'+.7[;:6SI M4WJ+>&%0P@1G$IY;EUTY9E(!0QP$AKSN`$C6VH]'Z*ZV35^O$2"Z@6564(1L MS`$F&FL5NL13XS3)7U)-: M'WD8:$N4:$BWK%@2EQFEA"I/>-X\EPHF>8M%""*CT1X85Y'71N+B)8]_;#9T M7+^[!6K@:*`.!%H^!;O6`-P>O+,A^*TH8$L]#I14B;>G-*Q.4JBTNX1!-AZ. M2KO+>JOW"H&\V-!=>3L"H:C6O,O[HPD$>2$RJ>0-ZX57\*=NU.CE\4T_ M:U@XK8Y3BO='*3G?ZBO"SPW2_;9%5;%#02QM+2FF!1K2S72R!S&1^',OB'B' MV8I4?9S`>%&O)+=&8(R:W6NWIE_6JW:-85B^T<99&A*N?+FFZIP'3ZT@:>6, MK]]==:#`0:^F7>RXC>;`4LV!UNXEJ.TQ08DADWL@&=O49(QC;?KB5=6V%1A'4B4X.H8A`]B& M*ZJN"U`;AC56=80=(_E_93X.X3&N#>'_G+A>M\%'QC=%6T.BB>[ M)SJ<$\):GX2@V(.G.B*>ZH;8R0DA-'P/C_(\4.5=0#*[@\F5MJVV_&I3S&SU M.-2/CQ."3$)0UO+KIQPA3;4UY"6VK5G[N,6E`R5W)@$9=OT&>SL`3X0435$P M<>_I2%$(*9V14+JN/!TI41;D)9H_^5.06WCY/^;UHY%;XQ#+C$:XOFW63&`7 MR4_!F0W80$)234/9)*XGKJM8LCT636/DB(!F0[2&^DATG9$[=D:&,3&=;G&M MJI)E&G(%7_N`_4S1:9JZMA=T*HA.I06=BFX;MB'K!\4G_7#3I&0'([+NB$D. M'\I'JD7T)UZ08/%\OU(X/^_9@0SST<$;A&15(N:G&I*^@E4+-&Y0(61Q,C0E M4=/&8]&6QHH([,%T)&.B*R:Q.^T/Z^6O'V3IGXT4@8-`>T%8U530RQZ'506Q M:@)6]7\J[V1E='S,=B2WF*O#P-D0+<4>>GJTU*[0VZYEV@HVJ-"'`+.M M341;!9HQ=$66+$/5)TS=Z!`2NFVO"9QJ`G7\=*UUZ%@UY$:VZH(E-A$U:P(L M'CX!BQ^[XE@Q)H:K2[JI6ZO(J.>SF-+3TK?(A[!6@QVA$KXW?#10H"B2(H\` M!2X.H[F.*CJCR40<2A-W-!XZIJT/$04*V+*_XKBBI(N*R7T?&]>]@[NC2DV5 M6(]25.X+![NZ0;8Z,DK3W,^/C&6:BBVI6SI"-B+AN`Q5DR5UHZ(TUD$Z&:8L MNL8(&*H%.I(]'LJB99N&Y"I#V5:'W2Q%EO2SY:A;@6^8MC.R;4$?"W0)6;<<6W>>#P,E'.S*0+].P36OH:NI$<0N^^:N:7V!EL2!3@]H2(5L` M<0JH86N-587#E753(Q*]TA1@$FX(%*UH>VJD\E8=28%U)^KUYMQ(H1^ MFCX![M/E`-H2PY&JRK7;!PV+-ZU74F7'<8!2@)=:Z'&?#(>B-9(GXDBV#!FT M-WLL31B#Z4QI.DY2(#&TM+NOC3AI"`Y$E_:UJ M!UMBM7IR%\O$?_FK="4INK*I/L8>P5_?*9.*IB'1HP,30\.?C"OED4[_SIHR M?RS\Y(]<:1"E*]GL+F;<`.>`E)93]'_'&"T?@B)[:EK35VA-O@*ESCP0K;4C MX`@8SY7I/>&[3;'=$N.UU-/B>&]1_F:/&-@3PGF3-E9R[TW$-._??:S0ZL\< M+!5]Y]./:+L4:SL(NW`5=:S)LB4ZF@ZB71J!(CD>NZ)K@V(YU-R))6M_=,KU M&K=0KDQY#WOQ..0<\"@TYCX?'F0MQ4,=_XU'WR\Q](Y7)+HNXQ?V+P]7 M-;)MY:'>YE4S-1ML]8JS_G&`[:4>;B?,C[[Y7U<.5U&D-:5ACU0.]Q`@=U?# M5>QU()^V&NX!,-$9!U,/JCMJ+=P#@-EMD=8W>T,IW"=5>CT`6-V%7I5F,<2C M%7H]`)CKJ_F>K,[K`2#MK#C1***T'8R'N24^!#_NO,DPI;IR?[J:GKN`/7*' MBFI-5%$:*IJHC1Q+M/61(ZJJ.QR.%4>177T=5]+T.OO=IJ+G$PKT'6!'.^OS M*8K248&ZO3[?GLI>'0#$3AU"UG1;>F35J[V5/SH`P)U%81S62> M.DKE2T18:;RBJ8AG*80(Z#LQIM@J& MVBY'KB-:\%S9S%:0;QL,U%01W&G;2DFS=3A6F MHZE#670PYUI3)D-QJ`P=T94F0U4%;C!T[(9EV4(2^^02>[[>;L'#(Z^WNUNF M-*^W)>U\K[??>=^"^7)^('+:+MFE9LWG=TRR8>WCHF]G3)SY=?=^$?^,KKNW M#9YY%T2G)OBZMEJ@7;:.&43$\7!1P09;,>^M@@TZ#88:[Y:N-.TY!ANTTL,Y M"`*Y[5PHFGK,7G$MLPE::U)9GM3,V`3O$[B$T88^U(VO`'ZNHIMJ-H<<7CCQ, M;,)A"]_)Z^(UY/,K?->%DWW&:\AKXC5D4WLR3LXG777?=<7D[[NN6!=2GU96 M3*:R8L8_U7<76U.LB9B#A!9MO.,\Y97_(V'?-K*H/:SJ\5?^!][W_=WV*ZV! M'F>[Z7N-\]C7IG.H:!E/@(H&@^&`U039`_\$GQ'AV.D,>R%-[X$[_>WE?98M M?O[IIZ]?OUZE_O3J+O[RD_OFOV#M`!1L.]AFW`%!6/$+%E9TZR;`1 M__I3ZT3ETGZJK^VO/]70\-<%W2!5(,G^?WO7UMRH#4;?.]/_P+A]98TDC&-/ MNC/;[>YL9YQN)MU.'S,**(EG,;A=(^BZZ MX$AL021V+1J:%J!Y+.\N$U*R%I*-3&2QK+U"HNM^(?/K?H;FF:`5O93ZT%)C MAP)*R(QY#PMS6#36ZVJ*Y%C?,0VGC&T6_>@V>$)Q5Q`\$;SM*'@EZU5R\-;F M6T^8WCVE'8=[IMY04=H],QQ/RA/U/O%P"9NX= MGLS=PW!\DZ(F)EPSWT48T'_C,K\*'M8.DR=3%?MR,80@.,WV0B4`M2.[9_E]2*%?]V0L1ZZB_+>9K M?M^/.&;C%/O#=-(7[#-U5"I4:VN?>XZR4!C5&VI5+&YP])TDG]/`ZRR>.P]T MD1S?>CT6RENMTO.MV_QJ+;;:):8[E\L34!.NW6#KN4!M0$]/!E(3/>L*<"MP M.)!>B_M`<_/8ROKI2V$CL$^OKI]ZQ&,KIMB(FB;<@_GU<6,3K<7V#,I\^!>S M%0U)U_F`A@[4?,AWJ2NN>+GU<=!5=NCP58=0UO&KEN,L0C0CJG5#:7&N#M%\ MH[K<1SR?)MB_I3*E",>3>;>AU!-!M?/E1#+)%=B61SP54T%5:6LZT'(0W^S# M^%;G1(K=?.LVOUJ+K0ZTZ,[E\@34A&LWV#K0T@;T=*!%3?0RQ_H(`.G1:\2Q MKGOG"H;H4%SCH3BI^:!#<1<.Q4G)#AV*ZQ#*.A378ISE3KOVT`L_7?-G(< MATS5BJ"//:@*FHWFJ(HC8P,>=P'105+@;75Y^H;DSK\YBPGPZ M%3WIG\$\36*>`IY?]=*]^R;5+F[D-%EG)%^=4=UU+F[TH687(GU;7)5TCYKQYF'%73@ZMS-4P0\&H-- MC8E9!\89:IU:=0&89.I1ZJ\S``!N#XUK.^%-)9$B*%ZB$``FN"B%M.6B.74T MIRQ'MJZ8UMERCJDS.]R45S@_W#1[92:LD/?B]G4__U]DP=Y:>[]PAO<]_=S] M6GX>/Q9V56KVWE_IC-IH25AB7/ZA++\QS:_\=5&C[>_S;/\@03B;!E49;ZO1 M*L_-EZ_[A;+OJ_J&_"JKL36G.7VZD06[6?TN:T#^^#$,DR!,R&0:?#=>??I[ M'(5^F7(LY;LP>NI#RT)]]KC/$O:R]`EMLI3WKPD)/.(M2R'R]T,W2_8=OEPM`Q[PPC5QV=T9%A(,GVMD'YC]_]]Y3G=%T%H]IB.K@6/C,?3]\$<\-JI_\N4/!@X\ MPULM@.`/?S6@91O+2R>_1,.K_-(&3IY5-L>>YX1+L^RS!-"V\[1P`+(K^RJ_ M,@8("D5TA<=VE#Y$KA%&'HE^ZX%W5BY?6HT]L&0I^H_83!ZC<';::!CN M8HQ`GY:@BGI250JUKU*PC4C!-B*%VH@4:B-2=AN1LM^*U/K@Q8Q`^N#GG\0# M>OD_4$L#!!0````(`+B`;$<[YHL\X0H``"*/```5`!P`&UL550)``,L_T16+/]$5G5X"P`!!"4.```$.0$``.U=;6_C-A+^ M7J#_0><"AQYP?DMVVR;8M'#B[,)`-@F<;+NX+P4CT3%1BG1)*8GOU]]0EBS+ M-B7:ED(I>U\V&V7(F6^NIAB@0+LW*,7SK@_=RX0=4.* M`JC-N2+LKPOY^,KYZC3=YQI$,Q.N]WGY^>.$%Y29^_;4.+8&7?&G16,_W3N.)-`[<\0FSL# M2IVQ*B6=,998/&&O$U=*8[@.:)3)L]8*PI<'03M]WOWZ^NG.GV$=MPF2`F)LIJ"K;5K1_I-?Z53'\(#C%8SQQ(AE.@_D,G[4D\6<4 MM^)O4X$G9RWQ0HC2_/O>R7%/E?]AR-W0QPR@>I-F\I$P:"&"Z"V71+&X MH$A*,B'8VUUTPWI?$\0M$GB/1MBA\F"*`^(B6CZL$8QK/A[0``L&S?^$#\*Q M65OU`A^N_>U55J?S"R2G'RE_EB/F$8'=X"#I-VL[6.`AD2[E,A3X&@7P[\WD M/)2$82D'S#M'DLB;R:V`H1Y&$&6M`\^+K!;1PT:E4MB6B1X'5US*6RSN0&8\ M"`)!'L(`/5!\SV'V\SF["[C[UY13#R;E^(LBE98#E/5\ZX4OG M2MZ(1\3(?R-F,%A*3HD7_;+%&TE\E2&6KB`+S3-OX+H0E`>$/=Y"89<`(_P2 MG%-HM]W58TO01JLY^=`8=2\%KEKMU_AY10P!R$/F+OX$$EY,$7O$$%6LTA"H M`AA78\2ER%.UTBZ18,!ZZ4]7H@D]$VOP[I5;7VHG*F)5-=2EFY/..M78=3XC MJS#+;U43=E5#OL?^C`MP@19^?R6-JN51-;C-N$;1IMJN!*TYTZKAISQO)JM. M[QA3(`$_6(*T:C@Y5V[Q+9K'K56!4@X5I>:J*G]L*$>@RCO86NA138?2,HGA MN>EZF\H99F`"+6:>RIXLOBI>Y>1^%KR[:\PKEL@PI1-)`7*`EC*\J4K><9%M M]9AUE*&;(/D0I>E"V7Y$:-95UM#%-)#)E\@^VKU^G*W[(?[\9^QJ2C!%97L7 MH5")@80310^8GK4*B+MVY!8A]JX(>B`4](AEH>@:>BO2+V/]6T2\$;M`,Q(@ MJI-=0VU%V7@`B/8=%8U"`J+ M6<:2K_^:C-8WP12+Q>!QS9F;*_)V6AM29_-=>1US&Z4EB6P)]^SGML974 MBLRF4(!R?+4*9NJ++'[)3L#^]!;`:SR9%^7/34*[Y":M@#8.O M%'S_#8$OGL53W$=O"/?V&3+%>OR&L!KYSRGT=\V!;AK]KFIC6Y2Y!-]O4-_> M!_PVJA1\@^:N?<#OX;&ENFG0C*=?1\FX:YH5_G0@^.4-0M8E!U+4)V\-M6YI M,[7M7G,@F_7TK6M<*=X&.3)F>#=7VE.P#?)DS,!JDV0IY@:Y,&:831:H4OC[ M!-SU3'UGSZ/9%G3SD)^%=:=/F&&!J-I)Z_F$$8C?(EEB]UZSRE14RL8*VHB! M(B'X6J@UEN0:5#]3Q\C!S/6KX49%;6`"O@N9U"DQC?!9&NM2#IX0H;JC:VI; MMVN"PZ`6*TA7;")C+#I,6GHK&<9$E%@(G45MTEF5MK`';*.TEL'=U40*"MG/ MZ0[)$_%@PI,+P983V,B?(3A:5\(P;'2JU1#B&2H3Q:?<]OJOPR=E!$ M09@Z5YP<=-1(ODYGU4O=.JUE,@;;^GXC4T"%4'/&BT:NG>SI#&14DM59(Q=3 M2E##;L.P9OVE77,U%;HPMA](=7\LO863?-FL?R8H`DEZM=-"TJ5QLT:VG:70"M%ZT' MIK4DK#&@]7+U0!/O*$J$V[JSR!BB46665LG5\'PKN`KDO/.YNBUJQ.)T%7N, MKQ=2V7>N;N4(X5OL"G"6L_A_2*4UTL-BYUS)>C"MM$9Z6'I_9>K!M%+KV:/: MYKB6A^CYP`4'2V#M#F[=BKAY!;7`M\.A#[.REDY&N1A[4H6.(RE#=<%U=&5" ML@:G35\4E:L/FL45HU\@&A+01T#5$&2I38S+^Q]6;XA0QJ9MQK*JMZV;.XA^ M/JN;;]5=E1`4<4HALE,#G(I'"ZUYCYKJ@%C=EK;CD+1##;81_H&$6OJY?,'" M)?K4=6Z1^N09(S#AXS2YZ`XZU@-A4;_Z`PPPP!`G3G9* M31[`QLXYPVUCB@:QAMCJ`M\^"SEKB:^#7,)&[L&M2&G&\<1A&QW?EM*,@]%4 M:B?+5M4\0UKF1^X/*5U9!WEJSE:B9H],!:M(M1S3R;H/RU5/^RE93-WB7K-A]$^2: MC:_?7+\UV-#2R!VRKZ2ICSPQJ*UB[.WO&FBR>[HZ>MSH;8Y&O/R_[]ZM297E=J[>BW'K/:]:J]!2P,[ MZ6"'?MG(T'\G951Q!Z&]Z6S')W4M2VOZ1FX=Q"SU*=M:`FJ2[C5/S-H6UNC5 M6"M"VGJ[]5L"NWPYM6:@2WG8M&:8]$^4-D70^#FYFHF;_UAHDX2MIWZU[W;6 M3$[S%S=K)OBAKV*^+3CU[`3ZUR>U@G[H*@&4(PB__`]02P,$%`````@`N(!L M1[=&EI+3(P,34P.3,P7V1E9BYX;6Q55`D``RS_ M1%8L_T16=7@+``$$)0X```0Y`0``[5UK;^.XU?Y>H/_!=8'B+5#'26:F[02; M%LYM&R`3!TYF=]$O`T:B;75U\9)2$N^O?P]IV9(BD:)LR:0T_K([D7DYS^'M M7,D?_OWFN;T73*@3^.?]DZ/C?@_[5F`[_NR\__5Q,'J\O+WM__M??_S##W\: M#'J32>\J\'WLNGC9^\7"+B8HQ+TG]!;X@;?L7>&IXSLA--:[<_Q?GQ'%?^NQ M_]H]^/3+Q>2N=WITTNO-PW!Q-AR^OKX>$6*O6SRR`F_8&PS6O?VTHNNL]_>C MT].CCZE?)D'DV_`]]>F28,0[MH&BL][I\H^!3Z&TMT#^LC=RW=Z$U:*] M"::8O&#[*&[4C>'V@*$^/>^G$+X]$_JO"9V_4R51X M_;`N?C+\Y*L#I"4NPOP;K8@/V:7!R.OAPIXRUGO?)F^.PW&?*AC<4<01$^V\)XY@Y9T:&TM>&NM$Z@YK?'$*8G MZV,\O7%\&$\'N0\!Y6OFTD64.E,'V]5)5VQWGR`>$,%;#$*%QL,Y#AT+N?7# MNH5-T,,C-\3$A^%_P3OAR+?6/,&[<[^XR>9X?HGH_,8-7NFM;SL$6^%.U.=; MVYG@*X=:;D`C@N]1"/\=3R\BZOB8TI%O7R#JT/'T@<#!`#L(FZTCV^:S%KF[ M[4JU=%LG>AS>!90^8/((-.-1&!+G.0K1LXN?`C@KOT;$GB7R+4BEU,WGB9MIHJ7M;P3+XT!4>/(W""'_(3<"'_!B/W- ME@(M_+@+ZRKT4B.VR\`'035T@(TPVZ>8$&QS/M:^S"KV5"/&]+RX_BT"":1V M<*I=U(V*:P%,D,8^Y3TPL=:.7-C.1I1&WH)]HU^AT%-PA>',\6"+VTRJ\73, M"_Q(T(Z3MWYB&N=4,W-`L9OFYT'D>8@LUTP=62!JP*QL8(P%'=6),'JF^+<( MMK[K%[;_U3]R2AW4(YK=!R&F3\%&"-\(5W1,9LAW?N>=P69)`]>Q^1\%TLA: M5KG"U"+.BO.^/;(L4.%#QY\]0&7+@8[P6WCAPKA59X\N0EO-YO6'UK![0W#3 M;+_'KRDR"""/?&OU$U!X.4?^#(-6D2[C0!/0<3.3N!9ZFF;:-2(^=+V1IQOA MA+@3;?">F%A?ZR(JZZIIJ!LQ)SEUFIG7\HZTPJQ_5%6Z:QKR$_86`0$1:"7W M-S*HPCZ:!I?7:UC9A-N-H%7OM&GX29_C:5KHG6`7BH`<3(%:MIU<,+'X`2WC MT6J`*;N28CBKZM\;ZB&H\07V3O5H9D$).XGA(6*I(A1XI-:^+N:*^L2!(]?M M]^*&TS`VM1P_'-J.-XS+#%F%!NF!KF`*P`08V'B*(C>L1EV^^GYH#3SD^%N3 MNJK=)*6\AX&'O6=,*I*9J=H@C7-H@EC1,QYL.%.-TJ(&8GKMC6^>N>8S-,,B MP[[-W(ZKKZRI>IRFJZZ'V;Z;I4?1$\J)`#)@<\GT[3*?=T`*!Y"S?8KH,^=] M1`^K0Z.3V(G]Y_CS]]B#8W"#LZV[,N(,'_:NB<7/6/W MO%]2>*B';A)A^\Y!SXX+?,2TE'1!>2W4;TQD#\BQ;_U+M'!"Y(IH%Y360CFE MF!F[BPE=_:B/KM$S#0FRA),@6T@?G25S-5-&.Y5*3'U?5@?5S+W.K$_P/Z;X MO""7VZ/"2T3(TO%G7-<5H%"KJP45.Q_&4Z[67<7R3#&$?$$M]`:>YX0;4V#` MS7_87]EUBPF7U-"%(/:'2Z?,^V(Z:+V*?<$3#+I)5')^"PKKH#MU$,.8YVT6 M`@2EU4S$4K*!*E?7C$T^MPR1K/)DJ'/?A#/L/O!A@6+L<0%;%/3Q)588"Q%5 M:D('QG$XQV0E-@"MEG1:%9?50766?;*#H:BD)HH7H#!A)YE1A46UT+RVCJ4UF-&;(R1<6%XK]7-@ M1+*X$;'6W<4.D:J^G;CVE`2>T)2Y[C(HL\OU`@+SC:=5?CH^[O<6Q`D(@#WO MG_9[$07B@L7*UFPT.+D@F&#\>XLQ"M2D!-P_6@QN[4=(T/S3<#0"H/Y]+C]F,O5F03N2?OA%LO7"<33]D-4,ALDB#^T'[$0VT=CL8F]0IG9*M-G MDZW7W'6I!K.:T33!;>YBK>I22'-#9@)/L'_N)':I\W$#_L3<3@-E>WK8Q4%.:6@#57R:T& M5A3+D"`U5^.MAE0^GKHTX5S8=!'04F-]YC@N$-\2$433*X]K6K-+15Q*?"J(Y$8C)7 MCJBN%V5#&A.,YHH/U3`*@^H3J.;*#]6@JL1=)*C-M:SOJN:E49IKT"CQK$I4 M>!579L(!M:/'Q,RG["U^AR#[)NG]=JH[J!Y&>TSXQ+#Y8;2^54($0:&F9D2K M._A&43B'M?=[LE3$2'(UC$!P2VFD3GU#,BD>`:FT# MD"D>`F6UC$$B/09D-8Q!4'X0E%8S/?+E$.!C9(!/_K*D;KK2]N(R_'9J`-*# MT[!>UYJR6-`=;V*IO*#=B=@LU+5`T88,E!U@9J2.-F2BJ&%5M>2T(3UE&\2R MY6JR@VU;I/G5:JZ#;7N4Q8O5X/A@-:A*SI8V1`57ABM9I@8'`&\),[=[P MW1*B8($>HJQ,\.CGWQ`TC![M<04CES<.9\[FKNST;=IQCIW`.J5868>][4?L M8X)<]CJ*[<&PLH@6QO"8)JG?0JVN#E2K^9/L5/%3LQ(?AJR&00BD(2+R.IU` MH2GFA3W(#$<'RXJ^PB_8#?@5!2IK1*7FP4O6L)=,BU%880]*BQ$E2T6[W53- M0EPG:"/,Q0H"L=(F]^ZFA?+=1+_OHP'DBM*&=E/QP4E0>5?86)?OJ4>Q2QCI$@XW+Z=?2,H M$A>W:T./_K2^F^@)NI*JK[F"^NF]A%UDQJRWG(O26:]0L6-X-&FR7]@&RA-A MQ],G..*N\((E\:1?RA5`4JFI!5'@X^471'[%X4WDV_+=55!X7V+DSOLO$S"V MW`([*(36PLY**\-\`76G`S(KO^;/'OWJN*KM171NBA$6[^XF(9;:7>H!W!Z; MB^K!7'ZM9[LL+MO@%AV15>TLVK0^#.HSW3Q:GDV?3GF:XY3R^`MW.U^_66X$ M%-P`&R^1:['<>KXK)FVFBI>UK,7SZ(>.[;@1LY,]8BL^HS*X`F\1A3&N]R^\ MKS+.18[)6MK6\K#=;I1?+(L;D*A83?;80@Z6^8UJ:]X[KA4I![1>CO1]AQ'VEO`G@J0Y]-*:NA`\#,B M!/FAE.9L&;W:TQ[.UHQSJ'2#TJ^1*"EAAO'-"%U.Z$FM6_S(^%]KWEH[:#K; MQS#4I+EHM[EMS<:\D)6[!4UTL+7!&+$-Z`HYO^:&P&\#_)T0H#U%4#W2H1$Y MM<9]0GYNFAUID=BX;I!#>%[/%XS8W_SI@\*/6HQ0_&K@#3D)V2+M45A>BPHL MHJ;D;;SR>EI4X$(KMOK8J-?7@6Y#1WP;M9^^,S]>!O;8G[!E3MB-FK[-+Y6( M_^0>KC+;5+U]M)5+,KM!?>UKY<[%14K:\:5.A!N M"/XMPKZU5`,EK*D5T:T/!SSE[#V5&DID-;0B*.*KU,*J4K-SB#29C>72U69Y M5T8G;N.[0&G2:&[.(K7M0U954XI9R?.;A7A*JVDQV=?U=KVFER85-(4M7TXU M^$*@K:!7T$7:<%O05CPH>4G6X`N#MH(K,05HOS)(Z&UH1*M,34\S8X M>KMNCH=@ZF@4OL(X=!N0C^P>C_V.*?OCT[=H/82,HG,FY MGXVB1I-!.'YD,?`6@0];M'0+*"[;2JIWXK;JZ-_A&7)78US@8"PJ44<4,AZ*M7Z&B.7CH:I^L!&5=1V_^ M!2?I8LD/6K5DBGR-PTMCW_%+8^\V9UD6H;R.MOR:U0745Q%3T!Y@D@1V6NI9 M"4,I-2`)LA3"W*G16DZ0)^3/XJ?#'Q`)?>CR;E&X/$J+&_`2UF;+'-G_BU9> M)@'O%2H:@.?P?EQ;WH\[O+ZF^34)H5=3:D8H3H@JD'4Z[&]49E"%)YW,34+: M%JW*&T#F9B'M-L:"1Y[,-4DKPU71.ML0E[0CX(U:VH;XHVWG!5M7VUX^-+:A(AXC`A6VR%066G37(',\Z!Q*!1.K]G"UQC$7&V9C MW!\,7:/*QO$VO2JN]'RZS(Z>!BLX<4S"JS*N.\'=9FO6%4"4OD)S!>80.?1] M10ZM*(GO0!F3B3.;A]=OL/D[%#\0Q\*;'VG\*Q7&YVS5UB%>J@*U%7TS*C4U M(U+TR#H5X*Z]FUJD!^GSSP^PB;''=*W5@[AY,:)"[5JH?43,[/[5=\+,HV)/,(DH M'(!.[KU`U5HU4W]I!]L-TE3XQY*Z\]-[N5'-GB\H?,@ZVI M/V0>:,T\V`,?[O$K_VDKO$GE0T:%2>^PU!6W7LVNLW$7GFH*MCD$LN\Y"%8E MLMO@. M"&'UF^P3]G1"<=I*;)4K&B" MP]RCI)84WU-SQ;Q2?(H!J0E6<\4?Y;$4O5A\JDL(J#.SV8!L0;W9K]W!+8 M>""U;UY)&$_'O,"/7/O2D0_\!;TY7N1)8T2R971$LGR!H2RE,E-&2Y0O*"98 M$I&6_*Z-.BD'TR6,IU#3S?NITXM9QB[>+_\1DR%GJX=3+I9)F=A!-'I%Q%:, M>MVQ?6TQLC*:122GGS-;;YK,L\(>&5W[V";Y1+/]]:N-F[D#)H_JN0HJ%F<@ M2J-NL,/.S,:?`A>:<4$@V?=\?-=S1SD:"QOZ&+LFH*O\78E)&OD;$]!Z_DX< M^NL-P?C6![$>TW!?^T%AOYWDYA[W`EGWW>3M_O8!6?>MY^W/F!G$L3UZP03- M\/[%`SD!K>)OSJ-9%]_N\K>!:;GY+VA\AR'>LT MLD(8A7"IF=3HF>+?(A:M]L)CU`X/-+3C6O'#!=$Z+X@^7.FY.9]D3R@7>R\D M-0Y7`FY-_>%*P"Y<"9@]CDL=@:+B!M`NWP,*RQI`M30FM:BH"31#?[+5+BAM M".5224E.S:C=RE\TI5S,CI%FVYMMH\'H=L-P.RW?887U`BDV5VIT)IHLL!`%684]MS[^:&&57AA^+= M)`9?7JN"5DU0T1Z(H1YP)5$8NIF.KPI8I)6T*">_ZMB:G8PO?7Q;KD.6#*PQ MI[:BD%(#V+:$[I8JJ1*T>1E;+61KO]ZK^R#$]"FX@;/#MQSD;E8C'9,9\IW? MN=,*A`@:N([-_[A`U(%U"MH3A7*K3_$ME:GK[T:^/;*L(/)#)IQ`90ODCB>@ M]<)E-Z-]/U#7'\R"?(]?4S03J!/YUNHG@',Y9QYQ>NNGRSC0Q,(U=A"O$?&! M3KJ^8+)M9/(#TK!9LHE[2)S?M.C#>4K5P:FP&UL550)``,L_T16+/]$5G5X"P`!!"4.```$.0$``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`ZU,,R*MN\'3F9/.2/#8I(O_CDA,2]K9.3DED\1N%J M3VO-.`H/T.8G4%3?A+[G>%@=PSL-0!!;Y4+5+B?6?#S?P6=&S2`H'B9@%7B* M`NK'F,C\ZA%5JQ1`_,0W]JO]X..S#8%VT("=ZL?Z<5/A0-FD9N/AI(29&*64 M!BBE!0J7@^2R2G*M.24#P"&PK1I@U(D/!(IH0P)@SW[P?"\A.&W$A>![O="H M9T+=BDBPDZ.#TD(%8O``Z4(ZJR@=_K'&09Q&<6'RC"/D<*+(W_8#C""Y(59` M)%$1"(Y<$J*DD!>@ ME!@0?KJ0S*I(MB:D3HADCE@R;4B1FUH))Q)5P*#D?S9QLB)`C>_#6TR%]7S\ M%2>7@1.N\%48D]_/[/CY)@I?/!>[GU]_C3%A_'I-MQ-)-+DDB[$7AOBFQ4\? M76G%9_?\*V\$3*R)E8$[9P,E($7O*4_$ M(WQ`.5MHRQ?\T@UML4ZWI<21*D:F MP^%HF#JBC#!BE$_X\5&1-DJ)`[F2'@1GSN%K&)PPW,=)Z/R1RNT4YU#L MMS+C$IK5%;<_/F/L?'P*7SZYV*/0G-`_4$1."H@D/_V^)%[%I9[EBV\_549Z M]]\UX&JG4^7IAB%QX'\6VK\]VWE0M.@AEPO(LA<$B2>Z_D; M,KGA.TP6^&R*N_CA^!LR"WXAHE!D;1(&K.O'"SL*R&08W^"(86^YHCM3(O_6 M"6V=,U$7#*L'<[-9=H18Z!=M.T99SXB:%"KTC<)'E/6.2/=\@AL@S@'0;*9? M>0SJ]R%9GB*;-:=ZL0D?)[DVXZTV<4F;3EF;.-,FB?=03!D"G1J[1&5IYNQL MD([067U^K2>P_.'%_1BUM,?C<6PR,901NV#_E;F[;Y0>U++>%`U9^VGH2#R3 M"@0[]%>-PW*$7NS*"_!E@E<]N:PM^>/Q3SG/ZFE+L^FDT]@+?:-,(,;%<;JP M/94H]5==*_%(O-P.1#MT:>5A,L=_?;57^#Q;T M=)[M*[*&_:"`[@-(4;`'T[/"#H.0=6T673*"DMUN18.SSJ;3]?)'VJUUC]3V M_$2;$8`_>CY`#NZT[^XN[N_@35AZ4KLK))Q)-R0VEK[1;M`M4_SH^>"D:,\] MYRRJN>.]A"AXY2PET13O+,M`W!$8W+"57';U6RA#;WU%8KR8UAN\(9[\(+F8 M0S\K63]L)H_,KH0P,,3/?[&]Z#?;W^!S+W;\,-Y$PO09X??:85'#A'IPNUC, MR]"@U!`CA[;T(&>&@\7;SA+PN)`8V"XV1)(;A0^EJ4/6S@2\M(ZEK=EXI(`; M0R:8SB2VMA(;,,DH6*,2J,`GG\]V[,77CY6+CZ_\_^_QC^0SZ?P/P1`K-M8( M,S6.E"UO>IKMK3+"],A@2WK`[[J^HF_I?RE]Q#H`@EP?TELEZ6\(WR1F8@<# MD"AL9[9%*+;0$00>:0+X,G#I?R[^MO%>;)\FC"^3,SN*7@FWS'\(AE^MK48T M*C&DO.X>C69I5C6[L$'O!+(_%$@/D)V@C#J?$GM!XAI'7NA>!*X,C3U(/RE) MS_*K\98T%3YYQ@C3VY*/B#/9H_QWB1TEFC4P5=+``W[R`GIFV;,>&CUR#QJP MI!J`=,JM?%?1)ZMKR1R7K+Y>5V\/[IH/6/!.AY.AU>B>-2[Q]X/FP1K8PM-H M5"KN!K13DCGH_`6O'G#4:N33)N`8Y'RT*,*3+5&$L$/?.$V@54EW8EK[BPF+ MMK(Y-@.LH!QS,'7#XJC+P(FP'>-SS/_;:M`%),`Q5\]7BSR-T^:IC_>!LD[0 M^ZR;#S!;W/UI@NUZTYOV;MH+ MSBJ+9N`:MLO7@PKD$ZN!"&W>YU/7DCF8O,5Q$GE.@ET9]ZW,0I$D.(+5^&QQ M-W,Q:@3VMD]T]/#O0W_,*U249)XO:`>:9A?10I-0GN.+'W[_2O1%_G@9O!!^ M:7&8P/WB!7;@E`K%*!^6'TQ6LP<;%0 ME$&G\7IUQCS'W6:]]C$M+V'[R-VJ(GQ$058=QBLI\3%7HB&UH;H"6]7K'#P2 M()['M^/X^O&.%O217K.J^5"G=]CIO46:^NDTQ3LE0BV5D0&^.W6H1%9+B;2A M2VA0);S42P^-@*N&.]#UWP+AX*KUQ5K+FDSJH7`%?KKDJ(C//I7#XTNR'J-RLPJ# M`[1F>C"B=M)!6*B!^!ZJ!'$!X6KE\0JG=-DL`D*AXECM1)')Q9J#:F*@%W)@>W^QHZNH[N$%M=E M2499V9GFT1.VA,&&B!UE\YH/%]8N6@:($*9!'B>=IM/E%8S`,=2-V$5491$> M$?M%E-,-@*LF0Q4@3:H?8.PQ1N+E)GD.(^_OVW=#Q:.]TP(&:U4V6A1LGD[K M,,8)HBU%<%P=)F(-GF(NHBT5$0!7(B,4X*E6+T;@Z#*.-^H82K^&Q`]G07E) M,%K,:Z*Y##L#Q,D9`IQ]9!.#QA.*!@:8LK5)P5+0A1%`N=XD]#UP^DJ[ZG`6 MFT!"IL"'^L7*T6@LPTV!IB'@V5M*,8)"N9!@,*JQ12F6JJH!!I3T@FCU,QC@ MM+KT-IF=3F9U8&%4C)EC]I"I!AK_//Q(OAEM5SH#-!H.!T/^O]V`[5_1;#)8 M3!:#D35B6W'6:+`XG0RLN56>J/@+FEM+I1'@(=0J M^Z@B?+R_]&`.2(18J0.J51N<`V*._R;3N\K!O+R5=NAL-.==;,J5VO_KMFF=WB]>[-C^ M?V,[N@C<XA<<;+#\L0#!QQIGI'H.U+=-K=-T*S@C MA%)*/3\DT#3[="&759(KXI0@)PRY;17G"8GX,*`@<;+CL2*EY,\^IG]8!BY9 MVI+)[._L=^%`*C35"IAF?M3+!TYG.7RV9`=%I0 MMU@9^$IP-VY_.AU#S@V=S2KKI2LF%4UR,1Z/9\/?Q]PD\V[0]2/*.D*D)\1K M+E^7:R[W?_VNSAMI4LG(4)4('98FO5A5O80%O=BY7L*6>NG;O1WL-:BO.TS% MNAW?O4V6R@<:":=AL,-C#*I:L#596-;>SHYU9:Z?VT,3^_JX'C71F7O;0QT[ MKNU@=9CFU4HN81^/MM4JR%HJKS]R_4@/]G$0,ZYNL4\O,)R%<1*S'?L'.\;N MC?W*K]/)BPT=2%3G^NL@3M5/?*SL+:SS4IV<8I-@M+?Y7&2[*97N4*HF^IMZ5M6K?IZ.9]TX'/"< M/*TJXX4GZ!%8JHABCT?A0N3(V/!<';EP^LQ2:3_W76D%?RX)Z MT>W1;)2!.:4TJ!Y!0V&S`\DXYO;(SG.SWF&!*;7&,N#$VNIF)R/=!2`+C8L@ M\9+7R^`QC%8,U8*07;V=]AT+!:94#6TV.UUDNQ0I669HF!%&WI;R1\V;$9T+ M.2H)29?8G#`J4`9;1O0DLW6XS'JV%5K@<[N5H*JN_C-U,E9X?@1_!N$+^:UZ M#B3_5E.NCI`!Y9R6T70TJ^`I36I)W_I@Y/0GZW0DF;6/9#JR=1K-+$O7D2M" M-QYHOI`:&K9?@F`A[UZ]PL1H/*Q'`DOO,@('>TI5BP*Y5/HQL&-:]0@HJT"? M_=]DSZ4*TC;KO]-L^Z7.U7<%AN-%Q?)3%PF7K-F!1%9;B73:?*TY52U^5WA] M]GY/R$K&A?VS9NNF?:J__C&?5!<*M#V<);?GWE+B7J?5%HVB:JRY?!#[91=V M1)]*CK,Z9`V'=\+/->Z8B7A0G]H7H_3`+2.U+:`'?HC6C716]@J?'\8QJXM< MO"B&[/7:]QQZMHPJ=UB?0]\E+((^O-%DD\5M,ZFZ3``4/=1WR/+\W/,WB;`> M6%,K0'A56%'WQ&-K(4+9@*5V.+SD"*=K!MH.$I:!;BN8*Q8,"DD"8Y0!JDXC M)N!*K9!*4RM`7.W]9N/I9"K&E6E%4SJ5.I_5KK)935CT%@IA"B525%1B`L+: M8LL(5+6W+/*G4W$T:!R`]A10`!VT3)+(>]@D62Q8O/BE5J7==_B)X_N*@?)5WM5=[97^YE6^R[WW:+@5?;^26H36SJ($H*R M\$/$L=J)H\_&Z\VH;.0U@H-L!?UM0YAI.@LL?Z1STZ?4L_I[V/-I=B+!","? M]1T@AZ4LA[:]FEJC*6W0[,H+9]WT5DL8D(6S]#G[^F^UVWJ%@19[?]:\9/(Y M(>!G[3L0RVHMEEXD"`QL%Q!U6H#`Q1?;B]BS"KR/KW`N.BUNA^X8_5V M=25_NJ=_9%ZN3248$LR.L_NK6SQFN&-WB@EG M/`SP234\3IOLS&'3Y7J5S,RKV&0 M1U`V>0GPU30'BN_/K_D?_\/#$='7\^L5?B%J_^$U+IWDC2&P+.6H12K&K&:Q MDQ-$WR@U:'!V*.K.*D1%5.VX5#+56C0VJPH8@P4?^"7"?]O@P'E5`Z"P)0SZ M1.PH;ZB-9UEU\`(IE-,R!7K=R&GM(R<`[IK,4P`ZJ9)`$;!(/@Y5'=25J-,=2FUXTMBC+7`$NG&%$0I+PIKVP!CJOVB M9C[-KBF+S,VI,98A.<#%J770;K31*S(-62OO0G:P&!I5TVU`VL M]HR)$QP@1A)9P"_\=28G`])U\DPOP'A/@??H.30[Z/HAQM$+VP?B/:#WJ>`? MC'B_3\%`:U$F4!YV36M%'^5=A]%L))]`2T?BA@2QG0DN MFT.5!0=%JL"$&P%:IS8(7/Y,G`*]4G\=D`7M.HP]_JH//X@4V(&\C48D2AE1 M?\`V7S]2>F3A1"A^H`?M!:+\?;IPC:/D%=WX=,E%;XDF2HG"3(^=2FI5);5+-$&1I6:2)6PIJ,9`=$G#4K6V MYB"MY6[C8C$Y5<4;<%S:@^`[\*L(;D(\VLIX6Z!Q[XA4\'#+SQ&954G@XV#L MQE^(")=QO+&)>.QEIJQ0165LV[34_7B+&ENJ!G,GBAQY-CQ M,WVYQ0^_(SKJR$N[H/%5L=XI_7M"FI'?UG;PJOF%ESXTP7T.TT)&&5'2**-- M'U0M5FP!>.6E#[FMK=SK3&XV].O-@^\Y9*`?<014C&8/'.=/O+3052?NYC_L M=8*#FV<[6MD.WB2>8_MQ[4S>^+ENQR+A1=&63FEBYIQ[$TX-K@(8\(_-@67$,&G^AK MC0&]@(46#R'-4MQP2B@G!9ZQUXEHUAZBZ0K.&XRM&([+=&$`3JYH3_0Y-G%B MN:P%'%Z*;+0HA+Z8"#"3T0--)N],QGKP*,@(A*`Z,Y2@:$DX:/)W9:R^Q_>8-1%4"H+`3<=6B/,ML(<5?W@-*NS!A^[$7+3!0 MGCV3+\FD2!/CPN7(U>J0C,@?!/AM>VYF8])$QZ6@13A?C#%X9+?/>M^U(3H:FN^>="4]@-_Y$`0K6>_J]WO[3M[.\O[,#2.G=#(6&8/BHXT;]F-FRAE6\Q.`'Z-V*9[41 M#P8[,E,48TFHFOX?@KLBRV2?/]%5,XW4?:'I^;=*M^HE6*;S=/'"**#L=4N` M6>-@,:P68O1M[Q)CR5YZJY,58G8H',4M`[?XXCM_EDC@KAJ;:9P9FGA1OY$] MRXZDB\^_T.TG3J@?1(2)[7WZ^ND`WMQ=?+FYO+\[1W?WUV7^B MY=?T3_]Q?75^<7OW)W3Q?WZ]O/]ODY$J.Q]KI5-@Y)[QI)UFZ\@^A$%CVKOR MK#&?S,8[N"-6R,F`3XE[B5.8!`U+M1+;DP`61?G-`(#Z9%5M``J(UNYY85D+ M,3!,FHX.DI!G8^RB!#3KHMGJY'`Y8-X07)B^6COBZ]';?]1]&3KO6?4>[6P^ M'<[XU6?2MM]+P74`/83KD1:NY5>9]V2=AWGT`-4/T(T=_9%G>7W9!*XA=Y=W M;#R_J5R6&F(>^L5.-A&#^/7CO;?"YYA5'XO/<>Q$WKH&'VU::IR9%-A1WQB; M#=/8;4N5UCJA=%%&>(`*I&'FJLYE3N%$U@@N\@+BZYF71"O>SRM:X\@+7<@9 MK(6]%J(]H*R;M##*WI/>R(1^@>4=X:VO8'OH?6M M&+ZW1I5":U2FE0H?,&&_);>VPH#47;I M@42-=`=UG*K?A"?KDKU=PP!M^T;;SF&.HW0J;)8IC!6W71<45N+$ZJO49Q^$R#HP@ MVNC8(%>2UXHX-(*0$8)W&1+NU)?;D[F:F]B663$_@NA,,;411*'LBM$1A`(* M%%Q`DR[-AOWA$80J42/=P2$3XG@T&ZGM0]2YAF.(('I16'T$4>XU>8-?X*Z"N"`F.T>6+[?G4?._# MP@-/Z>67SW;L.2H#ID`%"N?-K*E;VWPV$GJ"K!OJ!HH/GJ4]#1#KRP!P=:V0 M$OR0O5[[GI,IHOCX7=J#,0!5MWPAA!55"0/R[VEE&L?QTTEGSHAK=4=',ZO>@ZD-1YG/N([VM)$Y8[9A=)"[='2 MAUGOZ!MXQ2G]NF.QR"UV:!ZU4'VP3J0[9)4]2T>J[N2>T=X'K1=A)T`HGSZ&K^8W+/L>=^_W"2+(>$.L"%?O(R^[R7@#NC_6I M!JNJAIBI@1NZ4U1#6GL7O>G5HY-K?.J5H_%VAMUHUXA5(#O(:U)_0LV@*E)FLK13]2-1@% MEJ:SS\9V)H"G_9,),TL%1/!GF-U*S.:R:],1)3V(5%(($,(B[&*\HELH9]O" M8#=973"VG2*],M2*A%[<*?.E?H8^/-W&F%ORJ$`?Y1WPW4?@6T?]J8'?1<(1 M75HL3T9[ZT`C=%O;>@7%[30)`>C\=#+U,*(3P-WO-$)SIW/UI[P6D_2YZ>T1 M?48$)G@\4)9BT)A+A"42Z4*+T)"*D*@7W@B[;P@1Q=]#XJ!U@&0-L\I4NW@` MCP,[$L\JBY>!`S1!K='G$&'C" MV%>D65DDZ)0+B2W5@L"`](OKZ,D.TGUY$LC%H>^Y["_+P"717)P=6EP_IA?. M;#]_T+UQ8NF$MDZ(=<&PL@6/YN,,E(5^66[EMF=V>%+LFQZ>Y+VC;??P4YQ^ MY5F:E*?-?W0)QI+'Z6QLC/)1-*DEOGXL2O"9GNSAN%@:C,A8.*:F[S-YS6DE M_?9I@D_K0I`6R1236:.OXUEIK%9?D2OR<\I7L68?PW8Q)2/ES8`T%8-4S@\_ M:?D\=CZ?*Y(JKU;91KJ_+G&NY!8[&R@0=[E]./4K4;JT0'O]MSK=4QT#ZOM& MD\D\=2N%UX+9TZ-.GZ7:&SW`X5(5CGK@'P"6FE0)44+!P9#0-LV@H9%N;'1Q M(C^;%$$"D':@A)>.)-TY(T7O$W&!]\8VNK,HFQA23AR;3<9CGC?YZYJ$FFO[E24@DEC)1O$: M.]ZCA]TTBW+`T@AYFCTB';*_1K13>N=@G7+!L\Y8N%6\AD"SK6T20T0N675A M]-U+GEE[6M&0?4S_$F.'%W#>%G76G*;8K6*Y+WJA\W5&$V5$$:,*6@7'#Y`Y:9 M[LJBA-[4,,DK0:QMST6/8;3UV\0'K]-NF!:P3`NZXHCV=EZ,*5KJT0@@LT*_ M]V16+)3Y5363VK:0\*UC2/U!R_EB*$9N?4%D8Q#;@>0,K#<%>,9;D3VYR&#P ME%FO%)E"?742])?3M=R_ M=!SLI[>>LCB\^D*LF_:4KP]<>K>*E1'ZWYL`H_&01O,A^L5^1=8\>=8L M%NYR*LF,&564DD64+D#0WK&L5EE6-MP#NE#C-D%^JAU[L`A>&;^YH&0V'\MDP'F3[ZGD?B'=B M$C*[4`/#Z!?;B[9WP+-K$&RU7+@3X13N1(@BJ7X\%^GV(832T*B%BJKVU)-: M6JS?^E/+I'AEIC-;@9T$Y#ZS>3J0*-:@B8'=*6\7A&5MX%T_9Z1%$LULWNCK M.4VC7/L^8I;BK1AY<;PATI+E;T5T`W%7-DD%H!7T`X^L&SNZCACHW=_H%'&# M(\:?TI`+&X-A3<21\@1A31<3P7J'T*:58CAUQ,@C0I]#T`0$=B-\_?[#VDYC M"',0V&2Z8BA*%06/2>X@EIOD.8R\OV-7:?!W&H%AL,J)\DRPL/)SP2KV.$VT M)6H"W@X3M!YG::J&+144!F\BLQ3CK%9!IN#KDL48+08Z;0",*\Z%LDL?3F;U MV^.:#A>GV_T*ED&8%52EV]KEFTEGD->2.A?:*@J= M52-A4O.RC^D%(`-N,+4PW`KVE#0&@\70P=B-OQ!!J5^F-PBN'PNE_X56T-1. M*PX;F%%_XG&ZR+?J.4V>BI51I0=OQ:I+,=.4:_%96D?DP?'\DK?``E]GX]Q?/VH<"MC#TI`?DN1O1:/3\]G=2Z*]C-`64_\$9Z\ M+PJKWFYP[.-P>M$*\RTI58]?CS7P.L?^(!`Y@S;*-`'WM!9*RYN4+2@`XES" MEKHESX8C$;YY?1U]MRGW179G>JB)%EPO7HMKY%W*]J8N0W63(J'1_%<[ MB@A?%S]PY'CBHMC2)D!XK?*A;ICC:>W60$H0Y11[P2*Q?8^&>*IP/$S,<=MP M?4,K7+``/>V0?O&=\V!`V'&8-I@R?H[H6Z#E'9)\^1'Q(@R9\/V<;2AEH'=F MZ$*ALU&52POA>$5>2>1I:S4$Y%KKG?U7+(F,Q$WTNE8A'VUV(4]SUUJ,W%LJW.NR[1VS*!IR64`PJY6^"U7\0K?EMGS. M:'*:O>J4COYYN+*]`-)Z]Y'`4I-`JP6+GU.JB@EBQ=CQ[3CV'CW'3C>B[O%J M'49V]'H?WN!H90=D>KA@SP2+AJL5#9U(:,-8BWHT\S1=:H<^74/E/=`:('D? MB'<"A*?^],`0=_'#82^#ERZYRBYS>@'1C=K%3U#\[@..$L);*Q[&!\28:.69 MQ(/G^`7[(8L(6;9+6H^(Y[_`&3[:^1ER0XN'Y\ M%%IAQ]UH]23=\M[BN&1A9(Y95@DL2SQ+"",HY61;_[W`RP"E MW)R$CX]0;@E2J347],OGV?PBK$8FV'D.0C]\>DVWDZ`V MD8"MT]HQ3[=@GB8\Y=>7ARO[^AX&P9SI0%X]7=X&W%&WK2B^&&]#/('734F: MY#GWDE(*7O,P*ZF9WJP4X]`DWSY0:&D*LMHMUB>6-9JIX0OX[>C.A=Z%6U%H M$QZ);F&PRNC;>Y-#4,%4VMD-B]"N/*=FOFK;6G=-4W76E.O13T:C.2]NVA2B M(7<3T9175O24+,Y#%T789R4WR'*=_NJ$<1+3:QVAX['?\S1/FX8X],";I[#9 MQ3@Y(\*O@_`S29NT\B):WX\>JH3;-4N2KEEL])"M6IQM>*2YEFI?PU%V?4N! MZ^,=H+0'@/*J?8G/G&#:$CUBN`*J[?U(7DFUI6Z,"SW8PV7B'=WFEJ:$'IP= MY7."Z7S4M*&2$A[PQP5?T;?TO^`O#':N!WDT6BQ!9XLXXF2 MLQ0::H57$S?JAW3$[#*`<:(HHXK>%^BBE##02X!=2VRECSGDXKF<"BS25(VS MC#4ES<"@[04'&TP3,W]F":;"P:U^IQ5+E<[5GY4W\%COA4\"V.'@$V?28?',[_3@0,Z->-7AN3 M;69)?2-LNACR;=D"*;IUNB'44;*EB+X_>V1QOK+I0["T*@$FP0R)"?S\H=CP M\1&SC=OWES?7`[2.2!R>L!OV#JLG_V&`;-*FU`M[8);E.<2A[PY8KUF1QD&: MCQ73;^DZC%!TV)8P^TSS'FS7.F>>B]W1O'Y$E"PJ#@#YK4`98,^U:W&M&A-+ MY!)JV7I5]PGYEJNB:CIV65\W].PJ*]\@'[+*MW#NJ*YGK^A5WWO^(OM'HYY_2#LTM4++>NR MX:"]?LR6\5G=^WO[P1/V>`V[)CUT=)2> MK_7VQ&21)=7UAU7X[1QH!3-GF!44Y04&RZJD<7J,A!U M%MNB99)$W@/AD>HV"4N52I])H$VT\3:\HVPGJJZ@.^*-V9D*6W+LF*9UL8JHW`VG#5;)0E7#5H"017M:L&T3#7?ZP33;4< MJ#]M,QIE*6""A340?CH0B[\*%@8G]$X1S\=)Y7/ZED^A2%$G`\>]@T"R[!X[ MJ$.0HJGD"\3Z,,<-%/8I1=N4=)7"%BF%`)Q>M*37P\Z]%\_%@7MK)\*0M_=^ MP9U3A\(H!Z:GT^SQ>97=>NEF_:"X$"WP-T`9ARAC$5$>37*@8*I/ZV*F^G$S M_;QZV`>MOJ\-YLVNKNNQ`?.:#\V2/;21[!Y'JY',S/OI4+>?[$4*992.YMD# MDCH<).4-T"\:H.JR0_2]%[*^>^\%Z!7;45Q[ZUBK2^P5PSN^L+_Q>#.AXV\A MS9_RO>15=_!8Z?G8P\>R.,J@G9]:^Y)3`O:4>L/<> M0M:,S1OUG[_8/[S59@5G^!D#;\N;IE*I+PVM,9Q3I6\.,W;?K'?=:SA$3E:J MKC?D;2NN0;/3+0[96_6]7@#L>U,&WICOY5*I9^!,)B-(W\O9?;N^=Y_AD/A> ML;K>DN\MNP;=OKV^]^(\O$<:7`4$#CA-=NP:U_1ZKIZT3ID5YI#Q' MI3\'2SE$E$64\?A6-@P.USTO347(G#Q2!7F9@B*!@H[2D^O9T"!:^@U=>^J5V"6@'U[1'( MNG]3+K?E@G0T7\P`7>Z;V1[H;"P:7.X;VR!0\`IZ7>Y;VASX*Z;OLV)W^8(C M^PGKSRV0,W"L;E MHC<'W#QT1^6"K[P`7R9X)7H0H@/"Q^`R[.WO-"(P7&!BAGC4=_1Y9LW[&J^?-73T\1?J(O051T4]()[>^\T6"6A^L#H)V$=-)Q.')_5EE2I_^";^A31OW;L[3WX_1],I':G*5V M=RV]WB/N[/1EG"+&ZM&[RN[&H;3+=U*OKFT%^+?H4U6<1$^>MG$8CWR%79'O M%J]LCQ9K/PM)[&P[R<;V>[GG?@`GQ[DF5Q5/.;B:3BSM/CKG&A78/L9;\[K& MI]YWB]5HEO>&<3$];0:T&N#CC*K77L3:Q)\T.TMS-GMZ:BBY1WV6Q3) M&(W[\+HY1\@+$.>I6Y>ZX'H-V%:CVV\0?*AZ)[(M@S.;."_?Q\=9GZD9J]T& MLO5#<8SNC5?4SL3X.0KCSL^M)3T=D7NK8;_%"PVG/9P`<8ZVGHW^0K@ZSC7^ MP>J5;H@RZL?MVR1`[=*WB<;A^'U;)5)E_WA.9NT\)4F+93=S<;0^L5&T-AG0 M/1P=[?K+G94X^P11I@NYE&_!H78\-O4IDD],>R[5WB/5W@O+1&7/HU-.J4,. MT_<^GMZ:0U;V+OTY:[4Q/D9'?KU)XL0.7"]X*B=Z1MB=-N4NL!_39]NEZ_9C=9R.FNW24\M$Y-B1+KJ_'Y"7='F\?Y4IW(YO=7$*+I*,QI-1AQ<[ZV<0B&0OW5-+ M=V,Q:9OP]1;GH.[4.6VISKG.HFLSF,>812>63Y1;8O64QK0/)T>41;>' M>.H>8C'NKIR,XN3WUK+H>A^?/;+HS-I]@O$R72;2[3O&1JY88K7\;RPZL.AD MX=(M$R:M7SJ53/VX;SQKL1$6MTR(QO+CV*.XO`(X+GO>83'\W+47/](J!.]^ M2(_48>_D.<*X['9L')?3;B6;C!7RND/+X)5]W7B+3UTL>09]Z] MV^C4/;<<2G,\,^=_&;B79(R"Q'O!-\3$XIO0]YS75H8OIP3N*:7LM\]_I&@SV3,_S"JW&.'JN+U'1,B88VJS',X2FAH M=AS-"@1S`/%E'&^("Z.NB#@K]IO,.&J_UPWF.B;4ZZ;,1\5W66+$B0VJ\R`@ M`@^7C^/,]MEUA4W@)22,6C/YZ$4&^@,XV&26MP,IH49@@!-&"3W&N`Q><)RP M>$`XG#6?:H7+;O_JN=SC[7,:A,P),=X5*A""0LBA(ED5D3RY2/I0(3:K,B`$ M"@#!0F(G+"(^\^TXOGYD<_ORAR<$A/![G:@0,:$>S)R.AAP:C`3+9Z5$T#=* M!BIZZT8LJY58VM#19&@EB$@U`8J3B[]MO.251H=A0)&K@I7:-A!XJ6.DQ7/! MTQ0SG`S:TC$#-H=+9[653CMZ9.97BR"A4D!1=-7T/,7NAQ!XN6K["@+UP%G" M=4;$A&<@#A3(:B>0=E3LF%,M%*[@GT_(6+E^/+/CYR]^^#U>/L0LM:IIZ.J: M0&"BA@]U)SL70CH22 MT=3:_%9>&.L.G3^*YT/T-.@7+*M_(&FAU>Z%;"@;SW@^RQIE!U"Z:%O MG"(8)CJ2D0$D30=`28AN"*O/=HRIQ"LB:[JQ)A%6'W`:[;&,(KF&P"#U'/HN M&5Z^8R$;WO*'N@%4ZETY+IDL)J,";E(B?T+I;M,R22+O89-0Q\:LS8Z(G^L' M0K200R.$#I!RMBT7$9=DQ8P8.%1J[6P'(;L*,`,8C6L:80-0H+0-Y,>3T63< M&C`&K&6Z$=S:%9RCYR>SX"-?HDAU80:7E%[ M4+`)F&KQ-M%L(L$>)8^V],GB`3SQK1\55%'XISA5@5D@;+!A.29EB@*#*$\7 M.M]$7O#$`..^33Q,/B\Z2#B.H&\]Z4+K;#T=T>3Z&&$C MK@5WXGQV'.YA"C?."W_%W]D_[>5MMXU-\:HY1^H;1,/Q6-U[$OK\"Q-]Y)[" M\R2S@@<<\/+J<>H)C07QCNTJ@[6L*>-`R?ZQ4AI`^$A8>T*F@+66._6H?CSK MX0V MTKKDZH.9?@^+%LY$F^#]5(H73L\!@NQD.&!OK+[_=$I6?VVDML_\:.DH",TM6Z=@.K\?..L>"&#LMK8&[K54'^&Z%&\$))X1\MQ):0@D'Z.KC MS4?T_MW]V:I@H_!74@_$O'F/5^LPLJ-7I;QQT=<:YTP!"^K%4JUI M^E)T3BG+6(7>RNM$M#3G8IM.MB;6@J,(NSP%`S0UO,':BA.E3!D&`.7,CJ)7 M+WA:KL)-D!3O&=R'_):!VB`KT($#5S-SROMET\5\7@\[6C">=X-X/P.M]YQ: M@K)KE?#8%D<>CM&RE`9:P>T`_?/P(VD[0FL[0B_\C?71=$!^RI*J[$WR'$;> MW['[KVC(2M%.!Z/1L)QSQ7X/MX\Y(3M!=P2V;!I"X^$`40"PK\ZQD_XZ8K]. M!HC066.'%C?U7]%[TM3WB%I^F4S%(=L]G\ M)I_!>0*XFW5F%!"%EBM%8KW:#(`BF9*O(U8#Q/V-CDA#O7/5UG"@%+'4XIJ- M&)F$.`HCQ,DC1A^Z.'HOXI?#[`HP!]N0VB!D-AFR!)Y2G1F`49XBO!$T:4N_P1'_KY)DBW3%(Z*?V8F_-W3!97 M$4XV44`^2<*"%:.'3;+;.JINZ60$4[8&Z+M'*)"F+HZ]IU0HF]652OO,:6!B MS>RO_%[L1\TG65T.I=P;;JE"G&=U*2=SA2(/B*5BZCG)4G,QV],L!>48$VOP M:UIM9KRT!72,P=E0+RH\M83;[*67D`R*+?8142VN@+]EK&",C?%$03_&X.EZ M>X#09JB+S:"15>!%/<7U="A<2J?P*I`U"&-["ZL&M%`N-"C::DRU$7)5=?41 MPXLN@LB_!8[:VUZ4.)V?6N-I(5P/$H^$S>[V>.*1!+'T@:YX@&QVPD;^0`(( M^D^T+LXSO69/?DKKO]#0?!UY+YZ/V<_N=F>9G6N2<#I"*SNA*"'!N<^VM4C\ MG.1PQ4P.V(!Y3RT*LE;`;M-T*-I.UDK%TY@2%=?>IVG6`\R\G7+0>!A<_4[K MS%SI7/T"_'B6[Z1E]F_`V>Y!XEBMQ-$WJPH,J3R-UDF^O]W'V/GX%+Y\136?IN]?50U@=E=U_UV#9.YVJ+VQ&5N;C>7O$">@U MY0/YM]3X[]MVA:9!;;9>1`@?_6N,KQ\OXL0C(8NP4%KE(XW>N=QSBRI`T_1V M(R%`H[BVU&^*[U]5R9_G`(T!Z#>[(KNO$8M M$/CXJTWK;,FKKY2_T8B.4L?*$_U\/DVW$-+VP$56#I#"*DAA^.L7M894-/A= M-8#8.Z;+7.PN:1'4)\S+IUT_LDV)PI[$9SOVG&7@GGO^9O?T[T!B.A&T%X`LV[!(*F!O58)?78J7JRJL5,-S^AAUP? MKE@?VJ!\$$9*F-]?OQPDJ1JN"&'R=_(W\@=:!)+\Y?\#4$L#!!0````(`+B` M;$&UL550)``,L M_T16+/]$5G5X"P`!!"4.```$.0$``.U=Z6_C.);_/L#\#]X,L)@%)I6CJF>W M"ETS<*Z>8%-QD*2Z>_=+09%HF]LRY2:E5-Q__9*2;$F6>.DP95I?NBLRC_=^ MO![?Q1__^;;P1Z\`$QB@ST=G[TZ/1@"Y@0?1[//1UZ?C\=/E[>W1/__QYS_] M^&_'QZ/'Q]%5@!#P?;`:_>H"'V`G!*-GYRU`P6(U>L"``!0Z(6UN=`?1;R\. M`7\;L?]Z(_KIUXO'N]'YN[/1:!Z&RT\G)]^_?W^'L;=N\YT;+$Y&Q\?K_GY. M*/LT^ON[\_-W'W*_/`81\NCWW*=+#)*./4K3I]'YZ=D/QV=GQV>GSZ>GG\[/ M/[T_^]]\Z6"YPG`V#T=_=?^#%C[]X9C6>#]Z?/?X+L?DOX^>`D1HZ<720:O1 MV/='CZP6&3U25O$K\-ZEC?HINR,**2*?CW(TF_!&RW8+$+>-0IAN+I% MTP`O8JJ/1JS=KX^W!?)I&\NY0XO$\R=,9^,)*WHB;.VD*:V/M.:W)SKA`>MC M,KV!B(X0=/R'@$#6Q:7O$`*G$'CZI"NVNTLF'AP,:@R"1N/A'(30=?SVV;JE M&]L"C/T08$2'_Q4TXJ/<6O<$-T>_NLGN,+]TR/S&#[Z36^1!#-RP$?7EUAH3 M?`6)ZP">E_)].+B$`$"!DC[\(AD$RF^5-M['GQK'7\9KM2*]VVR3T( M[P)"'@!^HC2#<1AB^!*%SHL/G@-Z^BT"]!0&[F_SP/?HH9Q^847)]9OK1Q[P M;G"PN'1\-_)CZB;3K,U<<5G+C;#L#1,MCLR-`_'/CA^!+\!A?[.E0"H_-H%. MHY<6>;L,$!4^0TAAI+-]"C`&7HQCZ\M,LZ<6>1`M%@Y>K4$=NU34H+.R@S'F=-0FA]$+`;]'=.N[?F7[ M7_LCI]1!.Z+9?1`"\AQLA/"-<$4F>.8@^$?<&=TL2>!#+_ZC0AI9RRI7@+@8 M)L@C;^RZ]%(>0C1[H)5=2#L";^&%3\=-'QY3A.XUS.L/>P/WAN"N8;\'WW-D M8,IYA-SD)TKAY=Q!,T!O%?DRD#9!.^YF$K="3]>@73L8T:XW\G0G2/`[,<;> M,Q/K6UU$LJZZ9G4CYF2G3C?S6MR143;;'U65[KIF^1DLE@&F(E`B]WT0,^V0!][^&ZPJ MR*HNMS/Z,GM(8ER91"'S7&!>)7QB195V1?D-]`&^I#-K%F`^KL52NZ+M$.\LJN9B9;'NJ7O&#ANCI]7B)?`KR"K^OJ$G?^B/<9$V![OKAN@_2R=^ MT1GHT6J[-2'<) MKUP"8^I">IL`<4E6$P:84O#YZ/QH%!'*7+!,%+[[!<^6?)/A M#S@)Y90,J0\#4A+),\/JAP&KBG,IP^?O`SY\J2*#Z3\'F`0B=X;3?PTXB94+ M&50?!ZBX=XT-2E2X'%!2O$MFH'4MDO]XLJVE[%IWJ>I5GG8(0];V&9.43D?' MHTWMPK^#Z6C3UFC=V-]&N>9J7Q>G#GF)`8[(\"R4"QJAEPH-,-QX4P6Q!Q5`B6M<->&"&J8X2,4>X939+F:"UJM4Z'H$KP!% MDO.;4]@$W;F#F(YYV>V#PX&T6A]YD6R@RM4-\R:>6SV1K,IDJ*/?AS/L/D!T M@0*PB`5L7MS,%[!X`9C#D583)GBLN.%E'L9$=E#>A"WJ@H5#3!SQ/` M[!36V&Q%-8QP,`]P^`SPXI;N^R1<"&9495$C-*]59/D;S/@-<@GGEC=*_1V= MT+?TGU*RLX)&Z:U0;4ID):6J1GF*77=EU">%S-"I>,_IRZ1Y0OE9#C1=,`5_,@)!D$5'C2:$=$W8JL1:7&:4DFDE;'3#4@1&+QK8Z M8*CCP[ETVNIRH;NBFCI5!*'C[P,2'*50'A!%,$&KW.[?`:T\9)?:#.H['+> MU8:J^G:6P6.7[ZXV/$H*JPPMNSQXM='BXE+'7[?_^S??#EI882(-CJU!!'H0 MZ9D8;`TLJ&N\RR,I,C;9ZGC9!FY"%P%;?3';`(ZKS]B=+^;^@28JG>$V[&Z" MW8WCHI&A5T<4Z[_((7EC1+/<3<#RDXEE1Y0/,^N#"4[ M-59Z*(GGD9V:+*F]M"!K5=P),MG43A&+;Y(MWY^K)'8[%0MJJ*A+#+8&"-<-:@W,ZH)-?EQM8+,9%YRY2Z7R973_L%*SUE2K% MJ(4,'SOE:3U\N#%W&4QV"M1Z,*FX=&:(V15_7P\QL6:DCO:W_U<0B6.50&>I MXLF4H=>U9-G7R/+BRU!#U*%.S![%;H)CF+WX(%SG_>8QH%#3,$=)\H5Q%,[I M;/XCFWA\3DHU>L'!+2&1.O5IZ5Y0SD^BJ%1EB"3;14R6YL)7K&R>+\7E+ZG4 M%SZ$FX"@0E_HEV\%LEI#9-,0)31$"0U10HJQ'YK'FFKM'G"F>+#):O6&$^'1 M)JK1&P[DAYNT6O\=(`7>R,T:D/D*<1-.'+#TI6;AL MCP/1ADJP+5D:\E$3HM*>5"NFPUIX.!N2Y8+WX/G:O>?K`(XIQU>CSC^WB/X, MQCZE&-&>7C.$TL263"=> M:3.4T_4+2)C0E&)X3U?\$C!8T8R?F%:IJA''(9#2=!<0GI6Z6,8XE>-7!_J) M#VE.6YSRO:)>LLKE]8RD+E^3E!+#6Q_E MKI))YM[.WRYF@]A<`9W,J M+H]?Z52?@?N(N0_02S&3J',*%C61O&9C)J_$LGM3_G(LO:?8KL?4`:ONQ+)= MV2FY6!7C_DH[B>VN4!KH""0IVYV?ZJ"4E]B:.?/T/Q12`Q^%NY#M/CTZ:!7U M$,U<>:R:1WKR>3W?GH$<`C,F)G9&NBTU4;-?'VLFG9\B+C7= ML.VVY%K0R10IMF=^J06:$EYUW#O[OXE)%9U;[Q6(-#^V.^5I826U,=KNFZ>% M5H5UH)E#GL[*ZYN);4_\P'11C1YQ(,SZ(Z[3.WN.<%6HU!Q2!G0<7M_OF^^A.;8J M;&K%FZYP!SE0M/C1U4I[U8'9%>2H*4H^0_"PCOAKNXU/[H4NW.MLW[H&)WWA MM9:]9'GC!]_)+?(@!CGA('72_X$]V2ARTF`T;B`PZ8$WYUTH0 MU.I:R=6W\Q[Q]0#HMD+GEHL!/?FN0/)_+?8X39CBD6TA[-UJ^L_D[5BV8)"7 MAN?E%\\5)*X?D$@:EM.X63.965DN(D(W_74P79Q'.DU1!+PS'K/2>B:XN0+T M&'-A(OB"I0_BHY\*N(L`A_"/^#N'(:6J1GA:NR,4O11X;'!*&U&MTHL'.ZD--A:+MJ/WC: M>NM-F:'M>OW@9B/1I4]LR+7YJ@WT@[^'Y)GR-?B5SY4K\ZK4F*$`NRIQO4(T MD$5RZ3?4;WZ3!XLC^BV=J`$2Q$DV:;1'.&3B8<-Q%S74;WZ;C[MJHSW"05\3 M4*.A?O/;?-Q5&S4>2,UGRW!H)95!4]W2V*67=`PHQ!2W?[A) MXR":S2\B`A$@5-9:O$`4\_4+768A0)/I5,L;K$$W1ERQ*G=.GDM6=6'#K\YL M3*_JK\V4JY@TK7=I>\T;Z-5L"+9G"]@5VA(;0;V$`OL4:[DKH'E;F.WQY)_ M?8OREC]O+7MMO1CI?1+=VL:UY%>206CGNS@=`%AR98/B^AMR3J!=>#P[&9G:G#'([I:-V\&[J M[92A7$>?V/^,,O6]H`JS6LVJG^VT.CJM?1(]6X*SC@$V`]=.M51',U5@Z,T0 MM?6FU,UT%5K/,U#MO#NU`VE39\T,Y3JWJ[T]MC1M`[S,J^=V*N_:`:T;PTV& M_4%)LYK8ZR@5,D3MM(2WM@4T\H[.4+8SZ[>*ITH]/*NRZMJY]EO"4"A"V)Y% MIR4,A=J#@\FHHXBA7LZ!9AG][=L)%3-1-$KWOXS'@E*&PP,$[]MYW:3_!?BN M4<]OZ77`:V:D;_880+_3'F7\WC.U&IA,U_Y>%!_V&`)A^HO<('L>3$B^1=.` MMAG[Y_4F!8PPY:>PBI[C,X44QI2=?GQ_&M/%OGR[`L3%<)EXAXJ!O..D]ZS? MSJXYJ$KX6:\-,P'^:VWQ,^U*F+BW5-`\O9=T#YS1O21Q]!;.>H6*)OA)M?AT MRYU,G^&"BDZQX9/D)@^'(96:1C@*$%A]BSB%C;Q?BF<.2B<$ MO=:3P(>>DX83Y-?J9)J>EXZ_.8.E;\NVTK8)<:/Q?IZ7090FNZT7_T;G2E'? M5]ZR-TDI;=G6_GZ?V-7O-!R(R2F]?\PA##ERCDO8>8?HD]\J[?7#^B%##/ MADO'=R,_'9>LS5QQ64%(\]8PU?P1-P M4YFR,"[!8AFMUTOIZ<8X!HK':BMM[R$J%ZOJ!@0Z@2Y[W$,$>;JLUIOO#S;W M#KW%B=Y*DE8SET02/EO4;B=F.MJB&"0[2\`HAS<4R1@/YI1)&(=U!R[/8]LOH#D[Z@G.?=.L?`-<3 M#.3H:@NSMJI-=>6/XO,]@EW?=NU+'<"D@I'M2I@ZH&V=S,U.-`''NG?0$.^SO6V59^-*(.C).`;,C)R.;=Z;GE MC2@F>-3(=)K2>OUYTDM];-3KF^!N0T<"/B4TE_XC70;>!#VR304GSHGW`<+K M/V.CA4S+UFX?^XJ22)_37OM&T;E8;?[Y+P@P/2'GJSN6S4^@L5:L;)BOW(%P M@\'O$4#N2HTI;DVC'&6[CLS0)*QBE(=;1"4:$D^1I MV1>.2'DY:_/&;Z,W7&[V9+4I**IJ*(UYB*$;`J]:3N'P(ZUF)LVX\ALEXB=) M3*@Y5&7FK:2YDL&S7?51"S8-B;Y1V)>M^$FR!M4)\;(5*L%%OEGP5O\#,3NY M62IA>SCAUJW?2_/X*EU_K%?>[@IBX0J<2:K6+ MH.U>"AH:)!F*)07!P6`GT%6UO&S!Y77=:,V_N[IGB3Z*/]T#X=Z6;WZW!#@OIL%KR<>@(R1#^P?C/X/.?KIIV_7**2;0>5, M+OUL`MOD22GFI1*P%Z:$2ZZZ;/<8WH&9XR=(5=C^JDJTDOFDN$.NG^%),R1? M.6%EJA-YI?X\P)U2Q32*_$=NI17[PP])UK<6*^LZ9D-68I(N5O$!H19_4JYA MA`.`F3NA1NB0J(;1IV;SA[/`PX!?WBCU6UNS*%117,=82!)[[0-X5Q&[TB0Y M%/.G=7*(Y\37S-M2%+54O]%63I!G9Y-X^,'!(:)=WBTKEX>TN(EQV3Q!F;U><),>`%G";E5VRA5[P`^=,1,L/))`I)Z""/[DDZK.2K&7WCDGM#+]BJ19*!]<^`BI0">92D M,]WV6+:Z2/%W.]M-S\WF5F'OL5UCK`R5RO78=H^NAF!M[MZV>V[577^5\J;M MOEO*8"FH>!OY;=%67H*]1TM5+9E!9>?CP9:)S203:BYL M?WA>:!,I[EHE,UJ&C5WBI\`.PQ`I3RC;?3D4E/=K8$JX6>^\J0B.@A+>>@_, MNE!5:_S7<)T/<(DD!?M=2:5V+1Y*![-_JYC.\B!QI`+;<5(V`E6GL:M8I8>1 M5CF?V3B!;O"Q.RP?NX22-"?6!#_"V3R\?@/8A00\8.B"S8\D_95P/=EJM35X M%FI0JVD_5:EIF"-%NZFHQN#M::.WI\1]8ZO0(7BE/7:N)5O"&T? MI-?V+:+W*+"YC]\NEORS2:N)'O&X9Y[I18HT16/%RN;Y4A20)97ZPH?M*5>CW3W*3W\?4MG;_X!54,928#+))VC+PK%B(;+-F6&@=WCUTJ:[-H M[G`.\//<0<]S'$2S^47ZFAJ%_P6B6*_U"X8A%3,GTRF'[]:[:45ZJ*;J^HWE MS0XO@2JP8LWV[5$OM1@8/X'$2)3A<^!7`8$Q)\/H0*\!RF;0#*D##XFO&9:0X7?(=P%5A^!,EW_@ M%P*Q0TP&4PUQO]<"0TL)%L[MDE&EJ`A=V3-4[!*8I*CDG-KY.62V&3+;J'D'#YEM]BVSC?$\+2]4"/08``"1N+=L,8X)B18QN>0K+?0< M7`'*VX*NN,U[8.+:"'T(BZ6,4(E1'(J"V6,Q($Y:`8$,0O9[\:H$R*8 M+V$XBH@MDHOM+6;,;E>SY!G+BU56)EU(X^\.]A1CCAJV;RQ"240SC^3\<[/K MC9FY1KAT2UH[YSR6P_QWUZ\Q-$N'6)FK%QVNF$LF+]E.AQU:,QM_#N@YR=Y! M7NUZ/F[U;"FBZ4%N#M@U`;;BFX@@!O%-"=A[?!\A^>T&`W"+Z-4!D'!7^T%E MOU:BN<.]0-2]G=CN;A\0=;_WV/X"F)D)>.-7@)T9V+UX("9@K_`M.9VTA=M= M.6>L`15>._HR_9X;!D:1=VC M[4'7K:NW2JOL\.S'[0/9Q@%[`";%UL205K#7%LQM3UFPK^.SOI3:GBQA3\?' M_MP,>S`P$MVC[0DA]G>$RIN;G2[I>SM"]K\#NP=#(U'ZV9YBH\,1ZLC<;7LN MCSU8,]7N'+O+#=(_=\3>/!VW_XZ&G/2I]P$"BZ4?K`"HGLMI^I4DL=06(W5: MZ(^Y1Q':.9>#F3Q,WY%B4)=K8$G/A'EA5K`T';V-:DPC)SWJ[' MT';C3H^&J(9(9*F-:5>#TE"#WNM,%.UC64M>VIT*O'_2^U.T6#AXM0X3&KLA M7<7A:I#?S04*U=8@3-;[<9S$AIE=;U&((2+0C??LUAWFY1WNHPR98R?)^]:1 ME%CN9\_1VA+5"HF[NL=0V/N>K^,MWAX!BX*%:'89H'B?BAR_DXB8!I3LYUQ> M0AS7V5P_.INWY9[V$;'B72U.0;>3.W72TSXBEGM_H7A8=H0;O[\]1Z_3L[G< MSX"61C_?SO<=+P.RC&KO`[(=]6YRUC:0SOC<\:2S\X[DQ#J4]'(V/;<:_[BU,+F71_V&[-#. M=RC7-K(!+A/\0P>'AV(HZ50!,-C^M(>AQMYB>V1-_R9[I7ZPGO7P8S(,",P8 M+\-`-%UQ,?T;!&7U2J.`F$%,VLWMRO;0F!X.CZ9" MQ_;0F%Z.D*8JR/9@F;T]A0JR6IV`F4%6Z]I7Q_:7>SL:FET;<6Q_+[A_PU3+ M)ZO1V\.'.TS=.-DT>MKXL$^>CGR2=_>8LE'W^^B%@-\CVLWU:XQV7\)FJYZA MJ31;510T8883OA&W17)U61-4WP>(3FE`#PFZ!.@100^-$-)_/JQG>^$]Q$IF MM)IH)?!8_B!A@5"U.B;0%S_U6XFVL(H1\S,]>P`9:TP840TS!G3)ZU@E.SFO MO%'J14]7\3BHK-,[)X9D4R&0O5"?VV">@$N+AI"[5AHV:@2'XG%\)\O9S"O> M`]K%>T!EV1Y0+0OW"IX^JBO:!9MJ?:*?BE.X)Y4(ICU^^%2GH&=!= M&SMXE6SBR:YV[<,%1.PV524$R:J8O!SRY?W"A4\D;=ANX%6#2$^DMST58>M/ MG-N:]G1X(M:V)V(-X2218)7="Q6D_D;>M7N1@D0'3;$VP7;G5Q6DU.0FVQU8 M93>>P@JMO&$T^"`%Y#FZHI(-S5\=GTU"-+;6Z_>'J$=`)!%FV M8Q'E6LPJ-FD$`WK/QF`.$(&O:;90`XUDRIL22K98*3 M6_1*IU!L4%'B@5_>!/5T^@,J7[")?P5>@1\L8SU/DJ%9N)Q4:IKAB%YS(O`( MW&"&8A]/M7&1U^M/7IG)6E:@RYJ"3M?W@^\@\?97IR43''\E8#*])B%<4)&* MYR^Q56A_9&Y5*<3V1Q7T4-N>$[8;>?30490`;;?WM`&:JH!I^[.]>E@*1"#; M_4GT@%*036QW[M(%3$$\M=VW2P^R6A*C[3DO]""47DYM3T"A>90JZREVEQ2B M3RKA>_`]!RBF=2*Z").@3RIAS%D0)[E%^3*0-K'T>V-;2FFDU%YC'.#+@`Z: M&T>6*NN`%9HP$AC8QMA4\]Y*T_W8!=3'O^"AW0JVAVE&VCZ"C&X$V\1(%CVW M>!\4S;HJYGXL1=D(B*2782WQ`(E=L(P84_=Y13VY<^!%/IA,QW37]J`?L>M$ MYJ]^_>;Z$1U%YI_-1,,H&>W)5'3(WRP5B5JJN(DBR M_(553&P!8E#5F>C'PE09D?SBE'`_K+,2*.8.VOR+V2`D7X##*/,FZ)'MI2P6 M*[;(*4]>U6;ZLBI;V5GV:4TJC_-A+M.MJ+":)Z%:J#YO48G+FE@Y6\1D20()*YL!:58K$Q,DNSD6"QG+>:0$(N<: MJ%S??`(&Z2,S:C@L#LG\CX=A]M9<8R*SQ8E)94* ML_SR/4HEH9,DJ4>BY8\GC%BV>]`__A]02P,$%`````@`N(!L1S"%8"\*"@`` M>%4``!$`'`!R>&EI+3(P,34P.3,P+GAS9%54"0`#+/]$5BS_1%9U>`L``00E M#@``!#D!``#M7%MOVS@6?A]@_@/7#[L98&3%2=-.C*0#Y]+=`&EL..Z@V)>" MEFB;&(E42[_`+A`C]Z,A/A7-,:2^(@S]/EJ>(].VAV$9DI%7==]>GIJ"^%G2MH> M#UWD.%D!?R2F=-';]LE)^XV5,^0Q\R'=2KH6!"N01CX8T44GQYTSI]-Q.L>C MXS?=SKMNY[?_V](\6@@ZG2ETY/T"PL=G#B!.T;`];%M>_1L] M$*"A1DDT))*(.?';J5)IG$50@TQ>MBS_GD[;7$Q=**+C?OYXGU1*Z^>?4"+; M?1Z+@*XA=$J&.74IDPHSCUB0@+(_2Q`Z6]>Y74@.DIK5.3\_=TVN)1U+9XIQ MM)2?8#DVTFF&:RKWN..<=M91:A$160@S.<4X\4S7_8>$:(9%B$T\:,SQ^>FQ MA6#`3QP6UX"OA*L+<6>,4P]60PS61K5R:$D]8HQD+$%H2*Q!0(YFQB%Q92H!QP2&6&/5(U! MZ.="PM0'+L(;,L%Q`!7R-<8!G5#BMQ!62M!QK,B:0,Q6(N^UE@O,&%>FQS+_ M=4H443;AZ5](T,VR*WA`1A"82#]\&MZ5F*G2GM?5HNX-]V)M*&;^+5-4+>Y` M.8CJ(EN(^I>M4HFE&9DA/IE01HW!G>,./C4#0]@KTFH/J3#Y1! M3T]Q,.#2&',=8"G3N-*$#0'PI2*@G+]3(&VI".GQD/F$Z7'Z"@=ZN$&/,T)@ MG#OZQ'#L4T7\7QH6]V5Q@*$+5S.B*-1.;4H-^@5>W^S`*SI:LZOAN1K/=S`U M#DDO4$0P<&).B@G-BY4S>+:5P66J1'R"^I&>;E,]/6W:Z-[<56B9Q9@7V'R[ M%YM-R]R)W6LL9Q\"_B3OF$\%\50QH7FQ12ZT5&<=,RJW'WP!61([X< M^U;UV1=3S.A?QAVH;\D#ZIL_5UA2V9\,+'>O8DD9D?*&2$_02"?UF-_SS**+ MLND`P!Z%@LBSN@JX]Z<5%M_+@O*(^TU/K:GT`BYC0>#/`U;Z`8(L*\K,N(TI M.M4VI@FX70+N@3Q9?`G`Q#!K,EE`Y?4,LRF!#L.6H:`B"NK&U4$**@^?\\WP M&1)/=UTKG6B]X"9D=@F96RP8U*4<$/$(:%(O#K:C2\GM'.?Z!J+0/8<>`:82 MR*A"O70O`H\#@A37^Y@A9S!<@?H9#WPB&LIWHOP#IN(/',1DQ4#-YE^NH9SZ MSB;U6ADRVM!'@G5BTYQWYG9$PH@++!:W7V.J%O5HW0HN9_1DDU&8:?U:*ZNK9SWTTW>+<7_D2A1W1"^"^&K M:H65'@\C6*D9UX8$*H?XUUP"C7J4O-*O)P=XD;;?.F&P;QGEP?&F,#B7Q MD-M(W+)B;`C_GG/.&B%QF)+*@R:W?;AM_ME$397/<98UF8S%_4DV$L.(7S`U MZ/F^,10'^>]V#J*JE/R3_/9BG1F$@U9EVA\"H:,;HC!MWF16C!2B]*"=S0'L M$7O$D_':'J[3%"TJ;Y^](/:)_T'P\'I5??W)2JQ10F;H9P#61YC.7V M;K?-K4IF70WG-3BW]L:76^.F"54:,FNBR[G/[=^6[-LW@^)AZ,_OO5?BO2JL MG/#B/=F-#?N&Z0,R;98;]FI#GZ#QXP!FO3TIX]!LFLE/(#3B4+M$A#`Y7?;C M_4G?"/Q7X((QX/`%E$=/?O-WVXK*09D5>D9AV8&T(7KNL#3%'E7,EX1&06)/ M$W`'"+CJW4M%:'F0Y/9N2X*DZ6;^N6XF#D,L%EG[[GF*SJ%OK]B%;`&7,Y_; MM2WK'I(2K!:?%=*P7X_]C1=YU5I[)5`YV[D]V=R;P*:!0[+^T2U@2";('%3M MZF.:ERU)PR@@K30-"T_CRX^XNI'@D9Z=$^EF:C,%.?3ZF5H3-!OUEUJ5:9C! M=/^RI4^S.MEYP2^`:#^'02:BJ-*EV/L%6I'\%>$@:+FOU_-U&BLX#H`"QV^6 M:GX0OP,\)D%%ET&VP.5[K>$'\7:SF5=P&B`%3J_M!1?X?N':9UWAW_I9V`NJ M/Z)3B!4>S=UR/!XE)_#ON6<4E4#T/R?#.3K)Z9PXIYWVL_13$^M8L*KI>A9D MN+H6E!ZKWV:#*;_P'+]+`B67NIR5KOK547CVOE*MV,B'!*BKY5Q72^?M/I;L M9L5N)A3>#%`U*C*`+O2L=B!L7LNP1QSHE+IA\-(E!Z7F%.&R/\Y*R0Z&%%R9 M4,T2&[C\YZS4U+=EXQZ&2F9D&/VP5^&;-SI4*GT),D][143^;HA*%EBP]'FO M<,A=-5')B!4J>716"NJ;L'%S124#,HQ^V*_PC3LPJI6>@*A.G.G)Y;?-D-GDR:S&4Z7:D$95.=H=<3+83'D((]==E2 M(M8S(B,%,R7*_9'!^;%(UWF,!H%^/9?)2EB4P:PF3O;X>!QEA5!0O[?_YKN) MW7Q/H=_8;U]U9X`47CPV-;^E!M+K0'H%%XOT4J-LKRN)OR*&04S*@>`>(;[4 M+[+OI(SU;-)\C).]HK8\K`JP?8146.2+19&7$QS(%]Q,\L;)K0^00<94'<3Y M_^%($38P.RL>B^C7,=2*O6:^I2-8ZGIEW@!#2G3GPO;+KTDN2=+R;[;89I2^4G=(G`Q0````(`+B`;$?&$UX;3&L``(`T!``1`!@` M``````$```"D@0````!R>&EI+3(P,34P.3,P+GAM;%54!0`#+/]$5G5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`+B`;$<[YHL\X0H``"*/```5`!@````` M``$```"D@9=K``!R>&EI+3(P,34P.3,P7V-A;"YX;6Q55`4``RS_1%9U>`L` M`00E#@``!#D!``!02P$"'@,4````"`"X@&Q'MURX:%T5```7:P$`%0`8```` M```!````I(''=@``&UL550%``,L_T16=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`N(!L1_>Q*+8:/P``\F,#`!4`&``` M`````0```*2!`Q0````(`+B`;$&EI+3(P,34P.3,P7W!R92YX;6Q55`4``RS_1%9U M>`L``00E#@``!#D!``!02P$"'@,4````"`"X@&Q',(5@+PH*``!X50``$0`8 M```````!````I(&_[0```L` A`00E#@``!#D!``!02P4&``````8`!@`:`@``%/@````` ` end XML 39 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

Condensed Statements of Operations (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Research and Development [Member]

Non-cash stock-based compensation expenses $ 174 $ 216 $ 552 $ 632

General and Administrative [Member]

Non-cash stock-based compensation expenses $ 211 $ 238 $ 691 $ 770

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The Company categorized its restricted cash, cash equivalents and short-term investments as Level 2 hierarchy. The assets classified as Level 2 have initially been valued at the applicable transaction price and subsequently valued, at the end of each reporting period, using other market observable data. Observable market data points include quoted prices, interest rates, reportable trades and other industry and economic events. Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands:

Description
 September 30, 2015 Quoted Prices
In Active Markets
(Level 1) Other Significant
Observable Inputs
(Level 2) Unobservable
Inputs
(Level 3)

Assets:


Restricted cash
 $ 50 $ — $ 50 $ —

Cash equivalents
 1,500 — 1,500 —

Short-term investments
 8,000 — 8,000 —









Total
 $ 9,550 $ — $ 9,550 $ —









Description
 December 31, 2014 Quoted Prices
In Active Markets
(Level 1) Other Significant
Observable Inputs
(Level 2) Unobservable
Inputs
(Level 3)



Assets:


Restricted cash
 $ 50 $ — $ 50 $ —

Cash equivalents
 4,000 — 4,000 —









Total
 $ 4,050 $ — $ 4,050 $ —









Fair Value of Financial Instruments

The carrying amounts reported in the balance sheet for restricted cash, cash equivalents, short-term investments, accounts payable and accrued expenses approximate their fair values due to their short-term nature.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended

Oct. 01, 2015

Sep. 30, 2015

Sep. 30, 2015

Nov. 12, 2015

Subsequent Event [Line Items]

Number of overallotment purchase rights exercised 0 35,000

Gross proceeds from purchase rights exercised $ 16,000

Subsequent Events [Member] | Series A Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred Stock, shares eliminated 15,000

Subsequent Events [Member] | Series A-1 Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred Stock, shares eliminated 10,000

Overallotment Purchase Rights [Member] | Subsequent Events [Member]

Subsequent Event [Line Items]

Number of overallotment purchase rights exercised 400,000

Gross proceeds from purchase rights exercised $ 182,000

X

- Definition
The elimination of the preferred shares from the Company's Certificate of Incorporation and the unissued shares of the series were returned to authorized but unissued shares or preferred stock of the Company, without designation as to series or preferences or rights.
+ References
No definition available.
+ Details

Name: rxii_TemporaryEquitySharesEliminated

Namespace Prefix: rxii_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_NonredeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=rxii_OverAllotmentPurchaseRightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 64 144 1 true 20 0 false 4 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.rxipharma.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://www.rxipharma.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 104 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.rxipharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://www.rxipharma.com/taxonomy/role/StatementOfIncomeAlternative Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 106 - Statement - Condensed Statements of Operations (Unaudited) (Parenthetical) Sheet http://www.rxipharma.com/taxonomy/role/StatementOfIncomeAlternativeParenthetical Condensed Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 107 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.rxipharma.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 108 - Disclosure - Nature of Business and Basis of Presentation Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Nature of Business and Basis of Presentation Notes 7 false false R8.htm 109 - Disclosure - Recent Accounting Pronouncements Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock Recent Accounting Pronouncements Notes 8 false false R9.htm 110 - Disclosure - Net Loss per Share Attributable to Common Stockholders Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss per Share Attributable to Common Stockholders Notes 9 false false R10.htm 111 - Disclosure - Fair Value Measurements Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 10 false false R11.htm 112 - Disclosure - Convertible Preferred Stock Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsTemporaryEquityTextBlock Convertible Preferred Stock Notes 11 false false R12.htm 113 - Disclosure - Stockholder's Equity Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholder's Equity Notes 12 false false R13.htm 114 - Disclosure - Stock-based Compensation Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-based Compensation Notes 13 false false R14.htm 115 - Disclosure - Subsequent Events Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events Notes 14 false false R15.htm 116 - Disclosure - Nature of Business and Basis of Presentation (Policies) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlockPolicies Nature of Business and Basis of Presentation (Policies) Policies http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock 15 false false R16.htm 117 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss per Share Attributable to Common Stockholders (Tables) Tables http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock 16 false false R17.htm 118 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Tables http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 17 false false R18.htm 119 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-based Compensation (Tables) Tables http://www.rxipharma.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 18 false false R19.htm 120 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation Nature of Business and Basis of Presentation - Additional Information (Detail) Details 19 false false R20.htm 121 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Common Shares Excluded from Calculation of Net Loss per Common Share Attributable to Common Stockholders (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersCommonSharesExcludedFromCalculationOfNetLossPerCommonShareAttributableToCommonStockholders Net Loss per Share Attributable to Common Stockholders - Common Shares Excluded from Calculation of Net Loss per Common Share Attributable to Common Stockholders (Detail) Details 20 false false R21.htm 122 - Disclosure - Fair Value Measurements - Fair Value Measurements (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurements Fair Value Measurements - Fair Value Measurements (Detail) Details 21 false false R22.htm 123 - Disclosure - Convertible Preferred Stock - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformation Convertible Preferred Stock - Additional Information (Detail) Details 22 false false R23.htm 124 - Disclosure - Stockholder's Equity - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholder's Equity - Additional Information (Detail) Details 23 false false R24.htm 125 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used to Determine Fair Value of Option Grants (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockbasedCompensationScheduleOfAssumptionsUsedToDetermineFairValueOfOptionGrants Stock-based Compensation - Schedule of Assumptions Used to Determine Fair Value of Option Grants (Detail) Details 24 false false R25.htm 126 - Disclosure - Stock-based Compensation - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformation Stock-based Compensation - Additional Information (Detail) Details 25 false false R26.htm 127 - Disclosure - Stock-based Compensation - Summary of Option Activity (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureStockbasedCompensationSummaryOfOptionActivity Stock-based Compensation - Summary of Option Activity (Detail) Details 26 false false R27.htm 128 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.rxipharma.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) Details 27 false false All Reports Book All Reports In ''Condensed Balance Sheets (Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Statements of Cash Flows (Unaudited)'', column(s) 2, 3, 5 are contained in other reports, so were removed by flow through suppression. rxii-20150930.xml rxii-20150930_cal.xml rxii-20150930_def.xml rxii-20150930_lab.xml rxii-20150930_pre.xml rxii-20150930.xsd true true XML 43 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Loss per Share Attributable to Common Stockholders - Common Shares Excluded from Calculation of Net Loss per Common Share Attributable to Common Stockholders (Detail) - shares
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total amount of anti-dilutive securities excluded from computation of earnings per share 29,278,376 19,735,374

Options to Purchase Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total amount of anti-dilutive securities excluded from computation of earnings per share 3,308,761 2,987,264

Common Stock Underlying Series A and Series A-1 Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total amount of anti-dilutive securities excluded from computation of earnings per share 16,743,495

Warrants to Purchase Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total amount of anti-dilutive securities excluded from computation of earnings per share 25,969,615 4,615

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On July 9, 2015, the FASB voted to delay the effective date of the new revenue standard by one year but to permit entities to choose to adopt the standard as of the original effective date. The new standard will be effective for the Company on January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact the update may have on its financial position and results of operations.

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 4,035	$ 8,496
Restricted cash	50	50
Short-term investments	8,000
Prepaid expenses and other current assets	432	442
Total current assets	12,517	8,988
Property and equipment, net	162	183
Other assets	18	18
Total assets	12,697	9,189
Current liabilities:
Accounts payable	222	285
Accrued expenses and other current liabilities	1,443	1,002
Deferred revenue		47
Total current liabilities	$ 1,665	$ 1,334
Commitments and contingencies
Stockholders' equity:
Preferred stock	$ 0	$ 0
Common stock, $0.0001 par value, 100,000,000 shares authorized; 64,949,121 and 21,984,272 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	6	2
Additional paid-in capital	65,515	48,047
Accumulated deficit	(54,489)	(46,882)
Total stockholders' equity	11,032	2,745
Total liabilities, convertible preferred stock and stockholders' equity	$ 12,697	9,189
Series A Convertible Preferred Stock [Member]
Convertible preferred stock:
Series A convertible preferred stock, $0.0001 par value, 15,000 shares authorized; 0 and 5,110 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively (at liquidation value)		5,110
Series A-1 Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock		$ 1,578

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (7,607)	$ (6,496)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	60	68
Gain on disposal of equipment		(10)
Non-cash stock-based compensation	1,243	1,402
Fair value of common stock issued in exchange for patent and technology rights	228
Changes in operating assets and liabilities:
Prepaid expenses and other assets	10	(207)
Accounts payable	(63)	(26)
Accrued expenses and other current liabilities	441	(837)
Deferred revenue	(47)	(57)
Net cash used in operating activities	(5,735)	(6,163)
Cash flows from investing activities:
Purchase of short-term investments	(8,000)	(5,000)
Maturities of short-term investments		3,000
Cash paid for purchase of property and equipment	(39)	(86)
Proceeds from disposal of property and equipment		12
Net cash used in investing activities	(8,039)	(2,074)
Cash flows from financing activities:
Net proceeds from the issuance of common stock	9,266	1,947
Proceeds from the issuance of common stock upon the exercise of warrants	16
Proceeds from the issuance of common stock in connection with the employee stock purchase plan	31	30
Net cash provided by financing activities	9,313	1,977
Net decrease in cash and cash equivalents	(4,461)	(6,260)
Cash and cash equivalents at the beginning of period	8,496	11,390
Cash and cash equivalents at the end of period	4,035	5,130
Supplemental disclosure of non-cash investing and financing activities:
Exchange of Series A convertible preferred stock into Series A-1 convertible preferred stock	2,000	3,000
Conversion of Series A and Series A-1 convertible preferred stock into common stock	6,814	3,582
Fair value of Series A and Series A-1 convertible preferred stock dividends	209	3,668
Series A and Series A-1 convertible preferred stock dividends	$ 126	$ 447

Nature of Business and Basis of Presentation	9 Months Ended
Nature of Business and Basis of Presentation	Sep. 30, 2015
Accounting Policies [Abstract]
Nature of Business and Basis of Presentation	1. Nature of Business and Basis of Presentation RXi Pharmaceuticals Corporation (“RXi,” “we,” “our” or the “Company”) is a biotechnology company focused on discovering and developing innovative therapies, primarily in the areas of dermatology and ophthalmology, that address high unmet medical needs. Our development programs are based on our siRNA technology and immunotherapy agents. Our clinical development programs include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA^®) compounds for the treatment of dermal and ocular scarring and an immunomodulating agent, Samcyprone™, for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. In addition to these clinical programs, we have a pipeline of discovery and preclinical product candidates in our core therapeutic areas, as well as in other areas of interest. The Company’s pipeline, coupled with our extensive patent portfolio, provides support to further discover and develop innovative therapies either on our own or in collaboration with strategic partners. Basis of Presentation The accompanying condensed financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Certain information and footnote disclosures included in the Company’s annual financial statements have been condensed or omitted. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation of the condensed financial statements have been included. Interim results are not necessarily indicative of results for a full year. Uses of Estimates in Preparation of Financial Statements The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in certificates of deposit. Restricted Cash Restricted cash consists of certificates of deposit held by financial institutions as collateral for the Company’s corporate credit cards. Short-term Investments Short-term investments consist of certificates of deposit with original maturities ranging from 3 months to 1 year. Revenue Recognition The principal source of revenue consists of government research grants. Revenue is recognized provided there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured, and no contingencies remain outstanding. Payments received prior to the recognition of revenue are recorded as deferred revenue. Research and Development Expenses Research and development costs are charged to expense as incurred and relate to salaries, employee benefits, facility-related expenses, supplies, stock-based compensation related to employees and non-employees involved in the Company’s research and development, external services, other operating costs and overhead related to our research and development departments, costs to acquire technology licenses and expenses associated with preclinical activities and our clinical trials. Payments made by the Company in advance for research and development services not yet provided and/or for materials not yet received are recorded as prepaid expenses. Accrued liabilities are recorded related to those expenses for which vendors have not yet billed us with respect to services provided and/or materials that we have received. Preclinical and clinical trial expenses relate to third-party services, subject-related fees at the sites where our clinical trials are being conducted, laboratory costs, analysis costs, toxicology studies and investigator fees. Costs associated with these expenses are generally payable on the passage of time or when certain milestones are achieved. Expense is recorded during the period incurred or in the period in which a milestone is achieved. In order to ensure that we have adequately provided for preclinical and clinical expenses during the proper period, we maintain an accrual to cover these expenses. These accruals are assessed on a quarterly basis and are based on such assumptions as expected total cost, the number of subjects and clinical trial sites and length of the study. Actual results may differ from these estimates and could have a material impact on our reported results. Our historical accrual estimates have not been materially different from our actual costs. Stock-based Compensation The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, officers and non-employee directors, including stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.” Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the requisite service period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. Net Loss per Share The Company accounts for and discloses net loss per share attributable to common stockholders in accordance with FASB ASC Topic 260, “Earnings per Share.” Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares. Comprehensive Loss The Company’s net loss is equal to its comprehensive loss for all periods presented.

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	64,949,121	21,984,272
Common stock, shares outstanding	64,949,121	21,984,272
Series A Convertible Preferred Stock [Member]
Series A Preferred Stock, par value	$ 0.0001	$ 0.0001
Series A Preferred Stock, shares authorized	15,000	15,000
Series A Preferred Stock, shares issued	0	5,110
Series A Preferred Stock, shares outstanding	0	5,110
Series A-1 Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000	10,000
Series A-1 Preferred Stock, shares issued	0	1,578
Series A-1 Preferred Stock, shares outstanding	0	1,578

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Nov. 06, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	RXII
Entity Registrant Name	RXi Pharmaceuticals Corp
Entity Central Index Key	0001533040
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		65,349,121

Stockholder's Equity	9 Months Ended
Stockholder's Equity	Sep. 30, 2015
Equity [Abstract]
Stockholder's Equity	6. Stockholders’ Equity The Company currently has authorized for issuance 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. *Series A-1 Preferred Stock* As of September 30, 2015, the Company had authorized for issuance a total of 10,000 shares of Series A-1 convertible preferred stock (“Series A-1 Preferred Stock”), $0.0001 par value per share. There were no shares of Series A-1 Preferred Stock outstanding at September 30, 2015. As described in Note 8, on November 6, 2015, the Company filed a Certificate Eliminating the Series A-1 Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, in order to eliminate from the Charter all matters set forth in the Charter, including the related certificates of designation and increase, relating to the Series A-1 Preferred Stock. Dividends On May 22, 2015, the Company entered into the Acceleration and Conversion Agreement with TCP pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A-1 Preferred Shares outstanding after such date. There were no dividends paid on the Series A-1 Preferred Stock during the three months ended September 30, 2015, as all outstanding shares of Series A-1 Preferred Stock were converted into common stock on May 27, 2015. The Company paid dividends in additional shares of Series A-1 Preferred Stock of 57 shares for the three months ended September 30, 2014. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A-1 Preferred Stock dividends was $279,000 for the three months ended September 30, 2014. The Company paid dividends in additional shares of Series A-1 Preferred Stock of 21 and 209 shares for the nine months ended September 30, 2015 and 2014, respectively. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A-1 Preferred Stock dividends was $37,000 and $1,612,000 for the nine months ended September 30, 2015 and 2014, respectively. Conversion There were no conversions of the Series A-1 Preferred Stock during the three months ended September 30, 2015, as all remaining outstanding shares of Series A-1 Preferred Stock were converted into common stock on May 27, 2015. During the three months ended September 30, 2014, 2,557 shares of Series A-1 Preferred Stock were converted into 6,232,862 shares of common stock. During the nine months ended September 30, 2015, 3,599 shares of Series A-1 Preferred Stock were converted into 8,772,903 shares of common stock and during the nine months ended September 30, 2014, 3,416 shares of Series A-1 Preferred Stock were converted into 8,326,721 shares of common stock. *Common Stock* Hapten License Agreement On December 17, 2014, the Company entered into an assignment and exclusive license agreement, (the “Hapten Assignment and License Agreement”) with Hapten Pharmaceuticals, LLC (“Hapten”) under which Hapten agreed, effective at a closing that occurred on February 4, 2015, to sell and assign to us certain patent rights and related assets and rights, including an investigational new drug application and clinical data, for Hapten’s Samcyprone™ products for therapeutic and prophylactic use. Upon the closing of the Hapten Assignment and License Agreement on February 4, 2015, the Company paid to Hapten a one-time upfront cash payment of $100,000 and issued 200,000 shares of common stock, the fair value of which was determined using the quoted market price of the Company’s common stock on the date of issuance. Accordingly, the cash payment of $100,000 and the fair value of the common stock of $228,000 were recorded as research and development expense during the quarter ended March 31, 2015. Lincoln Park Capital Equity Line During the nine months ended September 30, 2015, the Company sold a total of 50,000 shares of common stock for net proceeds of approximately $64,000 to Lincoln Park Capital Fund, LLC (“LPC”) pursuant to and subject to the limitations and conditions set forth in that certain purchase agreement (the “LPC Purchase Agreement”) between the Company and LPC dated December 18, 2014. There were no sales made under the LPC Purchase Agreement during the three months ended September 30, 2015. Per the terms of the public offering (see below), the Company cannot access the equity line until the expiration of the 13-month Overallotment Purchase Rights (defined below). June 2015 Public Offering On June 2, 2015, the Company sold a total of 26,000,000 units at a price of $0.40 per unit in a public offering (the “Offering”). Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the “Overallotment Purchase Rights”) and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the “Warrants”). As a result of the Offering, the Company received gross proceeds of approximately $10,400,000 and net proceeds of approximately $9,200,000 after placement agent fees and estimated Offering expenses, and assuming the Overallotment Purchase Rights and Warrants are not exercised. The Company first assessed the Overallotment Purchase Rights and the Warrants under FASB ASC Topic 480 (“ASC 480”), “Distinguishing Liabilities and Equity” and determined that the Overallotment Purchase Rights and the Warrants were outside the scope of ASC 480. The Company next assessed the Overallotment Purchase Rights and Warrants under FASB ASC Topic 815 (“ASC 815”), “Derivatives and Hedging.” Under the related guidance, a reporting entity shall not consider a contract to be a derivative instrument if the contract is both (1) indexed to the entity’s own stock and (2) classified in stockholders’ equity. The Company determined that the warrant contracts are indexed to the Company’s stock, as the agreements do not contain any exercise contingencies and the warrants’ settlement amount equals the difference between the fair value of the Company’s common stock price and the warrant contract strike price, and the only variables which could affect the settlement amount would be inputs to the fair value for a fixed-for-fixed option on equity shares. The Company also assessed the classification in stockholders’ equity and determined the warrant contracts meet all of the criteria for classification as equity under ASC 815. Based on this analysis, the Company determined that the Overallotment Purchase Rights and the Warrants should be classified as equity. No warrants were exercised during the three months ended September 30, 2015. During the nine months ended September 30, 2015, 35,000 warrants were exercised for gross proceeds of $16,000. Refer to the Series A Preferred Stock and Series A-1 Preferred Stock conversions described above in this Note and Note 5 for shares issued as a result of the conversions of Series A and Series A-1 Preferred Stock during the three and nine months ended September 30, 2015 and 2014, respectively.

Convertible Preferred Stock	9 Months Ended
Convertible Preferred Stock	Sep. 30, 2015
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	5. Convertible Preferred Stock As of September 30, 2015, the Company had authorized for issuance a total of 15,000 shares of Series A convertible preferred stock (“Series A Preferred Stock”), $0.0001 par value per share. There were no shares of Series A Preferred Stock outstanding at September 30, 2015. As described in Note 8, on November 6, 2015, the Company filed a Certificate Eliminating the Series A Convertible Preferred Stock from the Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware, in order to eliminate from the Amended and Restated Certificate of Incorporation of the Company, as amended (the “Charter”) all matters set forth in the Charter, including the related certificate of designation, relating to the Series A Preferred Stock. Dividends On May 22, 2015, the Company entered into an agreement (the “Acceleration and Conversion Agreement”) with Tang Capital Partners, L.P. (“TCP”) pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A Preferred Shares outstanding after such date. There were no dividends paid on the Series A Preferred Stock during the three months ended September 30, 2015, as all outstanding shares of Series A Preferred Stock were converted into common stock on May 27, 2015. The Company paid dividends in additional shares of Series A Preferred Stock of 87 shares for the three months ended September 30, 2014. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A Preferred Stock dividends was $421,000 for the three months ended September 30, 2014. The Company paid dividends in additional shares of Series A Preferred Stock of 105 and 268 shares for the nine months ended September 30, 2015 and 2014, respectively. Included in the Company’s net loss applicable to common shareholders related to the fair value of the Series A Preferred Stock dividends was $172,000 and $2,056,000 for the nine months ended September 30, 2015 and 2014, respectively. Conversion There were no conversions of the Series A Preferred Stock during the three months ended September 30, 2015, as all remaining outstanding shares of Series A Preferred Stock were converted into common stock on May 27, 2015. During the three months ended September 30, 2014, there were no shares of Series A Preferred Stock converted into shares of common stock. During the nine months ended September 30, 2015, 3,215 shares of Series A Preferred Stock were converted into 7,837,400 shares of common stock and during the nine months ended September 30, 2014, 166 shares of Series A Preferred Stock were converted into 405,720 shares of common stock.

Stockholder's Equity - Additional Information (Detail) - USD ($)			3 Months Ended			9 Months Ended
	Jun. 02, 2015	Feb. 04, 2015	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Class of Stock [Line Items]
Preferred stock, par value			$ 0.0001			$ 0.0001		$ 0.0001
Preferred stock, shares authorized			10,000,000			10,000,000		10,000,000
Common stock, par value			$ 0.0001			$ 0.0001		$ 0.0001
Common stock, shares authorized			100,000,000			100,000,000		100,000,000
Fair value of Series A and Series A-1 Preferred Stock dividends					$ 700,000	$ 209,000	$ 3,668,000
Number of common stock issued upon conversion of convertible instrument			0			35,000
Research and development expenses						$ 228,000
Net proceeds from the issuance of common stock	$ 9,200,000					9,266,000	$ 1,947,000
Units issued, shares	26,000,000
Sale of units, price per unit	$ 0.40
Description of transaction	Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the "Overallotment Purchase Rights") and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the "Warrants").
Gross proceeds from public offering	$ 10,400,000
Gross proceeds from warrants exercised						$ 16,000
Series A-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value			$ 0.0001			$ 0.0001		$ 0.0001
Preferred stock, shares authorized			10,000			10,000		10,000
Series A-1 Preferred Stock, shares outstanding			0			0		1,578
Dividends issued on Preferred Stock			0		57	21	209
Fair value of Series A and Series A-1 Preferred Stock dividends					$ 279,000	$ 37,000	$ 1,612,000
Conversion of preferred stock into common shares			0		2,557	3,599	3,416
Preferred stock, accelerated dividend payment date						May 27, 2015
Tang Capital Partners, L.P. ("TCP") [Member]
Class of Stock [Line Items]
Dividend payment terms						On May 22, 2015, the Company entered into an agreement (the “Acceleration and Conversion Agreement”) with Tang Capital Partners, L.P. (“TCP”) pursuant to which the Company and TCP agreed to accelerate the next dividend payment date from June 30, 2015 to no later than May 29, 2015, and upon payment of such dividend immediately convert the dividend shares into common stock. In connection therewith, the dividend payment date was accelerated to May 27, 2015. There were no Series A Preferred Shares outstanding after the completion of the Acceleration and Conversion Agreement.
Hapten Pharmaceuticals, LLC [Member]
Class of Stock [Line Items]
License fee		$ 100,000		$ 100,000
Research and development expenses				$ 228,000
Common Stock [Member] \| Series A-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of common stock issued upon conversion of convertible instrument					6,232,862	8,772,903	8,326,721
Common Stock [Member] \| Hapten Pharmaceuticals, LLC [Member]
Class of Stock [Line Items]
Common stock, shares issued		200,000
Common Stock [Member] \| Lincoln Park Capital Fund, LLC [Member]
Class of Stock [Line Items]
Common stock, shares issued						50,000
Net proceeds from the issuance of common stock			$ 0			$ 64,000
Overallotment Purchase Rights [Member]
Class of Stock [Line Items]
Sale of stock, price per share	$ 0.455
Warrants to Purchase Common Stock [Member]
Class of Stock [Line Items]
Sale of stock, price per share	$ 0.52

Nature of Business and Basis of Presentation - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015
Cash and Cash Equivalents [Member]
Description of Business and Basis of Presentation [Line Items]
Liquid instrument maturity period	Three months or less
Short-term Investments [Member]
Description of Business and Basis of Presentation [Line Items]
Liquid instrument maturity period	3 months to 1 year

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events Subsequent to September 30, 2015, 400,000 Overallotment Purchase Rights were exercised for gross proceeds of $182,000. On November 6, 2015, the Company filed a Certificate Eliminating the Series A Convertible Preferred Stock from the Certificate of Incorporation of the Company and a Certificate Eliminating the Series A-1 Convertible Preferred Stock from the Certificate of Incorporation of the Company (together, the “Certificates of Elimination”) with the Secretary of State of the State of Delaware, in order to eliminate from the Charter all matters set forth in the Charter, including the related certificates of designation and increase, relating to the previously issued series of preferred stock of the Company. As a result, the 15,000 shares of unissued Series A Preferred Stock and 10,000 shares of unissued Series A-1 Preferred Stock were returned to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series or preferences or rights. The foregoing summary of the Certificates of Elimination is qualified in its entirety by reference to the full text of the Certificates of Elimination, which are attached hereto as Exhibits 3.1 and 3.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference.

Fair Value Measurements - Fair Value Measurements (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Assets:
Restricted cash	$ 50	$ 50
Short-term investments	8,000
Fair Value, Measurements, Recurring [Member]
Assets:
Restricted cash	50	50
Cash equivalents	1,500	4,000
Short-term investments	8,000
Total	9,550	4,050
Fair Value, Measurements, Recurring [Member] \| Other Significant Observable Inputs (Level 2) [Member]
Assets:
Restricted cash	50	50
Cash equivalents	1,500	4,000
Short-term investments	8,000
Total	$ 9,550	$ 4,050

Stock-based Compensation - Summary of Option Activity (Detail)	9 Months Ended
	Sep. 30, 2015 USD ($) $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Total Number of Shares, Beginning Balance	3,000,264
Total Number of Shares, Granted	390,164
Total Number of Shares, Exercised	0
Total Number of Shares, Cancelled	(81,667)
Total Number of Shares, Ending Balance	3,308,761
Total Number of Shares, Exercisable	2,376,045
Weighted-Average Exercise Price Per Share, Beginning Balance \| $ / shares	$ 3.39
Weighted-Average Exercise Price Per Share, Granted \| $ / shares	0.55
Weighted-Average Exercise Price Per Share, Exercised \| $ / shares	0
Weighted-Average Exercise Price Per Share, Cancelled \| $ / shares	3.07
Weighted-Average Exercise Price Per Share, Ending Balance \| $ / shares	3.06
Weighted-Average Exercise Price Per Share, Exercisable \| $ / shares	$ 3.33
Weighted-Average Remaining Contractual Term, Ending Balance	7 years 4 months 21 days
Weighted-Average Remaining Contractual Term, Exercisable	7 years
Aggregate Intrinsic Value, Ending Balance \| $	$ 0
Aggregate Intrinsic Value, Exercisable \| $	$ 0

Subsequent Events - Additional Information (Detail) - USD ($)		3 Months Ended	9 Months Ended
	Oct. 01, 2015	Sep. 30, 2015	Sep. 30, 2015	Nov. 12, 2015
Subsequent Event [Line Items]
Number of overallotment purchase rights exercised		0	35,000
Gross proceeds from purchase rights exercised			$ 16,000
Subsequent Events [Member] \| Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred Stock, shares eliminated				15,000
Subsequent Events [Member] \| Series A-1 Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred Stock, shares eliminated				10,000
Overallotment Purchase Rights [Member] \| Subsequent Events [Member]
Subsequent Event [Line Items]
Number of overallotment purchase rights exercised	400,000
Gross proceeds from purchase rights exercised	$ 182,000

Net Loss per Share Attributable to Common Stockholders - Common Shares Excluded from Calculation of Net Loss per Common Share Attributable to Common Stockholders (Detail) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	29,278,376	19,735,374
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	3,308,761	2,987,264
Common Stock Underlying Series A and Series A-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share		16,743,495
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total amount of anti-dilutive securities excluded from computation of earnings per share	25,969,615	4,615